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Abstract 
Despite considerable research on cancer treatments and preventatives, poor outcomes in 
cancer patients are common. The vital search for effective cancer drugs often begins in the 
laboratory, where unfortunately the effects of a drug in humans cannot be perfectly 
modelled. Epidemiology can play a vital role in determining the real world efficacy of a drug 
currently used for other purposes before clinical trials begin. This thesis therefore used 
primarily laboratory evidence to identify potential anti-cancer uses for existing common 
drugs. The drugs and cancers studied were; tricyclic antidepressants and both incidence 
and survival in a number of cancer types, particularly glioma; aspirin and colorectal cancer 
survival; and angiotensin converting enzyme (ACE) inhibitors and hepatocellular carcinoma 
(HCC) incidence. 
A series of studies using The General Practice Research Database as a data source assessed 
any potential associations: A case-control study for tricyclic antidepressant use and cancer 
incidence; cohort studies to examine mortality in colorectal cancer and glioma in relation to 
tricyclic use, and for colorectal cancer mortality in aspirin users; and a case-control study in 
relation to ACE inhibitor use and HCC 
A strong, cancer type specific, dose and time dependant protective effect was found for the 
incidence of glioma and colorectal cancer. This led to a further study examining mortality 
for these cancer types in tricyclic users. While no significant protective effects in all-cause 
mortality of tricyclic users were found, a larger study could still find such an effect in 
glioma. For aspirin and colorectal cancer mortality, a small but significant reduction in 
mortality was observed, though these effects were not entirely consistent throughout the 
study. There were no significant associations found between ACE inhibitors and HCC. These 
findings contribute to the knowledge of the anti-cancer effectiveness of these drugs, and 
may assist in designing future clinical studies.  
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1.1 Introduction 
Effective treatment and prevention of cancer is amongst the most sought after aims in 
medicine. It is certainly an area of research in which a vast amount of money is being spent. 
Cancer Research UK alone spent £334 million on cancer research activities in 2009/10. 
Advances in knowledge of the molecular biology of cancer have led to identification of drug 
targets. In vitro and in vivo laboratory drug testing can give important indications of their 
effects on cancer models. But while these approaches are vital, they cannot perfectly 
model of how a drug will behave in humans. 
However, testing the effects of a treatment in humans using clinical trials is extremely 
expensive. Despite good pre-clinical work and great expense, many drugs entering into 
clinical trials are found to be ineffective, for example, marimastat in treating breast cancer 
(Sparano et al. 2004). To reduce the likelihood of this occurring gaining as much data as 
possible about the effect of a drug in man before beginning full scale clinical trials is of 
great value. It is here that high-quality epidemiology can provide an important link 
between the lab and clinic, in providing real world data on patients, without the expense 
and long timescales inherent in clinical studies. In addition to this, epidemiological studies 
are inherently good for looking at long term effects of drugs, as data sources often have 
long patient follow up times, compared to clinical trials. 
This chapter provides an overview of cancer, its treatment, and advances in the molecular 
biology of cancer that are leading to increasingly targeted treatment. This ever improving 
understanding leads to in depth knowledge of the molecules involved in cancer 
development and how they interact with drugs. It is this mechanism led approach that has 
helped to identify the drug and cancer combinations found in this study. 
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The first such mechanism to be identified in this study is mitochondrial modulation. This led 
to the identification of tricyclic antidepressants as a potential anticancer drug (Daley et al. 
2005), and subsequently to two of the studies in this thesis involving incidence and survival 
in various cancer types. Recent interest in the effect of non-steroidal anti-inflammatory 
drugs (NSAIDs) and cancer, as well as their putative cyclooxygenase-2 inhibition mechanism 
led to another of the studies in this thesis, investigating NSAID use and colorectal cancer 
survival. Finally, angiogenesis is a vital step in carcinogenesis and while drugs targeting this 
process are already in use, other drugs that are thought to do so are being identified, such 
as ACE inhibitors. 
With this in mind, the aims of this thesis are: 
1. To determine the effects of tricyclic antidepressants on cancer incidence 
2. ...as well as determining their effect on post diagnosis cancer survival. 
3. To investigate aspirin and colorectal cancer survival. 
4. To determine if ACE inhibitors have an effect on hepatocellular carcinoma 
incidence. 
This chapter also contains an outline of each of the subsequent chapters, which include 
each of the studies carried out for this thesis. It also contains a description of the source of 
all data for this study, the General Practice Research Database (GPRD), as well as an outline 
of the commonly used methods within the thesis. 
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1.2 Cancer 
1.2.1 What is it? 
Cancer is a vast and diverse spectrum of diseases, all of which are characterised by the 
uncontrolled growth of cells, often involving invasion into surrounding tissues and 
sometimes metastasis into distant organs.  One particular review in the journal Cell has 
become almost ubiquitously cited in any description of cancer (Hanahan et al. 2000).  This 
describes the 6 major changes that occur in virtually all cancer types during cancer 
development: 
x Evading apoptosis 
x Self-sufficiency in growth signals 
x Insensitivity in antigrowth signals 
x Sustained angiogenesis 
x Limitless replicative potential 
x Tissue invasion and metastasis. 
Typically, development of cancer occurs in stages, from precancerous lesions through to 
metastatic malignancies. These stages often correspond to the changes described above 
and occur at a molecular level within the cells. This is driven by mutations in DNA, 
accumulated usually over a long time. These occur in two classes of genes known as 
oncogenes and tumour suppressor genes.  Sometimes one of the above changes can be 
attributable to a mutation in a single gene, as in the case when activation of the telomerase 
gene causes cells to have limitless replicative potential. In many cases however, multiple 
mutations are required in order to circumvent the redundancy commonly found in 
biological pathways. 
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1.2.2 Causes 
The causes of cancer mostly involve environmental exposures. This can be either through 
exposure to DNA damaging agents, such as ionising radiation or chemical carcinogens, like 
the polycyclic aromatic hydrocarbons found in tobacco smoke. For certain cancers, dietary 
exposure to carcinogens is thought to be an important factor, for example, heterocyclic 
amines found in red meat may be responsible for an increase in risk of colorectal and other 
cancers (Sinha 2002). 
Genetic background is also an important factor in the development of cancer, though 
environmental factors always play a key role in development, regardless of genetic 
background. There are a number of examples of commonly occurring mutations in genes, 
which can make people particularly susceptible to particular cancer types. Perhaps the best 
characterised of these are BRCA I and BRCA II genes, which greatly increase the chance of 
an individual getting breast or ovarian cancer when mutated (King et al. 2003; Kadouri et al. 
2007). 
1.2.3 Cancer staging/grading 
At diagnosis, cancer is typically given a number of classifications in order to aid in 
determining prognosis and the most effective treatment option. The stage of cancer 
describes how much a cancer has spread, usually taking into account factors such as 
tumour size, penetration into surrounding tissues, lymph node involvement and presence 
of distant metastases. The staging system differs depending on cancer type, but the most 
commonly used is the TNM system: 
T  relates to the tumour size (numbered 1-4) 
N  describes lymph node involvement (numbered 0-3) 
M  describes metastasis (numbered 0-1) 
16 
 
Other letters can be used to describe various parameters of the cancer, such as grade. 
Grading depicts the level of anaplasia in a cancer, which is an important prognostic 
indicator. A patient with a well differentiated (low grade) tumour will generally have a 
better prognosis than on one with a poorly differentiated (high grade) one. 
1.3 Conventional cancer treatment 
The mainstay of cancer treatment for the majority of solid tumours is surgery. This usually 
occurs early during treatment, with the aim of removing the bulk of cancerous cells. This 
can occur alongside other therapies, such as radiotherapy and chemotherapy, although for 
some cancer types one of these treatment options may be used in isolation. 
Outside of surgery, the basic premise of all cancer therapy lies in the presence of a 
therapeutic index. This means that a treatment is more toxic to cancer cells than normal 
ĐĞůůƐ ? 'ĞŶĞƌĂůůǇ ƚŚĞ ǁŝĚĞƌ ƚŚŝƐ  ?ŐĂƉ ? ŝŶ ƚŽǆŝĐŝƚǇ ? ƚŚĞ ŵŽƌĞ ĞĨĨĞĐƚŝǀĞ ƚŚĞ ƚƌĞĂƚŵĞŶƚ ? &Žƌ
conventional therapy this therapeutic index exists due to cancer cells being particularly 
sensitive to things relating to their high rate of cell division, such as DNA damage. 
Radiotherapy aims to damage DNA by bombarding the cancer tissue with ionising radiation. 
This happens either directly (i.e. the radiation directly breaks bonds in DNA) or through 
creation of free radicals which then go onto damage DNA (Dunne-Daly 1999). It is usually 
administered in a number of fractions, separated by a time period which allows the normal 
tissues to recover. 
 “ŽŶǀĞŶƚŝŽŶĂů ? ĐŚĞŵŽƚŚerapy drugs act through a variety of mechanisms, which can be 
classified into a number of different categories. Cytotoxic drugs aim to cause catastrophic 
damage to cancer cells, either through damage to DNA (e.g. alkylating agents, 
topoisomerase inhibitors), or by preventing DNA replication/division (antimetabolites, 
antimitotic agents). Hormonal therapies are used where the cancer type is reliant on 
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hormonal signalling for continued growth/existence (e.g. some prostate and breast 
cancers). Removal of these hormone signals by for example hormone receptor antagonists 
can lead to growth inhibition or death of the cancer cells. 
While often effective in treating cancer, all three of these treatment options are well 
known for their adverse side effects. These are due to damage to normal cells which occurs 
alongside damage to the cancer cells. For surgery, often a wide margin of surrounding 
normal tissue is removed with the tumour, in order to try to remove any cancer cells which 
have invaded the surrounding tissue. With radiotherapy, there is inevitably some 
surrounding tissue which gets exposed to the radiation. This can cause acute problems such 
as nausea or blood cell depletion, which are specific to the site being irradiated. Problems 
can also emerge later, such as increased tissue fibrosis, tissue damage and a small increase 
in risk of another cancer developing. As chemotherapy is almost always administered 
systemically, it is renowned for its detrimental effects to other rapidly dividing tissues, such 
as hair follicles, immune suppression. Though these can be managed to some extent during 
treatment, these side effects are often a limiting factor in chemotherapy and can lead to an 
enforced reduction or premature halting of therapy, while factors such as white blood cell 
count recover. This can of course lead to reduced efficacy. 
1.4 Targeted cancer treatment 
The relentless drive of cancer research has gradually begun to change cancer treatment to 
be increasingly targeted. This targeting is made possible by the vastly increased knowledge 
of the molecular biology of cancer cells. The development of new targeted agents typically 
follows a path involving identification of a target gene or protein involved in cancer, and 
then determining an agent which will act on it to repress or induce its function. Though 
many agents with potential for treating cancer have been identified, as yet relatively few 
have actually made it into clinical use. 
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Perhaps the most successful class of early targeted agents are monoclonal antibodies. 
These drugs are designed to bind to cell surface proteins and thus block their action An 
example of this is bevacizumab (trade name Avastin). This drug binds to a protein called 
vascular endothelial growth factor (VEGF), which is involved in induction of angiogenesis. 
Bevacizumab is often used in combination with cytotoxic drugs, and was first shown to be 
effective in metastatic colorectal cancer (Kabbinavar et al. 2003; Kabbinavar et al. 2005; Tol 
et al. 2010), but has also found use in other cancer types (Van Meter et al. 2010). Such 
versatility is due to angiogenesis being a vital step in cancer development for all solid 
tumours. 
Trastuzumab (trade name Herceptin) is another targeted cancer drug that has made it into 
clinical use. Another monoclonal antibody, it is primarily used in late stage breast cancers 
that over-express the HER2 protein. HER2 is a cell surface protein involved in cancer related 
signalling pathways such as the PI3K/Akt pathway (Bange et al. 2001; Menard et al. 2003). 
1.5 Chemoprevention 
Given the sometimes ineffective and side effect riddled nature of current cancer 
treatments, prevention is clearly a desirable aim. Cancer chemoprevention can encompass 
a multitude of different methods, from lifestyle choices to drug treatment. 
There have so far been few successful examples of drugs that can be used to protect 
against cancer. Aspirin is one of the only truly successful examples of a working 
chemopreventative drug, though vast amount of research, public interest and media 
attention is directed at this area. While some of the media interest may be somewhat 
sensationalist, the list of potential cancer chemoprevention compounds like resveratrol 
(Jang et al. 1997), antioxidants, curcumin (Patel et al. 2010), dietary fibre (Asano et al. 
2002) and capsaicin (Athanasiou et al. 2007b) is ever growing. There is of course some basis 
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for these claims, but it remains difficult for any nutritional compound to be proven as 
efficacious, as they are by nature not patentable and therefore of little interest to drug 
companies. 
The most obvious alternative to this is a novel drug, which may be patented and developed 
by drug companies. However, a third option exists in that there is a vast array of drugs 
already in common use, many of which may have as yet undiscovered functions. These 
functions can be assessed using epidemiology. 
1.6 Pleiotropy 
Due to the complexity inherent in all biological systems, it is a near certainty that any drug 
will have multiple pharmacological effects. This can be due to many factors such as drug 
binding to multiple target molecules, multiple downstream effects after binding with one 
target or differential effects in different cell types. In most cases, this pharmacological 
complexity leads to unwanted side effects. A good example of this is aspirin, which can bind 
to both the cyclooxygenase-1 and cyclooxygenase-2 (COX-1 and COX-2) proteins. This 
causes different effects in different cell types, due to variation in expression of these 
proteins among tissues, and leads to unwanted side effects, like gastrointestinal bleeding. 
It is therefore valuable in many cases to develop drugs that are as selective as possible to 
their intended target, in order to reduce such side effects. 
However, in the case of some drugs these alternative effects may be positive, and may lead 
to alternative uses for these drugs. Somewhat amazingly, aspirin is once again an example 
of this. Its Inhibition of the COX enzymes regulates compounds such as thromboxanes, 
which are involved in platelet aggregation. Through this mechanism, aspirin is thought to 
be beneficial in reducing cardiovascular events. 
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Aspirin is not alone in this amazing ability to perform multiple functions. All sorts of 
functions could exist for a huge array of drugs. It is simply a matter of testing for these 
functions. 
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1.7 Chapter outline 
Chapter 2 is a detailed review of mitochondrial modulation in cancer therapy, as it was 
pivotal in the initiation of this study and is relevant to chapters 3 and 4. 
Chapter 3 describes a case control study investigating whether tricyclic antidepressant use 
modifies the risk of subsequently developing nervous system, breast, colorectal, lung and 
prostate cancers. The study takes a particular interest in glioma (a subcategory of brain 
tumour), which is thought to be particularly sensitive to them. 
Chapter 4 describes a cohort study to determine whether tricyclic antidepressants affect 
survival in glioma and colorectal cancer patients. These cancer types were chosen after 
some associations were found between drug use and their incidence in the Chapter 3 
study. 
Chapter 5 describes a cohort study to determine whether aspirin and other non-steroidal 
anti-inflammatory drugs affect survival in colorectal cancer patients. Recent evidence has 
emerged to suggest that aspirin may improve post-diagnosis survival. 
Chapter 6 describes a case control study to investigate the effect of ACE inhibitor use on 
hepatocellular carcinoma (HCC) incidence. HCC is a cancer with well-defined high risk 
groups, meaning patients could benefit if laboratory evidence suggesting an anticancer 
action for ACE inhibitors translates to an effect in humans. 
Chapter 7 contains a summary of the findings in this thesis and attempts to put these 
findings into perspective in terms of implications for clinical use of the studied drugs. The 
chapter also includes recommendations for further studies relating to these drugs and 
cancers. 
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1.8 Cancer types in this study 
The cancer types used in these studies are a mixture of the most commonly occurring 
cancers such as breast cancer and less common cancers like glioma. These types of cancer 
were all chosen on the basis of previous evidence that they may be affected by specific 
drugs, as described in the introduction to each chapter. Statistics for cancer incidence, 
prevalence and death rates amongst other things are compiled routinely by Cancer 
Research UK (CRUK). All incidence and mortality statistics in this section relate to the 2008 
version of these CRUK data unless otherwise stated 
(http://info.cancerresearchuk.org/cancerstats/). 
Breast cancer is the most common cancer in the UK, with a crude annual incidence of 
around 78 per 100,000, making up around 16% of all cancer cases. This is despite affecting 
almost exclusively women (there are ~350 cases in males each year). The importance of 
this cancer can therefore not be overstated. As a result, screening for breast cancer by 
mammography is common in many countries including the UK. The benefits of this 
screening are questionable however due to the small absolute risk reduction, combined 
with problems such as over diagnosis caused by false positive results (Olsen et al. 2001). 
Prognosis for people with this cancer has been improving steadily over the last 40 years, 
with 5-year survival increasing from around 50% during 1971-75 to around 80% during 
2001-2006. 
Risk factors for breast cancer include intrinsic factors such as increasing age, later 
menarche, later menopause and genetic predisposition (such as BRCA 1 and 2 mutations). 
Lifestyle factors such as alcohol use, smoking, obesity contraceptive pill and childbearing 
have also been implicated in breast cancer development to some extent (Key et al. 2001). 
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Lung cancer has a crude annual incidence of ~75 per 100,000, only fractionally less than 
that for breast cancer. However, prognosis for lung cancer patients is dramatically worse 
than for breast cancer patients, with a 5 year survival of around 8% between 2001 and 
2006. This makes it the most common cause of cancer related death in the UK so it is 
clearly an important public health issue. 
Smoking is overwhelmingly the greatest risk factor for lung cancer, and in fact has been 
implicated in development of at least 12 other cancer types (Doll et al. 2005). Risk of lung 
cancer is strongly associated with the intensity and duration of smoking (Lubin et al. 2006), 
though this risk reduces substantially or even entirely after cessation of smoking (Crispo et 
al. 2004). Other more minor risk factors for lung cancer include exposure to air pollution 
and radon gas, physical activity, poor diet and alcohol consumption. 
Colorectal cancer is also common, with a crude annual incidence of ~65 per 100,000. It is 
the second most common cause of cancer related death after lung cancer, with a 5 year 
survival rate of around 50%. 
Diet is thought to be an important risk factor in colorectal cancer development, though 
gaining reliable data on dietary factors in patients is inherently difficult, due to factors such 
as recall bias. There are however large, multinational studies such as the European 
Prospective Investigation into Cancer and Nutrition (EPIC), which have investigated dietary 
components such as red and processed meat (Norat et al. 2005), and fibre (Bingham et al. 
2005).As alluded to above, tobacco use is thought to increase risk of colorectal cancer 
(Botteri et al. 2008), as is alcohol use (Fedirko et al. 2011). Obesity is also thought to be 
significant in colorectal cancer development, with increasing level of obesity corresponding 
to increased risk (Moghaddam et al. 2007). In contrast with these risk factors, regular use 
of non-steroidal anti-inflammatory drugs is thought to decrease risk of colorectal cancer 
(Cuzick et al. 2009; Half et al. 2009). 
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Prostate cancer is the most common cancer in the male population in the UK with an 
incidence of around 120 per 100,000.  Although this statistic seems higher than for the 
above cancers, it does exclude women as for obvious reasons the prostate cancer occurs 
exclusively in men. 5 year survival in prostate cancer patients is around 77%, though due to 
the often advanced age of many prostate cancer patients it is common for patients to die 
of factors not related to the cancer itself. Hence these patients may be described as dying 
with cancer rather than from cancer. 
Age is the most influential factor in determining risk of prostate cancer, with the incidence 
rising sharply from the age of 50 to peak at 751 per 100,000 between 75 and 79. Research 
on alcohol use and prostate cancer has been conflicting (Dennis 2000; Bagnardi et al. 2001), 
and the same is true for smoking (Doll et al. 2005; Gong et al. 2008). 
Brain tumours are substantially less common than the above cancers, making up just 2% of 
diagnosed cancers. With an annual incidence of 8 per 100,000 this may seem like a less 
important public health issue. However, with 5 year survival rates as low as they are (11-
16% between 2000 and 2001) and little improvement in this survival in the previous 30 
years, brain tumours appear to have had relatively little research directed at them. Gliomas 
make up around half of brain tumour cases and late stage high grade versions of these such 
as glioblastoma multiforme have especially low survival rates. 
Risk factors for brain tumours are not well defined. Age does play a role, with increasing 
age corresponding to greater incidence. However some types of brain tumour (such as 
medulloblastoma) are more common in younger patients. Previous radiotherapy treatment 
is identified as a possible risk factor (Little et al. 1998). Despite extensive research, 
evidence for other well publicised potential risk factors, such as mobile phone use is thus 
far unsubstantiated (Swerdlow et al. 2011). 
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Hepatocellular carcinoma is a subcategory of primary liver cancers and is the most 
common of these. Annual incidence of liver cancers in the UK is 5.9 per 100,000. 5 year 
survival for liver cancers is less than 6%, making the situation for liver cancer patients even 
worse than for those with brain tumours. 
Hepatocellular carcinoma is commonly a condition caused by chronic conditions which 
damage the liver. This can include cirrhosis, hepatitis B and C infection, alcohol use, and 
haemochromatosis. While these chronic liver diseases contribute greatly to risk of 
hepatocellular carcinoma, other predictors of the cancer include male gender, diabetes (El-
serag et al. 2004) and increasing age (Fattovich et al. 2004). 
1.8.1 Covariates 
The covariates used in this study were justified to a large extent on the basis of the risk 
factors detailed above. Covariates that are common to all the studies are age, smoking 
status, BMI and alcohol use. These factors were chosen as a priori confounders, due to 
their very frequent implication in cancer development. Age is known for 100% of the 
participants in these studies. Having a known age is a requirement of GPRD quality controls 
and is therefore effectively an inclusion criterion. It is also likely that the patient age is 
accurate, as this is recorded as year of birth and calculated using the date of (cancer) 
diagnosis. 
Smoking status recording in the GPRD is variable depending on when the data were 
exacted from the database. Early versions have only around 50% recording, whereas in 
later versions, recording is almost complete. Accuracy of smoking recording is potentially 
questionable however, as it is dependent on several factors, such as accurate patient 
reporting and frequency of status updates. Additionally it is possible that those with for 
example lung disease will have different reporting patterns than those without, which 
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potentiates some bias in the reporting. However, regardless of whether the categories of 
smoking status are accurately coded, it is certain that there will be differences in smoking 
habits between the people in different categories. This means that some assessment of the 
impact of smoking on an outcome can be made, so long as it is remembered that the data 
are not perfect and therefore residual confounding may exist. 
The issues with smoking status recording are essentially the same for alcohol use and BMI 
reporting. Alcohol use relies again on patient reporting, while BMI is measured by the GP 
taking weight and height measurements, which while common, are not carried out 
universally. Once again people with health issues relating to these factors may be have 
these factors reported more frequently. As with smoking though these data can still be 
used to inform about the effect of these factors, provided their limitations are 
remembered in interpretation. 
Other covariates that were used include: 
x Depression- this may be linked to cancer development (Reiche et al. 2004) and is 
clearly related to prescription of tricyclic antidepressants. This was defined by a 
medical code for depression. 
x Non-steroidal anti-inflammatory drug use- which is thought to reduce incidence of 
colorectal cancer (Elwood et al. 2009; Iwama et al. 2009; Din et al. 2010) and may 
well be concurrent with other drug use, such as tricyclic antidepressants. This was 
defined by a record or two or more NSAID prescriptions. 
x Comorbidity (Charlson Index)- is thought to be a predictor of prognosis to some 
extent (Charlson et al. 1987). It was derived using various code lists which code for 
multiple diseases, such as AIDs, heart disease, lung disease, diabetes and stroke. 
When the index is calculated, a score is created for each patient with each detected 
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disease in an individual adding 1, 2, 3 or 6 to their score. These scores depend on 
the perceived increase in risk of death caused by each disease (for example AIDs 
gives a score of 6, whereas dementia only increases the score by 1). The total score 
can then be used in a multivariate model to adjust for comorbidity, which should in 
part account for the differing prognosis of patients at the start of a survival study. 
The algorithm used to determine Charlson Index was adapted by me from an 
existing algorithm in my department (developed previously by Dr Tim Card). 
x Chronic liver disease- is a well-known predictor of HCC (Tsukuma et al. 1993; 
Fattovich et al. 2004). This was defined by a diagnosis code for: alcoholic liver 
disease, cirrhosis, haemochromatosis, hepatitis, cholangitis or alcoholic/non-
alcoholic fatty liver. Relatively few of the patients in the study had one of these 
codes, and the decision was taken to combine these into one category in order to 
maximise the limited power which exists for these variables and simplify 
interpretation. 
x Diabetes is thought to increase risk of hepatocellular carcinoma (El-serag et al. 
2004) and ACE inhibitors are sometimes prescribed as part of treatment for 
diabetes. They therefore could be a confounder between HCC and ACE inhibitor 
use. 
  
28 
 
1.9 The GPRD 
The GPRD is a prospectively gathered, anonymised database encompassing around 500 GP 
practices throughout the UK and is the largest of its type, with around 43 million patient 
years of data spread across approximately 4.8 million patients. This amounts to about 8% 
of the UK estimated population and covers around 7% of UK GPs. 
1.9.1 History 
Originally known as the VAMP (Value Added Information Medical Products Ltd) Research 
Databank, it was set up to supply participating GPs with computers and software, in return 
for providing anonymised patient data of a specified standard. After a brief spell under 
ownership of Reuters Health Information, the database was donated to the Department of 
Health. It is currently operated by the Medicines and Healthcare Products Regulatory 
Agency (MHRA). The business model has also changed since its inception. Rather than 
directly providing computing equipment in return for their data, the GPRD now gives GPs a 
financial contribution for each patient, as well as feedback on the quality of their data. 
1.9.2 Recording cancer in the NHS 
Cancer is initially identified and diagnosed in a number of different ways. These vary by 
things such as the type of cancer, the stage of cancer at diagnosis and on the presence or 
absence of screening programs. 
The most obvious first point of contact is a GP. If a patient is symptomatic, they will often 
see their GP, who would then determine whether it is appropriate to refer the case to a 
specialist. Where referral does take place, this usually causes a record to be created to 
document the occurrence. These records are however often non-specific and/or uncertain 
in nature due to the very early stage of the diagnostic process. For example, the read code 
1J0E.00 (Suspected lower gastrointestinal cancer) is commonly used to record a referral. 
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However the recording of this code is relatively uninformative for research, as it neither 
confirms the presence of a cancer nor does it specify the precise type of cancer. 
More useful records are usually generated when the specialist to whom the patient has 
been referred reports back to the GP.  In this situation, the specialist may for example write 
to the GP, who would then interpret this to determine the appropriate code to record in 
the patient record. This process could return a code which confirms the presence of cancer, 
sometimes with detail of what type of cancer, or may return a code such as 1I2..00 (No 
evidence of cancer found). This is clearly more useful for research purposes. 
As cancer is usually a condition that requires extensive treatment and often multiple 
consultancies to determine the exact type, there is often a great deal of dialogue between 
secondary care and GPs. This dialogue leads to further entries being recorded in the patient 
record, with more specific diagnoses, or treatments such as surgery or chemotherapy. 
These records are potentially useful to research, to give further detail or validation to the 
diagnosis of a patient. 
An alternative to identification of cancer than directly through the GP is through screening 
programmes. These only exist for some common cancers, notably breast, colorectal and 
prostate cancer. There are often read codes generated by the GP to denote attendance at 
such screening programmes. These codes are not in themselves informative, as patients are 
routinely invited to screening, regardless of the presence of cancer symptoms. However, 
the results of the screening are sent to the GP, which would provide information on the 
presence or absence of cancer. It is worth mentioning however that if there were a positive 
finding in a screening there would invariably be further diagnostic tests, such as a fine 
needle aspiration, biopsy, or radiological test to confirm the diagnosis. These would of 
course also create electronic records. 
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It is of course possible that information received from secondary care might be 
misclassified by the GP. This could occur either through miscommunication, or by a lack of 
expertise in the interpreter (communication from secondary care can be recorded at the 
GP by administrative staff rather than by a doctor. However, given that there are often 
multiple codes recorded for each patient, this allows for some checking of diagnoses. Also 
the multiple validations of GPRD diagnoses give some reassurance that events are 
accurately coded in most cases (Jick et al. 1991; Jick et al. 2003; Fombonne et al. 2004; 
Herrett et al. 2010). 
1.9.3 GPRD data collection and quality control 
All currently contributing practices use the same software program to collect data. This 
allows for easier and more consistent data collection across GPs. The Vision clinical system 
(In Practice Systems Ltd) is used in around 22% of UK GPs as a tool for practice 
management. 
Each patient has a unique record within each practice, which contains basic clinical details 
such as age, gender and height, all of which are entered by the GP. Each time a patient 
visits a GP, a consultation record is opened, which allows the clinician to enter any number 
of details about the patient, including symptoms, diagnoses and referrals. In addition to 
this, any prescription that is created for the patient is automatically added to the 
consultation record, which results in a very complete prescription record. For each type of 
record, standardised forms and pop up boxes are used to encourage data collection to be 
as complete as possible. 
Data from each contributing practice is collected at monthly intervals by the GPRD. At the 
point of collection, all records are anonymised by stripping out the name, NHS number and 
any other data allowing patient identification. The data is assessed by the GPRD at this 
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point and must reach certain standards in terms of completeness and accuracy of data. If 
the practice does not meet these standards, it is marked as not up to standard and data is 
not used until the required standard is reached. 
1.9.4 Advantages 
Perhaps the greatest advantage of the GPRD, over other data sources is its size. With 
around 11 million patients (both current patients and those who have died or left the 
practice) and also 66 million person years in most recent version, many studies using the 
database can have good statistical power. The additional benefit of this is that it allows the 
study of rare diseases and/or exposures, for example glioma. 
The database has been widely used in research, resulting in the publication of more than 
750 original research articles and reviews and its validity has been well documented in a 
number of studies (Jick et al. 1991; Jick et al. 2003; Fombonne et al. 2004; Herrett et al. 
2010). Due to the various requirements and controls specified by the GPRD, the quality of 
data is generally very high. For example, prescribing data is automatically recorded for 
every prescription, which allows all such data to be recorded with little potential for things 
such as recall bias. This makes the prescribing data much more accurate than patient 
recorded exposures. 
The database contains records of all data necessary for daily clinical management of 
patients. This allows various factors to be taken into account during study design/analysis. 
For example during cohort selection, patients can be included or excluded according to 
factors such as previous cancer diagnoses. Additionally, these clinical details can be used to 
adjust for confounding during analysis. 
Dose received can be derived from the data. This is in contrast to patient reported drug use 
data, which are often only qualitative or semi-quantitative. The studies in this thesis could 
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use the precise dose and number of prescriptions for a high proportion of cases. This 
allowed for more reliable assessment of dose response, which can give a better indication 
of whether an effect is causal. 
The data in the GPRD are readily available, in that it is a by-product of health care delivery. 
This saves money due to no need for additional data collection or surveys. It also has the 
additional benefit that there is no waiting for data to accrue as with a prospective cohort 
study, thus saving a substantial amount of time. The data are inherently less prone to 
selection bias than questionnaire based studies, as no informed consent is required from 
the patients, so a whole cohort can be selected without worrying about response rates etc. 
Practices from the GPRD are reasonably distributed to cover the whole geographical 
population, meaning that studies are therefore more easily generalised. Additionally any 
imbalance that does exist in the geographical distribution is unlikely to create false 
associations as patients can be matched by practice to virtually eliminate any biases. This 
matching of control patients within the same practice also helps to make them more 
comparable with cases. For example, it may limit differences in socioeconomic status to 
some extent. 
1.9.5 Disadvantages 
While data quality and completeness within the database is continually improving, there 
are some drawbacks to using the data. 
Despite the database being the largest of its kind, there are still insufficient data in some 
cases. For example in this thesis, only a small number of exposed glioma cases existed in 
the database (see chapters 3 and 4), though still the largest glioma study in humans. 
Additionally, there were only a small number of certain HCC patients (chapter 6). 
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The database only contains data that is routinely recorded by GPs and this limits 
ƉĂƌƚŝĐƵůĂƌůǇĂƐƉĞĐƚƐ ŝŶĂƉĂƚŝĞŶƚ ?ƐďĂĐŬŐƌŽƵŶĚ ?&ŽƌĞǆĂŵƉůĞ ůŝĨĞƐƚǇůĞĚĂƚa such as exercise 
and nutrition are recorded only sporadically. In addition, socioeconomic data, while 
available, is currently only recorded at a practice level and therefore generalises the 
socioeconomic status of every patient at a particular practice. It is therefore not possible to 
rule out confounding due to these factors. However, in for example the tricyclics and 
incidence study (chapter 3), good lifestyle is likely to be linked to both lower cancer 
incidence and lower antidepressant use. It is therefore an unlikely explanation for my 
findings, though the effect estimate may still be biased despite this. The recording of some 
other confounders may also be somewhat unreliable. For example alcohol use has far too 
many non-users, suggesting that these may be misclassified as ex-heavy users. These data 
may still be used to partly adjust for confounding, as there will still be differences in patient 
alcohol use between categories. Recording of data such as this has been getting better over 
time. For example the oldest data used in this thesis (Chapter 6) has ~45% missing smoking 
data, whilst the two subsequent versions have ~10% missing (Chapter 3) and ~5% missing 
(Chapters 4 and 5). 
While the database has been running for over 20 years, it is quite common for patients to 
ŵŽǀĞƉƌĂĐƚŝĐĞƐ ?ĂŶĚƚŚŝƐ ĐĂŶ ůŝŵŝƚ ƚŚĞĚƵƌĂƚŝŽŶŽĨĂƉĂƚŝĞŶƚ ?Ɛ ĨŽůůŽǁƵƉ ?This limited long 
term follow up means that for survival studies, it is difficult to say what the effects of 
treatment are after a few years.  
Data in the core database is also limited to things recorded at a primary care level and this 
does not reliably include important information such as reason for death or indications of 
disease severity, such as cancer grade or stage. This is important in that it would allow 
assessment of the effect of drugs on cancers prescribed at different stages. For example, 
early stage may respond to treatments better than late stage. Also cancers diagnosed in 
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late stage may be equivalent to one diagnosed in early stage before the study period (i.e. it 
is effectively a prevalent cancer, but was just not diagnosed early enough).Development of 
linkages to secondary care databases, such as hospital episode statistics and cancer registry 
data is on-going, and should help to address some of these issues. 
Despite good validation of diagnoses within the GPRD, Read codes were not designed for 
use in research. This means that some of them are ambiguous and/or give little information 
on the diagnosis. As a consequence, some patients could be included as cases erroneously, 
which would ůŝŬĞůǇƌĞĚƵĐĞĂŶǇƐŝǌĞŽĨĞĨĨĞĐƚĨŽƵŶĚďǇĂĚĚŝŶŐƌĂŶĚŽŵ ‘ŶŽŝƐĞ ?. Additionally, 
some true cases may be missed which would reduce the power of the study. 
The data do not include over the counter (OTC) drug use. This is more significant for some 
drugs than others, for example aspirin OTC use may be important, although studies on 
chemoprevention of colorectal cancer have shown that regular use is necessary for 
effective prevention. OTC use would most likely be occasional, for a headache etc., 
whereas GP prescribing would mostly be for low dose. The data also do not include hospital 
prescribing, though this is less significant for these studies as the drugs studied are most 
frequently prescribed for chronic conditions, and would therefore be infrequently 
prescribed in hospital. There is also some missing data which relates to prescription dosing. 
This missing data is usually due to non-completion by the GP. This means some patients 
would have to be excluded from the dose-response analysis. It is likely that exclusion of 
these patients is unlikely to introduce bias, but would reduce power. 
Though prescribing data are accurately recorded in the GPRD, there are no data on 
whether prescribed drugs are actually used. This may however reflect real world 
prescribing and use. Furthermore, mǇƵƐĞŽĨA? ?ƉƌĞƐĐƌŝƉƚŝŽŶƐŝŶĚĞƚĞƌŵŝŶŝŶŐĞǆƉŽƐƵƌĞǁŝůů
limit the effect of patients who receive one prescription and do not use it.  
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1.9.6 Data format and access to the data 
The database provides data on patients including clinical diagnoses, treatments and 
outcomes. This is received on a disc, which contains multiple files (Figure 1.1). These files 
contain separate types of data, such as clinical details, referral events, therapy events and a 
file giving general information on each patient in the dataset. 
 
Within each file there is a variable containing a unique anonymised code to identify the 
patient that each record relates to. Linked to these are various details relating to that 
patient. These details vary depending on the purpose of the file. For example the patient 
file (Figure 1.2) contains details such as dates of registration, death dates, year of birth, 
gender and ǀĂƌŝŽƵƐŽƚŚĞƌĚĂƚĂƌĞůĂƚŝŶŐƚŽƚŚĞƉĂƚŝĞŶƚ ?ƐƌĞŐŝƐƚƌĂƚŝŽŶ ? 
Figure 1.1 Files contained in a dataset distributed by the GPRD 
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Figure 1.2 Contents of the patient file from the GPRD 
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At the time of data extraction for the datasets used in this study, free access to GPRD 
datasets for academics was granted by the licence agreement with the Medical Research 
Council (MRC). This agreement has now ended, although it is believed funding for datasets 
is still available from the MRC via individual grant applications.  
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1.10 Common methods 
1.10.1 Medical code lists 
Diagnostic electronic records in the NHS are recorded largely using a medical term 
classification system known as Read codes. This is a hierarchical system, with similar 
conditions grouped together and sharing the earlier characters of the code. The most 
recent version uses 5 primary characters, with 2 additional characters to denote subtypes 
of a code. Each code has an associated description to allow the GP or researcher to identify 
what condition the code represents. 
While there is some organisation to the codes, they can be difficult to work with from a 
research point of view. This is because there can be many different codes for almost 
identical conditions, and some codes can be somewhat vague or ambiguous in their 
descriptions. &Žƌ ĞǆĂŵƉůĞ  ? ? ? ? ? ĚĞŶŽƚĞƐ  “ĂŶĐĞƌ ĐŽƵŶƐĞůůŝŶŐ ? ? ǁŚŝĐŚ ŶĞŝƚŚĞƌ ĐŽŶĨŝƌŵƐ
that the patient has cancer (they may be receiving counselling regarding a friend or 
ƌĞůĂƚŝŽŶ ?ƐĐĂŶĐĞƌ )ŶŽƌŝƐŝƚ ŝŶĨŽƌŵĂƚŝǀĞĂďŽƵƚǁŚĂƚƚǇƉĞŽĨĐĂŶĐĞƌ ?^ƵĐŚĐŽĚĞƐĂƌĞĂǀŽŝĚĞĚ
wherever possible and instead more specific codes are used. 
Another type of coding system, known as Oxford Medical Information Systems (OXMIS) 
codes exist in some versions of the GPRD. These codes are much less organised than Read 
codes, and were only in use early in the history of the GPRD. This means that there are 
relatively few diagnoses that are coded using this system. In later versions of the GPRD (as 
used in Chapters 4 and 5), OXMIS codes have been entirely converted into Read codes, 
making identification simpler. 
In the GPRD each Read/OXMIS codes have been converted further into a unique GPRD 
code set, in which all medical codes are recorded. The reasoning for this is not entirely 
clear, but it is easy to convert precisely between the two sets of codes. 
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Code lists for these studies were derived using a software tool developed by the GPRD, 
known as the medical browser. This is essentially a searchable database 
Initially, the codes for these studies were identified using common names for the disease or 
organ of interest and common cancer types associated with it. The medical browser 
accepts wild cards, so for example using *brain* would identify all codes containing the 
word brain. In addition to this, more obscure cancer codes can then be identified due to 
ƚŚĞŚŝĞƌĂƌĐŚŝĐĂůŶĂƚƵƌĞŽĨZĐŽĚĞƐ ?&ŽƌĞǆĂŵƉůĞ ?ƚŚĞĐŽĚĞĨŽƌ  ‘DĂůŝŐŶĂŶƚŶĞŽƉůĂƐŵŽĨ
the tapetum ? ? ? ?Ǉ ? ? ? )can be found as it is ĂĚũĂĐĞŶƚƚŽƚŚĞĐŽĚĞĨŽƌ ‘DĂůŝŐŶĂŶƚŶĞŽƉůĂƐŵ
ŽĨŵĞĚƵůůĂŽďůŽŶŐĂƚĂ ? ? ? ? ? ? ? ? ) ?It is then possible to then re-enter any the newly found 
terms in the medical browser to potentially find more. Using this iterative process it is 
highly likely that all relevant codes will be found. 
1.10.2 Acquisition/extraction of data 
All data from this study were sourced from the GPRD and were in the form of 3 datasets, 
each extracted separately. Data for chapter 2 were acquired after a successful application 
to the Independent Scientific Advisory Committee (ISAC), which regulates access to the 
GPRD. For chapters 3 and 4 a different dataset was acquired in the same way, though the 
same dataset could be shared for these two studies. For the chapter 5 study, data were 
obtained from an existing dataset within the Division of Epidemiology and Public Health. 
Data used in chapters 2-4 were extracted by the GPRD in accordance with a data 
specification (see appendices I and II), which was set out by staff at the GPRD in accordance 
with protocols written by me. For chapter 5 data were kindly extracted from the existing 
dataset by Dr Joe West, also from the Division of Epidemiology and Public Health. 
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1.10.3 Ǯǯ 
Though the data obtained from the GPRD were generally in good order, it is still good 
practice to check for anomalous data. This was done for each dataset by checking for the 
following situations: 
x WĂƚŝĞŶƚƌĞŐŝƐƚƌĂƚŝŽŶĚĂƚĞĂŶŽŵĂůŝĞƐ ?Ğ ?Ő ? ‘ƐƚĂƌƚŽĨƌĞŐŝƐƚƌĂƚŝŽŶ ?ĚĂƚĞďĞŝŶŐďĞĨŽƌĞ
 ‘ĞŶĚŽĨƌĞŐŝƐƚƌĂƚŝŽŶ ? date (any such patients were removed entirely) 
x Extreme ages (any patient with an age greater than 120 was removed) 
x Data inconsistent with inclusion or exclusion criteria 
Also, throughout the data analysis process, care was taken to spot other anomalies which 
might be encountered. Notable examples included; a female prostate cancer patient (this 
patient was removed from the dataset), and BMI values for patients that were beyond 
what could be might be considered physiologically possible (any values greater than 100 or 
less than 8 were discarded) 
1.10.4 Software used 
Virtually all data handling and analysis was carried out using the software program Stata 
(initially version 10.1, later version 11.1). This is a commonly used statistical software 
package, with a number of capabilities, including data management, statistical analysis and 
statistical graphics generation. 
For code list generation, software provided by the GPRD was used. This was in the form of 
 ‘ŵĞĚŝĐĂů ?ĂŶĚ ‘ƉƌŽĚƵĐƚ ?ďƌŽǁƐĞƌƐ ?dŚĞƐĞďƌŽǁƐĞƌƐĂůůŽǁĞĚǀĂƌŝŽƵs search terms to be used 
to find codes, including Read/OXMIS codes and terms for the medical browser and BNF 
ĐŽĚĞƐĂŶĚĚƌƵŐŶĂŵĞƐĨŽƌƚŚĞ ‘ƉƌŽĚƵĐƚ ?ďƌŽǁƐĞƌ ? 
 
41 
 
1.10.5 Conditional logistic regression 
   For case-control studies, investigating cancer incidence (chapters 3 and 6), conditional 
logistic regression was used to determine differences between drug use in cases and 
controls. This was possible because the cases in both studies were individually matched to 
controls by various factors. This technique allows factors such as age and sex to be adjusted 
for, as it means that each case is compared to controls that have the same characteristics. 
Other variables were taken into account by adjusting for them by including them as 
covariates in the conditional logistic regression model. 
1.10.6 Cox regression 
The cohort studies used Cox regression to determine differences in survival between 
patients with different categories of drug use. Multivariate modelling adjusted for various 
factors, some of which were a priori confounders and others which were included in the 
model according to the level of confounding they appeared to exhibit. 
1.10.7 Kaplan-Meier curves 
In the studies investigating mortality (chapters 4 and 5), Kaplan-Meier (KM) curves were 
drawn to visualise differences in survival for different drug exposures. These were created 
using Stata 11.1. Initially survival curves were drawn in an unadjusted fashion, giving results 
which approximate the univariate results from the Cox regression. They were then drawn 
adjusting for the covariates used in the multivariate Cox regression, which more closely 
reflected these analyses. KM curves were also used to give an initial impression of the 
validity of proportional hazards assumptions, while log-log plots and observed/predicted 
KM curves were used to assess this more closely.  
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1.10.8 Number needed to treat 
It can be difficult to determine the usefulness of a treatment or preventative drug using 
only odds or hazard ratios. It can therefore be useful to create additional statistics in order 
to assess the impact of a treatment. Number needed to treat (NNT) is an estimate of the 
number of patients in a population that would need to be treated in order to prevent one 
outcome (for example disease occurrence or death). NNT is calculated using the equation: 
ܰܰܶ ൌ  ?݅݊ܿ݅݀݁݊ܿ݁݅݊ܿ݋݊ݐݎ݋݈݃ݎ݋ݑ݌ െ ݅݊ܿ݅݀݁݊ܿ݁݅݊݀ݎݑ݃ݐݎ݁ܽݐ݁݀݃ݎ݋ݑ݌ 
In this study incidence values for the control group were taken from CRUK annual incidence 
data, as sated for each of the cancer types in Section 1.8. This means that values given are 
the number of people to be treated to prevent one outcome per year. Incidence in the drug 
treated group can be calculated using: 
incidence in drug treated group = incidence in control group × odds ratio 
Where the odds ratio used is taken from the results of the study. Taking the example of 
glioma, the incidence in the control population is 4/100,000 = 0.00004 (glioma makes up 
around half of brain tumour cases). The largest odds ratio found was 0.36 (>117 days in 
Table 3.9). This therefore gives the final equation: 
 ? ?Ǥ ? ? ? ? ?െ ሺ ?Ǥ ? ? ? ? ? ൈ  ?Ǥ ? ?ሻ ൌ  ? ?Ǥ ? ? ? ? ? ? ?ൌ  ? ?ǡ ? ? ? 
Incidentally, the reciprocal of NNT (in this example 0.0000256) is known as the absolute risk 
reduction. 
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2 Mitochondrial modulators 
An emerging anti-cancer field 
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2.1 Introduction 
Mitochondria are emerging as an important new target in the treatment and prevention of 
cancer. Compounds which act on the mitochondria have been known about for a long time, 
but many of these compounds have only recently been linked with an anti-cancer action. 
There are several types of compound with a proposed anti-mitochondrial action. These 
include existing anti-cancer drugs, other existing drugs such as antidepressants, novel drugs 
and naturally occurring compounds. 
The potential of naturally occurring compounds for mitochondrial inhibition has only been 
partly explored. However, there are good indications that there is a great deal of potential 
in some of these compounds as mitochondrial inhibitors. This hypothesis may go some way 
towards explaining the anecdotal and epidemiological evidence that the dietary sources of 
these compounds such as fruits and vegetables can have potential health benefits. This 
review details a number of compounds which have been shown to have actions on 
mitochondria. The focus of this literature review is on compounds which occur naturally 
and may be dietary, or may be obtained from plant extracts or other sources. This of course 
does not preclude man-made compounds from being mitochondrial inhibitors. One such 
class of compounds, the tricyclic antidepressants, is explored in detail in subsequent 
chapters. 
Despite the potential of naturally occurring compounds for therapeutic benefit in cancer 
patients, it is difficult to develop these compounds beyond the laboratory because of the 
difficulty of obtaining robust intellectual property in the form of patents which thus 
severely limits their sales and marketing potential. However, this does not rule them out 
from being useful. If enough evidence is accumulated that a particular molecule can be 
useful, then it may be that a drug company could develop a new, structurally related 
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analogue to the molecule, to increase its efficacy and allow a patent to be issued on such 
newly developed related compounds. 
2.2 Mitochondria as targets for cancer therapy 
Regardless of mechanism, the ultimate aim of any cancer drug is always induction of cell 
death by apoptosis or necrosis. ƉŽƉƚŽƐŝƐŝƐĂůƐŽŬŶŽǁŶĂƐ “ƉƌŽŐƌĂŵŵĞĚĐĞůůĚĞĂƚŚ ?ĂŶĚŝƐ
a common physiological process which occurs in various pathological (such as after viral 
infection (Everett et al. 1999)) and non-pathological processes (such as during development 
(Meier et al. 2000)). It is a tightly regulated process which results in a series of 
morphological changes to the cell, including cell shrinkage, DNA fragmentation, apoptotic 
body formation and eventual phagocytosis of resultant components by immune cells such 
as macrophages. In contrast, necrosis is a rapid and uncontrolled form of cell death and 
results in cell membrane rupture, organelle destruction and leakage of intracellular 
contents into the extracellular space, although some evidence now exists to suggest that 
necrosis is more tightly regulated than first thought (Henriquez et al. 2008). Because of this 
membrane leakage of intracellular molecules, necrotic cell death can have undesirable 
clinical consequences, such as inflammation. Apoptosis induction is therefore a better 
target for novel cancer drugs, as apoptosis is associated with limited or no inflammatory 
changes (Kanduc et al. 2002). Induction of apoptosis is however a complex process which 
can involve both intrinsic and external signals and numerous internal interactions, 
eventually leading to an apoptotic effector pathway (Fulda et al. 2006; Moffitt et al. 2010). 
The extrinsic apoptotic pathway involves cell surface receptors such as the TNF-related 
apoptosis-inducing ligand-receptor (TRAIL). These receptors then interact with downstream 
signalling molecules within the cell, which eventually leads to the activation of a family of 
proteins called caspases. These caspases (such as caspase 9) are the effectors of apoptosis. 
Amongst their functions is activation of enzymes which can cause DNA fragmentation, 
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which lead to the chromosomal breakdown characteristic of apoptotic cell death (Fulda et 
al. 2006). 
The intrinsic apoptotic pathway is arguably more important in cancer therapy. It is also 
known as the mitochondrial apoptotic pathway and can interact with the extrinsic 
pathway, or act independently of it. Mitochondria are central to the intrinsic pathway in 
that they mediate both pro- and anti- apoptotic signalling and provide a means by which a 
discrete commitment to apoptosis in an individual cell is made. This done through 
interaction with external stimuli such as oxidants and DNA damage, and is effected by the 
release of proteins, such as cytochrome c and caspases (Moffitt et al. 2010). 
An important point of intrinsic apoptosis is known as the mitochondrial permeability 
transition (MPT), which is a large increase in the permeability of the mitochondrial inner 
membrane to molecules of molecular weight less than 200 Daltons. A MPT is not absolutely 
necessary for apoptosis to ŽĐĐƵƌďƵƚŝƐƐŽŵĞƚŝŵĞƐĚĞƐĐƌŝďĞĚĂƐĂ ‘ƉŽŝŶƚŽĨŶŽƌĞƚƵƌŶ ?ŝŶƚŚĞ
process (Kroemer 2002). A MPT often occurs along with processes such as inner 
mitochondrial membrane depolarisation and release of cytochrome c, all of which are 
markers of apoptosis. The MPT is thought to occur through formation of a permeability 
transition pore (PTP), which is a large multi-protein complex. The formation of a PTP 
complex is thought to make the mitochondrial membrane permeable to small molecules 
such as water and can lead to morphological changes, such as mitochondrial swelling. 
Initiation of a mitochondrial permeability transition is a complex and as yet not fully 
understood process. However, it is known that induction occurs under conditions of cellular 
stress such as DNA damage. 
With mitochondria being so central in the process of apoptosis, they are a promising target 
for novel cancer drugs. Not only are they central to apoptosis, but they also exhibit a 
number of advantages as therapeutic targets. 
47 
 
There is a vast array of potential target proteins and complex metabolic pathways such as 
ŽǆŝĚĂƚŝǀĞ ƉŚŽƐƉŚŽƌǇůĂƚŝŽŶ ? ƚŚĞ <ƌĞď ?Ɛ  ?dƌŝĐĂƌďŽǆǇůŝĐ ĐǇĐůĞ ) ĐǇĐůĞand fatty acid oxidation 
processes that can be targeted within the mitochondria. For instance, it is known that 
mitochondrial protein content is approximately 10% of total cellular protein on average for 
all cell types in the body and in some tissues, such as the heart accounts for 50% of the 
total cellular protein (Bates T.E., personal communication). Although drug 
inhibition/interaction will not necessarily lead to apoptosis with just any protein, it is 
reasonable to postulate that sufficient disruption of suitable mitochondrial target 
proteins/processes may lead to effective apoptosis induction. 
It is well known that most cancer cells exhibit some sort of defect in the apoptotic process 
(Hanahan et al. 2000), which allows them to replicate without the usual control of non-
neoplastic cells. Therefore another advantage of the mitochondrial targeting approach is 
that relatively direct and specific induction of apoptosis can be achieved. This may allow a 
 ‘ƐŝĚĞƐƚĞƉƉŝŶŐ ?ŽĨŵĂŶǇĂƉŽƉƚŽƚŝĐĚĞĨĞĐƚƐ ŝŶĐĂŶĐĞƌĐĞůůƐ ? which may be associated with a 
lack of specific proteins associated with receptor mediated (extrinsic) apoptosis,  thus 
overcoming a major cause of resistance to cancer drugs. 
Perhaps the greatest advantage of mitochondria as a drug target is that there is great 
potential for development of drug specificity. This is an important aspect of any cancer 
drug as it allows high levels of drug to be used with minimal toxicity and therefore 
potentially a higher therapeutic index. Therapeutic index is an important term here, as it is 
a vital determinant of the effectiveness of any drug. Therapeutic index is essentially the 
ĐŽŶĐĞŶƚƌĂƚŝŽŶ ‘ŐĂƉ ?ďĞƚǁĞĞŶĂŶĂŐĞŶƚŚĂǀŝŶŐĂƚŚĞƌĂƉĞƵƚŝĐĞĨĨ Đƚ ?ŝŶƚŚŝƐĐĂƐĞŬŝůůŝŶŐĐĂŶĐĞƌ
cells) and the agent causing toxicity (i.e. killing or damaging normal cells). 
There are two potential approaches to achieving a high therapeutic index in targeting 
mitochondria. The first is perhaps generic to many cancer drug types. This would involve 
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selective delivery of the drug to cancer cells, perhaps through a differentially expressed cell 
surface receptor. Drug delivery to the mitochondria of cancer cells may be more effective 
for some types of drug molecules, as it is known that lipophilic cations can accumulate in 
mitochondria (due to the mitochondrial membrane potential) (Modica-Napolitano et al. 
2001). This could also provide increased selectivity due to the higher membrane potentials 
often exhibited by cancer cell mitochondria (although this is often heterogeneous within a 
population of cancer cells). 
The second approach could exploit phenotypic differences between mitochondria of 
normal and neoplastic cells. These differences include lower levels of oxidative 
phosphorylation, greater reliance on glycolysis, often higher mitochondrial membrane 
potential and high production of reactive oxygen species (ROS) (reviewed in (Fantin et al. 
2006)). The significance of these phenotypic differences is that the concentration at which 
a mitochondrial inhibitor is toxic to a cancer cell may be lower than that for a normal cell 
(Daley et al. 2005; Athanasiou et al. 2007a; Athanasiou et al. 2007b). Studies have shown 
that inhibition of particular enzymes within the mitochondria, such as cytochrome c 
oxidase will cause a relatively small drop in respiratory function at low inhibitor 
concentrations, but once a threshold concentration is reached, a dramatic reduction in 
respiratory function is observed (Mazat et al. 1997). It may be that this threshold 
concentration is lower in a cancer cell than a normal cell, due to the mitochondrial defects 
ŽĨƚĞŶ ĞǆŚŝďŝƚĞĚ ŝŶ ĐĂŶĐĞƌ ĐĞůůƐ ? dŚŝƐ  ‘ĐŽŶĐĞŶƚƌĂƚŝŽŶ ŐĂƉ ?ŝƐ ǀŝƚĂů ŝŶ ĚĞƚĞƌŵŝning the 
therapeutic potential of a drug. Both targeted delivery and exploiting phenotypic 
differences between cells are common approaches in pharmacology. 
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2.3 Naturally occurring mitochondrial modulators 
2.3.1 Cyanide 
Well known as a highly toxic poison, cyanide (CN
-
) is a potent inhibitor of cytochrome c 
oxidase (mitochondrial complex IV). It occurs naturally (in small amounts) in apple seeds, 
mangoes and almonds. As cyanide is such a well described inhibitor of mitochondrial 
activity, it could potentially be a candidate as a mitochondrial inhibitor with anti-cancer 
activity, though there has been little research into such effects. However it is often used in 
research if artificially induced mitochondrial dysfunction is required. 
2.3.2 Rotenoids 
Rotenoids are a class of compounds of the flavonoid family. Rotenone is the best known of 
these compounds and has been used for many years as a pesticide and insecticide. 
Rotenone occurs naturally in the roots of several plants including Lonchocarpus utilis 
(commonly known as cubé). The anticancer properties of rotenoids have been 
demonstrated in a mouse model, where a dose dependant tumour size reduction in 
hepatocellular carcinoma was shown (Cunningham et al. 1995). Rotenoids found in cubé 
include: rotenone and  deguelin, which are known to exhibit very strong mitochondrial 
complex I inhibition (Fang et al. 1998). 
2.3.3 Vanilloids 
Capsaicin is a vanilloid receptor agonist which occurs in chilli peppers and is the main 
component responsible for the burning sensation occurring when eating food containing 
chilli. The capsaicin molecule is highly lipid soluble and is part of a small family of related 
compounds also found in smaller amounts in chillies. A major molecular target of capsaicin 
is the cell membrane bound VR1 receptor (also known as the transient receptor potential 
V1 channel TRPV1). The VR1 receptor and its various ligands may in fact have anti-
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proliferative and/or apoptotic functions themselves (Athanasiou et al. 2007b), but capsaicin 
is also thought to have other potential apoptotic effects independent of the VR1 receptor. 
Although vanilloid receptors are thought to be expressed in a number of cell types, there is 
significant evidence that suggests that mitochondrial mediated mechanisms may be 
responsible for their apoptotic action.  
An example of this is the demonstration of a reduction in oxygen production and an 
increase in hydrogen peroxide levels when cells were treated with vanilloids (Hail et al. 
2002). These occurrences are associated with apoptosis and are indicative of inhibition of 
mitochondrial respiration. The precise mechanism for the apoptotic effects of vanilloids is 
not yet certain. While membrane depolarisatrion and decreased oxygen consumption have 
been observed (Athanasiou et al. 2007b) along with caspase 3 activation and intracellular 
Ca
2+
 release (Wu et al. 2006), the actual function of the vanilloid is less clear. It has been 
postulated that activity inhibition of mitochondrial complex I of the respiratory chain may 
be a vanilloid target (Athanasiou et al. 2007b). 
2.3.4 Cannabinoids 
Cannabinoids are compounds found naturally in the Cannabis sativa plant and are ligands 
for the CB1 and CB2 receptors (Howlett et al. 2002). Their interactions are complex however 
as they have also have been shown to interact with vanilloid receptors such as TRPV1. Like 
vanilloids, they are also known to be able to induce cell death. Another similarity with 
vanilloids is that they are also thought to induce apoptotic cell death through a 
mitochondrial mechanism. This was shown in a study using isolated rat heart mitochondria 
(Athanasiou et al. 2007a). Here it was demonstrated that cannabinoids can cause a 
reduction in oxygen consumption and decreased mitochondrial membrane potential. Their 
mode of action was thought to be inhibition of complex I and complex II-III activity. 
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2.3.5 Resveratrol 
Resveratrol was originally identified as a potential anticancer agent for its ability to inhibit 
cyclooxygenase (COX). Resveratrol is found in the skin of grapes and in high levels in red 
wine and has therefore received extensive attention for its potential chemopreventative 
role. Resveratrol has been found to exert a number of effects of cells, including 
cycloxygenase-1 (COX-1) inhibition and modulation of antioxidant activity (through a 
variety of mechanisms (Rubiolo et al. 2008)). It has also been found to inhibit cancer in 
both in vitro and in vivo models (Jang et al. 1997). More recently, evidence for a 
mitochondrial mechanism in inhibiting cancer has been revealed. A number of studies have 
shown the ability of resveratrol to specifically induce apoptosis in a number of cancer cell 
types such as acute lymphoblastic leukaemia cells (Dorrie et al. 2001), U251 glioma cells 
(Jiang et al. 2005) and neuroblastoma cells (van Ginkel et al. 2007). In these studies it was 
shown that resveratrol has the ability to induce mitochondrial membrane depolarisation 
along with activation of caspase 3 and caspase 9. 
2.3.6 Jasmonates 
Jasmonates are a group of plant stress hormones with putative anti-cancer activity. One 
group has demonstrated its anti-cancer activity and the mechanism of action of the 
compound. In their initial paper, Fingrut and Flescher describe high levels of cytotoxicity in 
4 different cancer cell lines. This was particularly notable when treating with methyl 
jasmonate. The study also investigated mice bearing EL-4 mouse lymphoma, where a 
significantly higher survival rate was observed in the mice treated with methyl jasmonate 
(Fingrut et al. 2002). 
Evidence for the mitochondrial action of jasmonates is demonstrated in a further paper 
from the group (Rotem et al. 2005). This mitochondrial action was demonstrated by 
measurement of mitochondrial swelling, membrane depolarisation and cytochrome c 
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release. The group also showed that the mitochondrial toxicity is dependent on the PTP, as 
inhibition of the PTP prevented membrane depolarisation. The study also demonstrates 
selective mitochondrial toxicity towards chronic lymphocytic leukaemia cells expressing 
both wild type and mutant forms of the tumour suppressor protein p53 (Rotem et al. 
2005). 
2.3.7 Arsenic trioxide 
Arsenic trioxide is a major active component in Traditional Chinese Medicine and is found 
in Arsenicum Sablimatum. It can also be made synthetically. The compound has long been 
known to have anti-cancer properties and has been used for some time in the treatment of 
acute promyelocytic leukaemia (Antman 2001), with high levels of clinical complete 
remission observed (Niu et al. 1999) (known commercially as Trisenox). As with so many 
cancer drugs, this compound has been used extensively before its mechanism of action is 
known. There is still debate over this matter. 
Various different proposals have been put forward to explain the anti-cancer action of 
arsenic trioxide. Inhibition of thioredoxin reductase and therefore downstream induction of 
oxidative stress and inhibition of DNA synthesis is one possibility (Lu et al. 2007). Other 
groups have suggested that autophagic cell death may be responsible rather than or 
alongside apoptotic cell death in malignant glioma cells (Kanzawa et al. 2003) and in 
leukaemia HL-60 cells (Yang et al. 2008a). There is also data to suggest the involvement of 
mitochondrial toxicity and several groups suggest that mitochondria involved in the 
apoptosis induction (Zhu et al. 1999; Shen et al. 2002; Yu et al. 2007). Moreover, other 
groups have investigated the direct involvement of arsenic trioxide in mitochondrial 
interactions (Korper et al. 2004). One such group demonstrates more direct effects on the 
PTP, as in a cell free system, apoptosis only occurs in the presence of the mitochondria and 
inhibition of the PTP abolishes induction of apoptosis by arsenic trioxide (Larochette et al. 
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1999). A good short review of these mechanisms can be found in (Kroemer 1999). All these 
mechanisms are not necessarily mutually exclusive, as it is possible that the compound acts 
on multiple parts of the cell to elicit apoptosis (either extrinsic and/or intrinsic) and/or 
necrosis, dependant on both cell type and concentration of the agent concerned. 
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2.4 Summary conclusion 
Within all of these compounds exists the potential to be anti-cancer drugs. Some 
compounds are further along this path than others, but in all cases strong anti-cancer 
activity at least in vitro has been demonstrated. What connects all of these compounds is 
that they all have putative mitochondriotoxic activity. However, some of the compounds 
have been more strongly linked with this activity than others. Some caution must be 
exercised in determining if a compound directly interacts with the mitochondria. There can 
be a clear distinction between a compound that directly interacts with the mitochondria 
and one which affects the mitochondria via a different, possibly parallel cellular process 
which leads to mitochondrial apoptotic cell death. The implication of this is that it is not 
sufficient to measure changes in the mitochondria brought about by a particular agent 
within a cell. For example, an observation showing membrane depolarisation in the 
mitochondria of a target cell does not demonstrate direct mitochondrial inhibition. 
Methods to determine direct interactions therefore have to involve using isolated 
mitochondria and measurement of effects such as depolarisation and cytochrome c release 
in absence of any upstream pathways which may indirectly act on the mitochondria. 
Methods involving detection of direct mitochondrial protein interactions and measurement 
of mitochondrial enzyme kinetics may also be valuable in this approach. Another important 
consideration when studying naturally derived products is their source. Studies using 
isolated purified compounds are far more valuable than those using extracts that may 
contain a large number of different compounds, often at varying concentrations depending 
on the source and methods of extraction. 
2.5 Importance to this thesis 
The natural compounds reviewed above are not generally used extensively in medicine. 
This means that their putative anti-cancer actions are not testable in a primary care 
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database such as the GPRD. However there are compounds that are known to modulate 
mitochondrial activity, that are also commonly prescribed in the general population. The 
best known example of this is tricyclic antidepressants (Daley et al. 2005). The next two 
chapters explore the potential anticancer action of these drugs, in terms of both their 
effect on cancer incidence and mortality 
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3 Tricyclic antidepressants and cancer incidence 
A case control study using the GPRD 
  
57 
 
3.1 Introduction 
3.1.1 Study background 
This study was conceived after laboratory findings demonstrated an anti-cancer action for 
tricyclic antidepressants, coupled with a mitochondrial inhibition mechanism (Daley et al. 
2005). This led to further investigation into such anti-cancer actions, which gave further 
indication of their potential (detailed below). Although there is extensive evidence for the 
anti-cancer action of tricyclics, it was felt that there were few satisfactory studies in 
humans and the obvious choice to remedy this situation was a large-scale epidemiological 
study. The background contained in this introduction is also largely applicable to chapter 4, 
which is also based around tricyclics. 
Tricyclic antidepressants are widely prescribed for a variety of conditions, including 
depression, anxiety, insomnia and certain types of chronic pain management. They have 
been in clinical use for over 40 years, and were originally developed as derivatives of the 
antipsychotic chlorpromazine, with imipramine being the first tricyclic to be used as an 
antidepressant. Their psychoactive mechanism of action is thought to involve inhibition of 
serotonin and norepinephrine reuptake. Side effects under normal dosing are generally 
mild, but include dry mouth, constipation, urinary retention and restlessness. However, in 
overdose they can cause severe cardiovascular and neurological toxicity. 
3.1.2 In vitro evidence 
Tricyclics have long been known to interact with the mitochondria (Eto et al. 1985), but 
their anti-cancer action is somewhat more recently discovered. Chlorimipramine is 
probably the most studied of the tricyclics with regard to its anti-cancer action. One such 
study shows that chlorimipramine has the ability to kill cultured brain tumour cells and also 
demonstrates the mechanism by which the drug acts (Daley et al. 2005). It demonstrates 
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inhibition of the mitochondrial complex III, which is accompanied by a decrease in 
mitochondrial membrane potential and morphological changes to the mitochondria. 
Intriguingly, it is noted that primary human glia (non-cancerous cells) are not affected by 
the drug, although the reason for this selectivity is not entirely clear. This has been further 
investigated using various tricyclic drugs in combination with dexamethazone (an anti-
inflammatory drug often used in the treatment of glioma), where it was found that 
amitryptyline, chlorimipramine and dexamethazone were all able to inhibit cellular 
respiration, leading to cell death and a possible synergistic effect existed between 
chlorimipramine and dexamethazone (Higgins et al. 2010). 
Another example of combination therapy in glioma used chlorimipramine along with 
imatinib, though in this case a murine model of glioma was used (Bilir et al. 2008). This 
glioma killing action is also aptly demonstrated in a study which found that 
chlorimipramine, amongst other drugs caused apoptosis induction in glioma and 
neuroblastoma cell lines (Levkovitz et al. 2005). The group also suggest in this paper that 
proteins involved in mitochondrial pathway of apoptosis, such as cytochrome c and 
caspase-3 are involved in the cell death triggered by the drugs. 
Other studies using other tumour types support the findings of Daley et al for both 
chlorimipramine and other antidepressants. Human peripheral lymphoblasts and acute 
myeloid leukaemia cells have been used to demonstrate the ability of the drugs 
imipramine, chlorimipramine and citalopram to induce apoptosis (Xia et al. 1998b; Xia et al. 
1999). The later study here shows that the apoptosis occurs via caspase-3 activation, 
although it does not demonstrate the mechanism by which this occurs. Caspase-3 is known 
to be intimately involved in apoptosis. Other studies by this group give further confirmation 
that a mitochondrial pathway is involved in apoptosis induction (Xia et al. 1998a). 
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Other tricyclic drugs such as amitriptyline and desipramine, have been shown to induce 
apoptosis in human colon carcinoma cells (Arimochi et al. 2006). In this case, desipramine 
has been shown to act through both mitochondrial and non mitochondrial mechanisms, 
depending on the colon cancer cell line used (Arimochi et al. 2008).  This gives an insight 
into the reasons for observing differential sensitivity, in that cancer cells may or may not be 
sensitive to a drug according to their mitochondrial phenotypes. 
3.1.3 In vivo studies 
In vivo studies provide further evidence for the efficacy of these drugs. Interestingly, many 
of the in vivo studies precede many of the in vitro studies. Also, rather than look at the 
efficacy of the antidepressant drugs alone, they are used as an adjuvant treatment, in order 
to overcome drug resistance. One such study demonstrates the ability of chlorimipramine 
to partly overcome vincristine resistance in P388/VCR-bearing mice (Tsuruo et al. 1983). 
This study showed an increased survival time of around 30%, and therefore only a partial 
response. Another study used clorimipramine in combination with another drug, verapamil, 
to overcome actinomycin resistance (Merry et al. 1991). Further evidence of in vivo efficacy 
ŝƐ ƉƌŽǀŝĚĞĚ ďǇ Ă ŐƌŽƵƉ ůŽŽŬŝŶŐ Ăƚ ĚŽǆŽƌƵďŝĐŝŶ ƌĞƐŝƐƚĂŶĐĞ ? dŚĞǇ ĚĞƐĐƌŝďĞ Ă  “ƐŝŐŶŝĨŝĐĂŶƚ
reduction in growth of doxorubicin-ƌĞƐŝƐƚĂŶƚƚƵŵŽƵƌƐ ?(Pommerenke et al. 1995).  
3.1.4 Epidemiological evidence 
A number of epidemiological studies have been carried out to investigate tricyclic use and 
cancer incidence. Oddly however, despite the greatest amount of laboratory research 
being directed at glioma, there are no epidemiological studies relating to this cancer type. 
Breast cancer is the most widely studied in this area, mostly due to an apparent concern 
that antidepressants may increase cancer risk (Cotterchio et al. 2000; Bahl et al. 2003; 
Lawlor et al. 2003; Gonzalez-Perez et al. 2005; Fulton-Kehoe et al. 2006; Wernli et al. 2009). 
Consensus here seems to be that there is little meaningful increase in risk. 
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Colorectal cancer risk has also been investigated in relation to tricyclic use and small but 
non-significant decreases in risk among tricyclic users have been observed in three 
separate studies (Xu et al. 2006; Coogan et al. 2009; Chubak et al. 2011). Both lung (Toh et 
al. 2007b) and prostate (Tamim et al. 2008) cancer have also been involved in similar 
studies, but neither of these demonstrated a significant protective effect. 
3.1.5 Clinical use 
Despite there being no formal clinical trials using tricyclics as an anti-cancer agent, there 
are anecdotal reports of clinical use of chlorimipramine in the treatment of primary brain 
tumour. Around 350 patients are thought to be using chlorimipramine in this way (detailed 
in (Higgins et al. 2010)). Though relatively few of these cases are well documented, a study 
on a small group of glioma patients (n=27), has shown a good partial response from 
chlorimipramine treatment in around 80% of patients (Beaney et al. 2005). 
3.1.6 Conclusion 
There is strong evidence for activity of some antidepressants in reducing incidence of or 
even in treating cancers such as glioma. This evidence would be further supported by an 
epidemiological study, which would allow widespread analysis of antidepressant usage and 
brain tumour incidence. If positive results were to emerge from such a study it would 
provide a very clear indication of the efficacy of antidepressants and would most likely lead 
to further studies into their potential therapeutic usage. There would also be increased 
incentive for the investigation of other mitochondrial inhibitors many of which show 
promise. 
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3.1.7 Cancer types in the study 
 
Due to the large volume of research involving glioma and tricyclics, this was the first cancer 
type to be selected, along with all other primary brain tumours. There are also in vitro and 
epidemiological suggestions that some types of colorectal cancer may be sensitive to 
tricyclics, so this was also chosen to be included in this study. 
The other cancer types, breast, lung and prostate cancer were included mainly due to their 
high incidence, giving a great deal of power to the study. Because there is relatively little 
evidence that they are sensitive to tricyclic antidepressants, these may appear to be of 
secondary interest, but in fact provide an important role in determining whether any 
observed effects are selective to cancer type. 
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3.2 Methods 
3.2.1 Study design 
A matched case-control study was be used to determine the relationship between tricyclic 
usage and cancer incidence. 
3.2.2 Patients 
Cases were defined as any person with a recorded diagnosis of brain tumour, breast 
cancer, colorectal cancer, lung cancer or prostate cancer within the GPRD (for diagnosis 
codes see Appendix I). Gliomas were also considered separately. I excluded cases with less 
than 5 years of data contributions prior to the first recorded diagnosis of the relevant 
cancer. This was to assure sufficient duration of data on aspects such as therapy for each 
patient, and also to increase the likelihood that cancer diagnoses relate to incident, rather 
than prevalent cases. I also excluded patients aged less than 18 years, or with a diagnosis of 
any other cancer prior to the index cancer. 
Controls were contributing data at the time of the case index date, had at least 5 years of 
follow-up prior to that date and had no recorded medical diagnosis of cancer. Controls 
were matched to cases by year of birth, gender and GP practice in a ratio of 2:1 where 
possible. In addition, a pseudo-diagnosis date was assigned to each control, which 
corresponded to the diagnosis date of the matched case. 
3.2.3 Variables 
The primary exposure was the prescription of any tricyclic antidepressant (section 4.3.3 of 
the British National Formulary). I abstracted data on all such prescriptions at least one year 
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prior to the date of diagnosis of the index cancer (or the equivalent pseudo-diagnosis date 
of the cancer for controls).  
A number of approaches were taken to classify these exposures for analysis. Firstly, I 
created a binary variable defining a tricyclic user as anyone with A?6 prescriptions for any 
tricyclic antidepressant, and comparing these to non-users (those with <6 prescriptions). 
This was later refined to A? ?ƉƌĞƐĐƌŝƉƚŝŽŶƐ (and <2 prescriptions for non-users), in order to 
be more consistent with other similar studies. For example, the same exposure definition 
of A? ?ƉƌĞƐĐƌŝƉƚŝŽŶƐ was used by Fulton-Kehoe et al (2006) and Chubak et al (2011). 
 Assessment of dose response was initially handled by grouping the number of 
prescriptions that each patient received into 4 categories (unexposed, 1 W10 prescriptions, 
11 W50 prescriptions and >50 prescriptions). Though this provided some indication of the 
total dose received by each patient, it was felt that it did not truly reflect whether patients 
were receiving high or low dose prescriptions. This was amended by determining the dose 
received for each prescription. This was standardised across drug types by dividing by the 
maximum recommended doses for each drug (determined from the BNF). These 
standardized doses were then used to calculate the mean dose across all prescriptions for 
each patient individually. Patients with prior tricyclic use were divided into 'high' or 'low' 
dose groups based on the median corrected dose, which was 0.35 times the maximum 
recommended dose. 
The time of exposure was also categorised, initially with exposures divided into 1 W5 year, 
5 W10 year and >10 year categories according to the time of the first prescription for each 
drug type. This somewhat crude method of categorisation did give some indication of the 
length of time patients had been exposed for, but did not give an indication of the 
consistency or overall length of exposure. This was assessed by determining the number of 
days of exposure over a 10 year period before the index date. Any patient contributing data 
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for less time was excluded for this part of the analysis. Exposed patients were then divided 
into 2 cohorts around the median level of exposure time.  
3.2.4 Drug specificity/confounding by indication 
Confounding by indication is a situation where another condition (such as depression) is 
linked to both the outcome (cancer) and the exposure (in this case tricyclic drug use). 
Clearly depressed patients are often prescribed antidepressants, and depression may be 
linked to cancer development (Reiche et al. 2004). It is therefore important that this 
potential confounding is assessed, as it is a potential alternative explanation for any effects 
found. 
In order to assess any potential confounding by indication, use of another class of 
antidepressants, the Selective Serotonin Reuptake Inhibitors (SSRIs) was investigated in 
parallel with tricyclic use. This is because their use is also associated with depression, and 
any similar patterns in the results for this drug may indicate confounding by indication. 
As well as doing some of the analysis directly using SSRI as the primary exposure in place of 
tricyclics, further investigation was carried out by re-categorising exposures into patients 
exposed to only SSRIs, only tricyclics, and both SSRIs and tricyclics. This helps to further 
scrutinise the effect of SSRIs and tricyclics, and may help to clarify if there is confounding by 
indication. 
Stratification of the tricyclic analysis according to whether a patient had diagnosed 
depression was also carried out. This was in order to determine the indication for tricyclic 
prescription. Any differences in the results between the strata may indicate whether 
depression is a confounder. 
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Finally the relationship between depression and tricyclic dose was investigated, in order to 
determine if depression was a marker for the dose prescribed. 
Other indications for tricyclic prescriptions (i.e. chronic pain management) were not 
investigated. This is because chronic pain is virtually impossible to classify in the GPRD as 
most patients will have a code relating to pain at some point in their record (there are over 
27 million events relating to it in the GPRD), and there are very few codes specifying 
chronic pain. 
3.2.5 Other covariates 
I extracted data on smoking status, body mass index (BMI), alcohol use, diagnosed 
depression, and prescriptions for non-steroidal anti-inflammatory drugs and statins which I 
considered as possible confounders.  
3.2.6 Statistical methods 
Data were analysed with conditional logistic regression, initially using univariate analysis, 
then using a multivariate model. Results were presented as odds ratios (ORs), with 
accompanying 95% confidence intervals (CIs). Potential confounders were retained in the 
model if their inclusion altered the effect size by more than 10% in either direction. 
Analyses were performed on all cancer types together, followed by individual cancer types 
to look for specific effects. All data handling and analysis was done using Stata v10.1 SE 
(Statacorp, 4905 Lakeway Drive, College Station, Texas 77845 USA). 
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3.3 Results 
3.3.1 Study population 
31,953 cases were matched to 61,591 controls by age, gender and general practice. The 
cases were broken down by cancer site, into 1,372 cancers of the nervous system (of which 
773 were glioma), 10,293 of the breast, 6,232 colorectal, 6,537 of the lung and 6,537 of the 
prostate. Median age of patients across all cancer types was 68.2. Female patients made up 
50.7% (16,212) of the study, and had a median age of 65.6, male patients had a median age 
of 70.9. 18.9% of cases and 17.6% of controls were exposed to one or more prescriptions 
for a tricyclic prior to a year before the index date. These data are described, stratified by 
cancer type in Table 3.1. 
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Table 3.1 Population characteristics 
Cancer   Cases Controls 
    Number % Number % 
All Total 31,953  61,591  
  Male 15,740 49.3 29,998 48.7 
  Female 16,212 50.7 31,593 51.3 
  Mean age 68.3 
Glioma Total 773  1,502  
  Male 468 60.3 906 60.5 
  Female 305 39.7 596 39.5 
  Mean age 60.1 
Colorectal Total 6,232  12,010  
  Male 3,496 56.1 6,704 55.8 
  Female 2,736 43.9 5,306 44.2 
  Mean age 70.9 
Brain Total 599  1,164  
(excluding  Male 214 35.7 413 35.5 
 glioma) Female 385 64.3 751 64.5 
  Mean age 65.8 
Breast Total 10,293  20,096  
  Male - - - - 
  Female 10,293 100.0 20,096 100.0 
  Mean age 62.5 
Lung Total 6,537  12,514  
  Male 4,035 61.73 7,653 61.16 
  Female 2,502 38.27 4,861 38.84 
  Mean age 71.0 
Prostate Total 7,531  14,329  
  Male 7,531 100.0 14,329 100.0 
  Female - - - - 
  Mean age 72.5 
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3.3.2 Covariates 
Table 3.2 describes covariates with all cancer types grouped together. Some large 
differences in between different cancer types mean that the breakdown by cancer type 
(Table 3.3) is potentially more informative. As can be seen from Table 3.2, smoking was 
associated with an increased risk of cancer (OR=1.47 CI=1.42 W1.53). This risk is almost 
entirely attributable to lung cancer, with an odds ratio of 7.4 (CI=6.74 W8.12) in smokers 
compared to non smokers. There is a slight increase in risk of cancer for alcohol users 
(OR=1.09 CI=1.05 W1.14), which was mostly due to breast (OR= 1.11 CI=1.04 W1.18) and 
colorectal cancers (OR=1.12 CI=1.02 W1.23). There is an apparent decrease in cancer risk as 
BMI increases. This effect is mainly found in lung cancer patients, where the decrease is 
caused by confounding by smoking status, and is not statistically significant if only non-
smokers are considered. NSAID use is not significantly different when all cancers are 
considered together, but does show a significant reduction in colorectal cancer (OR=0.93, 
CI=0.87 W0.99), as has been reported previously (Cuzick et al. 2009). 
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Table 3.2 Covariates- all cancers 
Exposure Status Case Control OR 95% CI  
Smoking status No 15,369 32,153 1     
 Ex 5,911 10,263 1.23 1.19 1.28 A? 
 Yes 7,978 11,615 1.47 1.42 1.53 A? 
  Missing 2,695 7,560 0.69 0.65 0.72 A? 
Alcohol use No 4,778 9,542 1     
 Ex 348 572 1.24 1.08 1.43 A? 
 Yes 21,028 38,670 1.09 1.05 1.14 A? 
  Missing 5,799 12,807 0.87 0.83 0.91 A? 
Mean BMI Normal 10,713 19,466 1     
 Underweight 701 1,020 1.26 1.14 1.39 A? 
 Overweight 10,086 19,005 0.96 0.93 1.00 A? 
 Obese 3,191 6,240 0.93 0.89 0.98 A? 
 Morbidly obese 961 2,008 0.88 0.81 0.95 A? 
  Missing 6,301 13,852 0.79 0.76 0.82 A? 
NSAID use No 21,122 41,006 1     
  Yes 10,831 20,585 1.02 0.99 1.05  
Statin use No 26,957 51,933 1      
  Yes 4,996 9,658 1.00 0.96 1.04  
Depression No 23,890 47,458 1      
  Yes 8,063 14,133 1.15 1.11 1.19 A? 
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Table 3.3 Covariates- by cancer type 
Cancer type Exposure Status Case Control OR 95% CI  
Brain Smoking status No 339 621 1      
 (excluding  Ex 76 159 0.89 0.65 1.22  
 Glioma)  Yes 135 240 1.02 0.79 1.32  
    Missing 49 144 0.57 0.39 0.83 A? 
  Alcohol use No 104 180 1     
   Ex 9 11 1.34 0.53 3.35  
   Yes 364 708 0.86 0.65 1.15  
    Missing 122 265 0.74 0.52 1.05  
  BMI Normal 15 16 1     
   Underweight 186 402 0.46 0.21 1.00 A? 
   Overweight 176 295 0.61 0.28 1.32  
   Obese 74 115 0.66 0.29 1.49  
   Morbidly obese 27 50 0.57 0.24 1.39  
    Missing 121 286 0.40 0.18 0.87 A? 
  NSAID use No 397 805 1     
    Yes 202 359 1.16 0.93 1.46  
  Statin use No 527 996 1     
    Yes 72 168 0.79 0.57 1.08  
  Depression No 414 884 1     
    Yes 185 280 1.43 1.15 1.79 A? 
Glioma Smoking status No 415 737 1      
   Ex 105 196 0.96 0.73 1.27  
   Yes 168 343 0.86 0.69 1.08  
    Missing 85 226 0.60 0.44 0.82 A? 
  Alcohol use No 88 199 1     
   Ex 3 8 0.91 0.24 3.53  
   Yes 532 945 1.28 0.97 1.70  
    Missing 150 350 0.91 0.65 1.27  
  BMI Normal 11 28 1     
   Underweight 253 443 1.49 0.72 3.08  
   Overweight 251 456 1.43 0.69 2.96  
   Obese 75 155 1.26 0.59 2.71  
   Morbidly obese 23 52 1.17 0.49 2.78  
    Missing 160 368 1.07 0.51 2.25  
  NSAID use No 601 1,132 1     
    Yes 172 370 0.86 0.69 1.08  
  Statin use No 675 1,319 1     
    Yes 98 183 1.04 0.79 1.36  
  Depression No 597 1,190 1     
    Yes 176 312 1.14 0.92 1.42  
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   Table 3.3 Covariates- by cancer type (continued)  
Cancer type Exposure Status Case Control OR 95% CI  
Breast Smoking status No 6,218 11,911 1      
  
 
Ex 1,181 2,172 1.05 0.97 1.14  
  
 
Yes 2,001 3,825 1.00 0.94 1.07  
    Missing 893 2,188 0.74 0.67 0.81 A? 
  Alcohol use No 1,845 3,805 1 
 
   
  
Ex 75 121 1.30 0.97 1.75  
  
Yes 6,533 12,289 1.11 1.04 1.18 A? 
    Missing 1,840 3,881 0.96 0.88 1.04  
  BMI Normal 202 452 1 
 
   
  
 
Underweight 3787 7,327 1.16 0.97 1.37  
  
 
Overweight 2779 5,273 1.18 0.99 1.40  
  
 
Obese 1142 2,093 1.22 1.02 1.47 A? 
  
 
Morbidly 
obese 484 917 1.18 0.97 1.44 
 
    Missing 1899 4,034 1.02 0.86 1.22  
  NSAID use No 7,478 14,582 1      
    Yes 2,815 5,514 1.00 0.94 1.05  
  Statin use No 9106 17,842 1      
    Yes 1187 2,254 1.01 0.96 1.05  
  Depression No 6927 13,978 1      
    Yes 3366 6,118 1.11 1.06 1.17 A? 
Colorectal Smoking status No 3,236 6,202 1      
  
 
Ex 1,225 2,139 1.11 1.02 1.21 A? 
  
 
Yes 1,162 2,131 1.05 0.96 1.14  
    Missing 609 1,538 0.71 0.64 0.80  
  Alcohol use No 923 1,868 1      
  
 
Ex 62 116 1.12 0.81 1.54  
  
 
Yes 4,056 7,419 1.12 1.02 1.23 A? 
    Missing 1,191 2,607 0.89 0.80 1.00 A? 
  BMI Normal 121 191 1      
  
 
Underweight 1841 3,607 0.81 0.64 1.03  
  
 
Overweight 2074 3,761 0.88 0.69 1.11  
  
 
Obese 694 1,194 0.93 0.72 1.19  
  
 
Morbidly 
obese 184 365 0.81 0.60 1.09 
 
    Missing 1318 2,892 0.70 0.55 0.89 A? 
  NSAID use No 4,087 7,693 1      
    Yes 2,145 4,317 0.93 0.87 0.99 A? 
  Statin use No 5126 9,869 1      
    Yes 1106 2,141 1.00 0.92 1.08  
  Depression No 4924 9,444 1      
    Yes 1308 2,566 0.98 0.91 1.06  
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   Table 3.3 Covariates- by cancer type (continued)  
Cancer type Exposure Status Case Control OR 95% CI  
Lung Smoking status No 1,286 6,096 1      
  
 
Ex 1,497 2,318 3.45 3.13 3.81 A? 
  
 
Yes 3,231 2,446 7.40 6.75 8.12 A? 
    Missing 523 1,654 1.36 1.19 1.55 A? 
  Alcohol use No 999 1,943 1      
  
Ex 115 145 1.59 1.23 2.06 A? 
  
Yes 4,105 7,758 1.03 0.94 1.13  
    Missing 1,318 2,668 0.94 0.84 1.04  
  BMI Normal 274 199 1      
  
 
Underweight 2369 3,671 0.46 0.38 0.56 A? 
  
 
Overweight 1772 4,058 0.31 0.25 0.37 A? 
  
 
Obese 499 1,299 0.27 0.22 0.34 A? 
  
 
Morbidly obese 134 364 0.26 0.20 0.35 A? 
    Missing 1489 2,923 0.36 0.29 0.43 A? 
  NSAID use No 3,958 7,957 1      
    Yes 2,579 4,557 1.15 1.08 1.23 A? 
  Statin use No 5430 10,403 1      
    Yes 1107 2,111 1.01 0.93 1.09  
  Depression No 4923 9,870 1      
    Yes 1614 2,644 1.24 1.16 1.34 A? 
Prostate Smoking status No 3,878 6,598 1 
 
   
  
 
Ex 1,833 3,284 0.97 0.90 1.04  
  
 
Yes 1,283 2,635 0.83 0.77 0.90 A? 
    Missing 537 1,812 0.46 0.41 0.51 A? 
  Alcohol use No 823 1,550 1      
  
 
Ex 82 172 0.92 0.70 1.21  
  
 
Yes 5,447 9,568 1.09 0.99 1.20  
    Missing 1,179 3,039 0.69 0.61 0.77 A? 
  BMI Normal 78 137 1      
  
 
Underweight 2279 4,019 0.99 0.74 1.31  
  
 
Overweight 3041 5,168 1.03 0.78 1.37  
  
 
Obese 707 1,388 0.89 0.66 1.20  
  
 
Morbidly obese 109 263 0.73 0.51 1.05  
    Missing 1317 3,354 0.64 0.48 0.85 A? 
  NSAID use No 4,610 8,853 1 
 
   
    Yes 2,921 5,476 1.02 0.96 1.09  
  Statin use No 6105 11,519 1      
    Yes 1426 2,810 0.96 0.90 1.04  
  Depression No 6117 12,110 1      
    Yes 1414 2,219 1.27 1.18 1.37 A? 
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3.3.3 Binary exposure 
The initial definition of a tricyclic user was someone with six or more prescriptions. This 
gave the results seen in Table 3.4. A significant reduction in tricyclic usage in colorectal 
cancer patients is observed (multivariate OR=0.87 CI= 0.77 W0.99). While tricyclic use is also 
lower in glioma cases than controls this effect is not significant (OR=0.70 CI=0.45 W1.08). 
Patients with other cancers of the nervous system had non-significantly higher tricyclic use 
than controls. For most cancer types there was little evidence found of confounding of the 
results by the available potential confounders, except for lung cancer patients, where 
smoking status had a large confounding effect. The significant increase in tricyclic use 
observed in the univariate model (OR=1.34 CI=1.20 W1.49) is reduced when adjusted for 
confounders (OR=1.15 CI=1.01 W1.30). This change is mostly attributable to confounding by 
smoking status, as adjusting only for this gives an odds ratio of 1.16 (CI=1.05-1.28). Other 
cancer types show little variation in drug usage, with odds ratios very close to unity. 
Table 3.4 Binary analysis- initial results 
        Univariate  Multivariate*  
Cancer type Exposed Case Control OR 95% CI  OR 95% CI  
Glioma No 735 1,390 1      1      
  Yes 38 112 0.70 0·46 1·08  0·70 0·45 1·08  
Colorectal No 5,823 11,105 1     1     
  Yes 409 905 0·87 0·77 0·98 A? 0·87 0·77 0·99 A? 
Brain No 1,267 2,444 1     1     
(excl glioma) Yes 93 198 1·22 0·86 1·74  1·17 0·82 1·67  
Breast No 9,321 18,167 1     1     
  Yes 972 1,929 0·98 0·91 1·07  0·98 0·90 1·07  
Lung No 5,929 11,607 1     1     
  Yes 608 907 1·34 1·20 1·49 A? 1·15 1·01 1·30 A? 
Prostate No 7,172 13,638 1     1     
  Yes 359 691 0·99 0·87 1·13  1·00 0·88 1·15  
All No 29,512 56,961 1     1     
  Yes 2,441 4,630 1·03 0·97 1·08  0·99 0·94 1·04  
*All cancer types adjusted for smoking status, BMI, alcohol use and diagnosed depression.  
Colorectal cancer is also adjusted for NSAID use. 
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It was suggested that the original definition of a user being someone with six or more 
prescriptions might introduce a disease severity bias. This led to a change in the definition 
such that patients with two or more prescriptions were users. It was also decided to add 
diagnosed depression into the multivariate model (see section 3.3.6). As a result of these 
changes the binary analysis results changed somewhat (Table 3.5). This analysis  still 
demonstrates a significant reduction in tricyclic usage in colorectal cancer patients 
compared to controls (multivariate OR=0.84 CI=0.75 W0.94). Tricyclic use is now significantly 
lower in glioma patients compared to controls, and has a larger effect estimate (OR=0.59 
CI=0.42 W0.81). Other brain tumours no longer exhibited higher tricyclic use in cases, while 
other results remained largely similar to the previous analysis. 
 
Table 3.5 Binary analysis- refined results 
        Univariate  Multivariate*  
Cancer type Exposed Case Control OR 95% CI  OR 95% CI  
Glioma No 706 1,317 1      1      
  Yes 67 185 0.66 0.49 0.89 A? 0.59 0.42 0.81 A? 
Colorectal No 5,574 10,543 1     1     
  Yes 658 1,467 0.85 0.77 0.94 A? 0.84 0.75 0.94 A? 
Brain No 505 1,013 1     1     
(excl glioma) Yes 94 151 1.26 0.95 1.67  1.00 0.72 1.38  
Breast No 8,651 16,834 1     1     
  Yes 1,642 3,262 0.98 0.92 1.05  0.97 0.91 1.04  
Lung No 5,555 10,992 1     1     
  Yes 982 1,522 1.30 1.19 1.42 A? 1.14 1.02 1.28 A? 
Prostate No 6,861 13,112 1     1     
  Yes 670 1,217 1.06 0.96 1.17  0.94 0.84 1.04  
All No 27,841 53,790 1     1     
  Yes 4,112 7,801 1.03 0.99 1.07  0.93 0.89 0.97  
*All cancer types adjusted for smoking status, BMI, alcohol use and diagnosed depression.  
Colorectal cancer is also adjusted for NSAID use. 
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3.3.4 Dose response 
When tricyclic exposure is coded as an ordered categorical variable with categories created 
according to the numbers of prescriptions used, an increasing protective effect with higher 
prescription numbers was observed for glioma, (test for trend P= 0.006) (Table 3.6). 
Colorectal cancer showed a slight trend towards lower occurrence in higher prescription 
categories, but there was no statistically significant trend (P=0.104). For other cancer types, 
no statistically significant trends were present.  
Table 3.6 Number of tricyclic prescriptions 
Cancer type Number of 
prescriptions 
OR 95% CI  
Glioma 0 1     
  1-10 0.88 0.65 1.19  
  11-50 0.51 0.29 0.89 A? 
  >50 0.46 0.20 1.08  
Colorectal 0 1     
  1-10 0.93 0.84 1.03  
  11-50 0.97 0.82 1.15  
  >50 0.85 0.67 1.09  
Brain 0 1      
  1-10 1.14 0.85 1.54  
  11-50 1.51 0.94 2.44  
  >50 0.87 0.41 1.82  
Breast 0 1      
  1-10 0.97 0.91 1.04  
  11-50 0.99 0.88 1.11  
  >50 1.10 0.94 1.30  
Lung 0 1      
  1-10 1.18 1.06 1.32 A? 
  11-50 1.07 0.90 1.28  
  >50 1.17 0.92 1.48  
Prostate 0 1     
  1-10 1.07 0.97 1.18  
  11-50 1.01 0.84 1.21  
  >50 0.94 0.71 1.25  
All 0 1     
  1-10 1.01 0.96 1.05  
  11-50 1.00 0.93 1.07  
  >50 1.02 0.92 1.13  
All cancer types adjusted for smoking status, BMI and alcohol use.  Colorectal cancer is also 
adjusted for NSAID use. 
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tŚĞŶƚƌŝĐǇĐůŝĐĞǆƉŽƐƵƌĞŝƐĚŝǀŝĚĞĚŝŶƚŽ ‘ůŽǁ ?ĂŶĚ ‘ŚŝŐŚ ?ĚŽƐĞĞǆƉŽƐƵƌĞ ?Table 3.7), odds of 
high dose users developing cancer are lower for both glioma (OR=0.49 CI=0.30 W0.78) and 
colorectal cancer (OR=0.79 CI=0.67 W0.93). Highly significant trends validate these findings 
further for glioma (P=0.0005) and colorectal cancer (P=0.0010). Other cancer types were 
considered in the same way, though no notable or statistically significant trends were 
present. 
Table 3.7 Dose response according to mean corrected dose 
Cancer Exposure Status Case Control OR 95% CI  p-trend  
Glioma Unexposed 707 1,323 1       
  Low dose 38 97 0.67 0.45 1.01     
  High Dose 28 82 0.49 0.30 0.78 A? 0.0005 A? 
Colorectal Unexposed 5,592 10,595 1       
  Low dose 382 821 0.87 0.76 1.00 A?    
  High dose 258 594 0.79 0.67 0.93 A? 0.0010 A? 
Brain Unexposed 619 1.218 1      
 Low dose 68 85 1.54 1.08 2.19 A?   
 High Dose 37 103 0.70 0.47 1.04  0.0780  
Breast Unexposed 8,651 16,834 1      
 Low dose 875 1,747 0.97 0.89 1.05    
 High dose 767 1,515 0.98 0.89 1.07  0.6993  
Lung Unexposed 5,555 10,992 1      
 Low dose 526 893 1.13 0.97 1.25    
 High Dose 456 629 1.16 0.98 1.35  0.0811  
Prostate Unexposed 6,861 13,112 1      
 Low dose 385 699 1.04 0.91 1.18    
 High dose 285 518 1.07 0.92 1.24  0.6132  
All cancer types adjusted for smoking status, BMI, alcohol use and diagnosed depression.  
Colorectal cancer is also adjusted for NSAID use. High and low dose categories are created 
according to whether a ƉĂƚŝĞŶƚ ?Ɛ corrected dose was above or below the mean. 
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3.3.5 Timing/duration of exposure 
I then went on investigate the relationship between the timing of the first prescription of 
tricyclics and cancer risk. Glioma exhibits a strong, significant trend (P= 0.006) towards 
reduced cancer incidence with tricyclic treatment beginning earlier (Table 3.8). A similar 
trend is shown with colorectal cancer, with lower cancer incidence observed with earlier 
treatment with tricyclics. Colorectal cancer incidence is almost 25% less in the earliest 
treatment category and the test for trend confirms this (P= 0.003). As with the dose 
response analysis, the data from the other cancer types were analysed in the same way, 
but this analysis did not demonstrate any statistically significant trends. 
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Table 3.8 Timing of exposure 
Cancer 
type 
Time of 
exposure 
(years) 
OR 95% CI 
 
Glioma Never 1      
  1-5 1.03 0.65 1.62  
  5-10 0.82 0.54 1.25  
  >10 0.57 0.32 1.02  
Colorectal Never 1      
  1-5 1.11 0.96 1.27  
  5-10 0.93 0.82 1.06  
  >10 0.76 0.66 0.89 A? 
Brain Never 1     
  1-5 1.15 0.79 1.68  
  5-10 1.01 0.71 1.44  
  >10 0.91 0.61 1.38  
Breast Never 1     
  1-5 0.97 0.88 1.07  
  5-10 0.97 0.89 1.05  
  >10 1.03 0.93 1.13  
Lung Never 1     
  1-5 1.17 1.01 1.36 A? 
  5-10 1.25 1.09 1.43 A? 
  >10 1.02 0.87 1.19  
Prostate Never 1      
  1-5 0.97 0.84 1.11  
  5-10 1.12 0.99 1.28  
  >10 1.04 0.89 1.21  
All Never 1      
  2-5 1.03 0.97 1.09  
  5-10 1.02 0.97 1.08  
  >10 0.96 0.90 1.02  
All cancer types adjusted for smoking status, BMI and alcohol use.  Colorectal cancer is also 
adjusted for NSAID use. 
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It was decided that the above analysis did not provide a sufficient indication of the length 
and consistency of exposure. Categorising by the number of days the drug was prescribed 
for seemed a better way of doing this. When this analysis was carried out (Table 3.9), long 
term tricyclic use is significantly lower in glioma cases (OR= 0.36 CI= 0.19 W0.69) and 
colorectal cancer cases (OR= 0.82 CI= 0.68-0.97). Highly significant trends were observed 
for glioma (P= 0.0005) and colorectal cancer (P= 0.0086). No notable or statistically 
significant trends were present for other cancer types. 
Table 3.9 Duration of exposure 
Cancer Total days 
of 
exposure 
Case Control OR 95% CI  p-trend  
Glioma Unexposed 399 1,051 1       
  1-117 22 71 0.65 0.37 1.13     
  >117 14 75 0.36 0.19 0.69 A? 0.0005 A? 
Colorectal Unexposed 3,598 7,752 1       
  1-117 345 747 0.84 0.70 1.01     
  >117 305 785 0.82 0.68 0.97 A? 0.0086 A? 
Brain Unexposed 699 1,820 1      
 1-117 53 133 0.81 0.55 1.18    
 >117 50 132 0.77 0.52 1.14  0.2850  
Breast Unexposed 6,751 13,383 1      
 1-117 646 1,318 0.91 0.82 1.02    
 >117 632 1,267 0.89 0.80 1.01  0.0854  
Lung Unexposed 2,711 8,577 1      
 1-117 273 581 1.13 0.93 1.39    
 >117 284 618 1.15 0.94 1.41  0.2449  
Prostate Unexposed 5,185 10,044 1      
 1-117 261 483 0.91 0.77 1.08    
 >117 231 422 0.89 0.74 1.07  0.3211  
All cancer types adjusted for smoking status, BMI, alcohol use and diagnosed depression.  
Colorectal cancer is also adjusted for NSAID use. 
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3.3.6 Confounding by indication 
When SSRI use was examined in the same way as tricyclics were in the binary analysis, no 
significant multivariate results are found (Table 3.10). However, the results do exhibit a 
similar pattern to the tricyclic analysis, which warrants further investigation. 
Table 3.10 SSRI use- binary analysis 
        Univariate  Multivariate* 
Cancer type Exposed Case Control OR 95% CI  OR 95% CI 
Glioma No 729 1,391 1     1    
  Yes 44 111 0.77 0.53 1.10  0.77 0.53 1.11 
Colorectal No 5,808 11,118 1      1     
  Yes 424 892 0.93 0.82 1.05  0.92 0.82 1.05 
Brain No 539 1,064 1      1     
(excl glioma) Yes 60 100 1.21 0.86 1.70  1.14 0.81 1.62 
Breast No 9,126 17,840 1      1     
  Yes 1,167 2,256 1.02 0.95 1.10  1.02 0.94 1.10 
Lung No 5,982 11,640 1      1     
  Yes 555 874 1.27 1.13 1.42 A? 1.09 0.96 1.24 
Prostate No 7,103 13,550 1      1     
  Yes 428 779 1.06 0.94 1.20  1.04 0.92 1.18 
All No 29,275 56,581 1     1    
  Yes 2,678 5,010 1.05 1.00 1.11 A? 1.01 0.96 1.06 
*All cancer types adjusted for smoking status, BMI, alcohol use and diagnosed depression.  
Colorectal cancer is also adjusted for NSAID use. 
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Dividing the exposures into those given only tricyclics, only SSRIs and those given both 
drugs (Table 3.11) appears to negate most of the apparent effects in SSRIs, while a lot of 
the effects for tricyclics remain. For glioma, SSRI use without tricyclic use showed little 
deviation between cases and controls (OR= 0.96 CI= 0.61 W1.53). This is in contrast to 
tricyclic use with (OR= 0.50 CI= 0.27 W0.92) and without (OR= 0.74 CI= 0.52 W1.06) SSRI use. 
Colorectal cancer was similar to glioma in terms of exclusive SSRI use (OR= 0.95 CI= 0.81 W
1.12), and showed a similar pattern to the above binary analysis for tricyclic use with SSRI 
use (OR= 0.85 CI= 0.70 W1.02), and exclusive tricyclic use (OR= 0.85 CI= 0.76 W0.95). Patients 
treated with both drugs exhibiting a stronger effect size for glioma could be indicative of 
confounding by indication, but this is dissected further in the investigation of the effect of 
depression. 
  
82 
 
 
Table 3.11 Tricycic/SSRI exposure stratification (multivariate) 
Cancer 
type 
Exposure OR 95% CI  
Glioma Unexposed Reference  
  Tricyclic only 0.74 0.52 1.06  
  SSRI only 0.96 0.61 1.53  
  Both 0.50 0.27 0.92 A? 
Colorectal Unexposed Reference  
  Tricyclic only 0.85 0.76 0.95 A? 
  SSRI only 0.95 0.81 1.12  
  Both 0.85 0.70 1.02  
Brain Unexposed Reference  
  Tricyclic only 1.11 0.79 1.57  
  SSRI only 1.00 0.61 1.64  
  Both 1.33 0.83 2.14  
Breast Unexposed Reference  
  Tricyclic only 0.97 0.89 1.04  
  SSRI only 1.02 0.92 1.12  
  Both 1.00 0.90 1.12  
Lung Unexposed Reference  
  Tricyclic only 1.13 1.01 1.27 A? 
  SSRI only 1.08 0.91 1.28  
  Both 1.14 0.95 1.38  
Prostate Unexposed Reference  
  Tricyclic only 1.03 0.92 1.16  
  SSRI only 1.03 0.88 1.21  
  Both 1.07 0.88 1.29  
All Unexposed Reference  
  Tricyclic only 0.92 0.87 0.97 A? 
  SSRI only 0.92 0.86 0.99 A? 
  Both 0.90 0.83 0.98 A? 
All cancer types adjusted for smoking status, BMI, alcohol use and diagnosed depression.  
Colorectal cancer is also adjusted for NSAID use. 
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Due to the long term nature of diseases such as depression it is not possible to directly link 
each prescription to an indication. It was however possible to determine whether each 
patient had a diagnosis of depression at any point during their registration, and this 
seemed to be the best proxy for antidepressant indication. If depression is added as a 
covariate in the regression model the size of effect appears to increase the size of effect of 
tricyclics on glioma. This is reflected in the stratified analysis and interaction terms (see 
table below). Depression appears to have little effect on colorectal cancer. 
 
Table 3.12 Effect of depression 
Cancer 
type 
Analysis Exposure Odds 95% CI  
Glioma Depression as a covariate Unexposed Reference  
   Exposed 0.59 0.42 0.81 A? 
  Stratified- Depression Unexposed Reference  
   Exposed 0.35 0.15 0.81 A? 
  Stratified- No Depression Unexposed Reference    
   Exposed 0.90 0.52 1.54  
  Interaction terms Unexposed Reference      
   Tricyclic 0.93 0.57 1.50  
   Depression 1.50 1.16 1.95  
    Tricyclic x Depression 0.46 0.24 0.87 A? 
Colorectal Depression as a covariate Unexposed Reference  
   Exposed 0.84 0.75 0.94 A? 
  Stratified- Depression Unexposed Reference  
   Exposed 0.94 0.73 1.22  
  Stratified- No Depression Unexposed Reference  
   Exposed 0.98 0.81 1.19  
  Interaction terms Unexposed Reference     
   Tricyclic 0.94 0.79 1.12  
   Depression 1.07 0.97 1.17  
    Tricyclic x Depression 0.83 0.66 1.03  
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Although it is still possible that confounding by indication may explain these data, it 
appears unlikely that depression would reduce the risk of any cancer. It seems more likely 
to us that depression is a proxy for high dose tricyclics (Table 3.13). Depression tends to 
require higher doses than other indications such as pain management and as is 
demonstrated in the dose analysis, tricyclics appear to be more effective at higher dose. 
Table 3.13 Depression vs dose 
Depression Tricyclic dose 
  Low dose 
(frequency) 
% High dose 
(frequency) 
% 
No 2584 75.71 829 24.29 
Yes 4008 47.15 4492 52.85 
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3.4 Discussion 
 
3.4.1 Summary of findings 
The data presented in this study shows that tricyclic use in man may be associated with a 
subsequent reduction in the risk of developing glioma and colorectal cancer. These 
protective effects appear to be specific to these particular cancers, as such protection was 
not observed for the other cancer types studied, although a protective effect in cancer 
types not included in the study cannot be ruled out. The data also indicate that these 
apparent protective effects are greatest for patients receiving high dose prescriptions over 
a long period of time. 
There did appear to be an increase in risk of lung cancer development in tricyclic users. This 
increase in risk is observed to be highest in the unadjusted model, and is more than halved 
when the various covariates are taken into account. Smoking is thought to be the primary 
cause of this confounding and given that there is missing smoking data, coupled with the 
potential for misclassification of smoking status by GPs, it is highly likely that a large part of 
the remaining observed effect (a marginally significant 15% increase in risk) is due to 
residual confounding by smoking. The lack of a consistent tricyclic dose or duration based 
trend also suggests that there is no true association between lung cancer and tricyclic use. 
3.4.2 Method refinements 
As this was the first of the studies carried out within this thesis, there were a number of 
substantial refinements to the methods during the study. The most obvious of these are 
the changes to the dose and duration analyses. 
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Originally I used the number of prescriptions that each patient received as a proxy for dose. 
This was a somewhat crude method, and there was also an element of exposure duration 
in this analysis. To better determine the true effect of dose it was decided that the mean 
dose per prescribed day would be used. This was not a perfect method of determining 
dose, due to the need to standardise the dosing across multiple drug types. However, it 
does still provide a good measure of what dose each patient received, and produced a 
good dose response correlation. 
For the analysis of duration, the original method of using the time of first exposure was 
again somewhat crude, as it did not account for the consistency of exposure between first 
prescription and diagnosis. The revised method instead used the total number of days for 
which tricyclics were prescribed. While this method did not describe the total time period 
over which a patient was exposed to tricyclics, it did offer a much better representation of 
the number of days exposed for. 
Though it seemed logically unlikely, confounding by indication was still a possible 
alternative explanation for the results found. However, the investigation of this matter by 
looking at the effect of SSRIs and diagnosis of depression confirms that confounding by 
indication is not a likely explanation. 
The fairly substantial changes to the methods seen in this chapter, such as the confounding 
by indication investigation, could have led to the results changing in either direction. 
However, despite these various changes, the message delivered by the results throughout 
was consistent, with the odds ratio for glioma and colorectal cancer showing a fairly 
consistent protective effect for tricyclic use in terms of size and direction. The other 
cancers consistently did not exhibit this protective effect. 
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3.4.3 Strengths and weaknesses 
The data presented here have a number of important strengths compared to previous 
reports. The use of routinely collected general practice records (from the GPRD) ensures 
that there is no opportunity for recall bias to effect the ascertainment of exposures. In 
addition, by selecting all relevant malignancies within the population and a random sample 
of the suitable controls, the possibility of selection bias was dramatically reduced. 
However, the selection of data does have some weaknesses. Though the numerous 
validation studies of a variety of diagnoses in this dataset suggest that the outcomes are 
likely to be accurately coded (Jick et al. 1991; Fombonne et al. 2004; Herrett et al. 2010), 
and the prospective electronic recording of prescription data suggests the same for the 
primary exposure, it is difficult to be equally confident about the recording of all potential 
confounders. As can be seen from Table 2 there is much missing data with respect to 
smoking, obesity and alcohol. There is clearly therefore a potential for residual confounding 
by these factors. However I believe that with the exception of lung cancer where this is 
clearly an issue (and residual confounding by smoking might account for the positive 
association with tricyclics), the close similarity between univariate and multivariate models 
suggests that any residual confounding from these additional factors will be minor. A 
potentially greater issue is that the study lacks any data on other potential confounders 
such as diet and exercise, and therefore their impact on the results cannot be assessed. 
Another strength of the study is that I have been able to study several cancer types and to 
demonstrate that the protective antineoplastic effect of tricyclics appears to be specific to 
certain malignancies. I have also been able, due to the size of this study, to subdivide 
exposure further and hence demonstrate that longer term use and higher doses of 
tricyclics appear to give greater protection from developing glioma and colorectal cancers. 
As the proposed anti-cancer mechanism of action is a mitochondrial one (Daley et al. 2005) 
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and independent of the psychoactive mechanism of action, there is good reason to believe 
ƚŚĂƚƚŚĞƐĞĨŝŶĚŝŶŐƐĂƌĞŐĞŶĞƌĂůŝƐĂďůĞ ?ĂŶĚŶŽƚƌĞƐƚƌŝĐƚĞĚŽŶůǇƚŽĂ “ĚĞƉƌĞƐƐĞĚ ?ƉŽƉƵůĂƚŝŽŶ ? 
3.4.4 Confounding by indication 
Confounding by indication is an important factor to investigate in this study. In the binary 
analysis of SSRIs, they display a similar pattern to tricyclics, this may be due to SSRI use 
being predictive of tricyclic use. If patients using SSRIs exclusively (i.e. no tricyclics) are 
considered, most of the effect disappears. The multivariate results were adjusted for 
diagnosis of depression, and this adjustment increased the apparent protective effect of 
tricyclics. From a biological plausibility point of view, depression seems more likely to 
increase cancer risk than decrease it. This has been suggested in a variety of studies, and 
could possibly be mediated through depression causing suppression of the immune system 
(reviewed in (Reiche et al. 2004)). It is therefore likely that depression is a proxy for high 
dose tricyclics (as depression is usually treated with a higher dose than other tricyclic 
indications, such as pain). This is supported by a relationship between dose and depression 
(where those without depression have a higher proportion of low dose and vice versa). 
3.4.5 Comparison with previous literature 
As mentioned above there have been previous epidemiological studies in this area. These 
have examined the incidence of colorectal cancer (Xu et al. 2006), prostate cancer (Tamim 
et al. 2008), breast cancer (Cotterchio et al. 2000; Gonzalez-Perez et al. 2005; Fulton-Kehoe 
et al. 2006; Wernli et al. 2009) and lung cancer (Toh et al. 2007a) in relation to tricyclic use.  
However, little consistent, significant evidence has been found to link tricyclics with 
changes in cancer incidence. Of perhaps greatest interest here are the studies looking in 
more detail at the malignancies in which relationships have been shown. 
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In their study on colorectal cancer Xu et al (2006) hypothesized that tricyclics may be 
genotoxic, and would therefore increase cancer risk. However, their results suggest a non-
significant protective effect, while another recent study using a different type of data 
source (Coogan et al. 2009) confirms these findings. The Xu et al study used data from the 
Saskatchewan Cancer Agency registry, which contains broadly similar data to the GPRD. In 
the study there were approximately half the number of cases than in the present study, 
which pay in part explain the lack of significant findings, despite the similar effect size. 
Additionally, the present study uses slightly more extensive analysis, in that dose could be 
investigated, where as It was not by Xu et al. The prostate cancer study (Tamim et al. 2008) 
also uses the Saskatchewan database. While this study does find a small increase in risk of 
prostate cancer in tricyclic users, the authors attribute this to detection bias. This is due to 
the apparently short latency period between exposure and diagnosis, and therefore the 
lack of etiological plausibility. 
Coogan et al (2009) used survey based data, which were collected at various times and 
locations. While this approach can provide richer and more specific data, it is also more 
labour intensive (as it is not routinely collected). Hence this study has a smaller sample size 
than in this thesis, which is likely to have contributed to the lack of significant findings. The 
findings in this thesis for colorectal cancer fit well with these previous data, with the added 
benefit of ƚŚĞƐƚƵĚǇ ?Ɛ ability to show statistically significant protection. This is a function of 
the greater numbers of cases and case controls used in the study. 
The previous lung cancer study (Toh et al. 2007a) showed an apparent increase in risk of 
lung cancer with tricyclic use, which is largely mitigated by adjusting for confounders 
(including smoking status). This is remarkably consistent with the data presented in this 
thesis. Another UK primary care database, The Health Improvement Network (THIN) (which 
shares many GPs with the GPRD) was used as a data source in this study. Despite smoking 
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status being more comprehensively classified in this study, there was still substantial 
missing data on this clearly important confounding variable. 
Studies which looked at breast cancer are slightly more numerous, perhaps reflecting the 
greater incidence of breast cancer. Of these, the study by Cotterchio et al (2000) is the only 
study to find an significant change (increase) in breast cancer risk. These results are 
margŝŶĂůůǇ ƐŝŐŶŝĨŝĐĂŶƚ ? ďĂƐĞĚ ŽŶ Ă ƐŵĂůů ƐĂŵƉůĞ ƐŝǌĞ  ? ? ? ? ? ĐĂƐĞƐ ) ĂŶĚ ƚŚĞ ĂƵƚŚŽƌ ?Ɛ
conclusions have been criticised for being somewhat overzealous (Lawlor 2000). The other 
studies (Gonzalez-Perez et al. 2005; Fulton-Kehoe et al. 2006; Wernli et al. 2009) are based 
on larger datasets of 3-4 thousand patients and do not find any associations between 
antidepressant use and breast cancer risk. 
3.4.6 Interpretation 
How then should these findings be interpreted? I have found a significant reduction in 
incidence of colorectal cancer and glioma in a manner consistent with previous laboratory 
evidence (Daley et al. 2005) and not inconsistent with other epidemiological studies. The 
findings show specificity of protection against those malignancies I originally hypothesised 
might be affected and show a dose response relationship and a clear temporal relationship. 
It remains credible that the associations I have found may be causal, however the modest 
size of the effect demonstrated limits the potential of these drugs as a chemopreventative 
agent in the general population. Groups at increased risk of colorectal cancer (e.g. those 
with a familial or other genetic predisposition to the disease) might still represent a group 
in whom an RCT could be appropriate as they would have the best chance of benefitting 
from chemoprevention. Even here though, one would need to balance potential benefits 
against possible side effects. As glioma is a rare cancer with ill-defined high risk groups, 
prescribing chemopreventative drugs is of limited value in the general population. As an 
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illustration of this, I estimate that approximately 40,000 people would need to be treated 
(for >117 days) in order to prevent one glioma. 
If the antineoplastic effects of this group of drugs are to be therapeutically useful 
therefore, it is likely to be either after the identification of an individual compound within 
the group which is the most potent, or in post diagnosis treatment of both colorectal 
cancer and glioma. As an illustration of the potential of the latter, aspirin, a recognized 
prophylactic for colorectal cancer has recently been demonstrated to reduce colorectal 
cancer specific mortality when used after diagnosis (Chan et al. 2009; Zell et al. 2009). The 
effect demonstrated here is of a magnitude similar to that achieved previously only by far 
more toxic compounds and it would therefore certainly be useful to discover whether 
tricyclics have similar effects on colorectal cancer and glioma. 
This is the aim of the next study.  
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4 Tricyclic antidepressants and cancer survival 
A cohort study using the GPRD 
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4.1 Introduction 
The reduction in incidence of glioma and colorectal cancer caused by tricyclic 
antidepressants described in the previous chapter is intriguing and further hints at their 
anti-cancer action. However, their immediate use as an anti-cancer agent is more likely to 
be in treatment, rather than chemoprevention, as explained at the end of Chapter 3. The 
premise of this chapter is therefore to attempt to determine whether the previously 
suggested cancer prevention action of tricyclics translates into a reduction in mortality in 
cancer patients using these drugs. 
4.1.1 Conventional treatment for glioma/colorectal cancer 
Conventional chemotherapeutic agents often have unpleasant side effects and despite 
advances over recent years often produce benefits which are limited for many patients. 
For both glioma and colorectal cancer, curative treatment can sometimes be achieved 
through surgery alone. This is highly dependent on the stage of the cancer, with most 
localised colorectal tumours being treated in this way, while later stages are likely to 
require chemotherapy and/or radiotherapy. First line chemotherapy for colorectal cancer 
often consists of either 5-fluorouracil/leucovorin or oxaliplatin. These are also commonly 
used for adjuvant treatment. Also, recently the use of bevacizumab in combination with 
one of these drugs has become more common in metastatic disease. Radiotherapy is not 
commonly used for first line treatment of colon cancer, but is often used as a neoadjuvant 
in rectal cancer, or for palliative treatment. 
For later stage glioma, treatment options are more limited. Combinations of radiation, 
surgery and chemotherapy using temozolomide are often used. Despite this, prognosis for 
grade IV gliomas such as glioblastoma multiforme is bleak, with the main aim of treatment 
in these cases to extend life and palliate symptoms rather than cure. 
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The search for less toxic and more efficacious drugs is therefore vital to patients. 
4.1.2 Tricyclics and cancer 
As this has been covered in detail in Chapter 3, only a brief revision of previous evidence of 
the anti-cancer effects of tricyclics is included here. 
Tricyclic antidepressants, conventionally used in the treatment of psychological disorders, 
such as depression, anxiety, insomnia and some types of chronic pain, may have an anti-
cancer action. Laboratory evidence has demonstrated anticancer effects in several 
tricyclics, including chlorimipramine (clomipramine), imipramine, citalopram, amitriptyline, 
and desipramine (Xia et al. 1999; Arimochi et al. 2006). This includes in vitro data which 
suggest tricyclics can have cytotoxic actions in various cancer cell lines including glioma 
cells (Xia et al. 1999; Daley et al. 2005; Levkovitz et al. 2005) and colorectal cancer cells 
(Arimochi et al. 2006). The mechanism for this anticancer action may be inhibition of 
mitochondrial complex III activity, leading to a decrease in mitochondrial membrane 
potential and apoptosis (Weinbach et al. 1986; Daley et al. 2005; Higgins et al. 2010). 
Animal studies substantiate this anticancer action in various cancer models, such as 
sarcoma, lymphocytic leukaemia and leukaemia grown as a solid tumour (Tsuruo et al. 
1983; Merry et al. 1991; Pommerenke et al. 1995). Glioma is the most studied of the cancer 
ƚǇƉĞƐ ŝŶ ƌĞůĂƚŝŽŶ ƚŽ ƚŚĞ ƚƌŝĐǇĐůŝĐƐ ? ĂŶƚŝĐĂŶĐĞƌ ĂĐƚŝŽŶ ĂŶĚ ƌĞƐĞĂƌĐŚ ŝŶ ƚŚŝƐ ĂƌĞĂ ĞǆƚĞŶĚƐ ƚŽ
preliminary clinical studies in humans using chlorimipramine therapeutically (Beaney et al. 
2005). 
4.1.3 Rationale for study 
The previous chapter demonstrated that tricyclics appear to reduce the incidence of both 
colorectal cancer and glioma in vivo (Walker et al. 2011). This study showed that glioma 
incidence was reduced by around 50% with higher dose tricyclic use, while colorectal 
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cancer incidence was reduced by a more modest but still highly significant amount. The 
need however to treat large numbers of people when using drugs as chemotherapeutics 
means that they cannot realistically be so used at present. The reason for this is that their 
side effect profile would outweigh any benefit from reduction in cancer incidence if used in 
the general population. My previous results do however encourage the search for evidence 
of the efficacy of tricyclics as an adjuvant treatment in glioma and colorectal cancer 
patients, which could be of immediate benefit to patients. This is because the side effects 
of tricyclics are very mild in comparison to chemotherapeutics. 
The BNF (edition 60), is very clear about the risks of cytotoxic drug use. It states that in 
addition to their anti-cancer action, they have the potential to damage normal tissue and 
are teratogenic. In addition to this it has stringent guidelines for their handling, including: 
Use of trained personnel, protective clothing, eye protection and monitoring of staff 
exposure to the drugs. Side effects common to most cytotoxic drugs are listed as: 
x Severe tissue necrosis if leakage into an extravascular compartment occurs- 
common if incorrectly administered. 
x Oral mucositis is common with fluorouracil, methotrexate, and the anthracyclines. 
x Tumour lysis syndrome is a condition caused by rapid destruction/necrosis of 
cancer tissue. This can cause imbalances in various electrolytes in the blood, renal 
damage and arrhythmias. 
x Nausea and vomiting is common with most cytotoxics, especially cisplatin, 
dacarbazine, and high doses of cyclophosphamide. 
x Bone marrow suppression is caused by all cytotoxic drugs apart from vincristine 
and bleomycin. Due to increased risk of infection, and other conditions such as 
anaemia, it is a common limiting factor in treatment, as it often requires reduction 
or delaying of treatment to allow blood cell counts to recover. 
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x Alopecia is a well known side effect that occurs with some drugs, though it is 
generally reversible. 
x Reproductive function can be affected, sometimes including permanent male 
sterility, premature menopause. Also due to their teratogenic properties, use in 
pregnancy is not recommended. 
x Venous thromboembalism risk is increased by cytotoxics (beyond the increase in 
risk already seen in cancer patients). 
While tricyclic antidepressants do have a number of side effects associated with them, 
these are generally less serious and/or less common than for cyctotoxic drugs. Additionally, 
some tolerance to these side effects can develop: 
x Risk in overdose due to their cardiovascular and epileptogenic effects is an 
important consideration when determining dosage. 
x Arrhythmias and heart block can occur occasionally, particularly in patients with 
cardiovascular disease. 
x CNS side effects, including anxiety, dizziness, agitation, confusion, sleep 
disturbances, irritability, and paraesthesia are quite common. 
x Antimuscarinic side-effects including dry mouth, blurred vision, constipation, and 
urinary retention. 
x Endocrine effects including breast enlargement, galactorrhoea, gynaecomastia and 
sexual dysfunction may occur. 
x Other side effects can include nausea, vomiting and suicidal behaviour in some 
patients. 
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 Given the apparent anti-cancer effects of tricyclics and their great advantages in terms of 
toxicity, I therefore carried out a cohort study using the General Practice Research 
Database, with the hypothesis that tricyclic use would improve survival in patients with 
glioma or colorectal cancer. 
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4.2 Methods 
4.2.1 Study design 
A prospective cohort study was carried out using the GPRD to determine the relationship 
between tricyclic drug usage and survival, post cancer diagnosis. 
4.2.2 Subjects 
Any person with a recorded diagnosis of colorectal cancer or glioma within the GPRD was 
selected occurring at least one year after their entry to the database. Patient data were 
collected from the beginning of the GPRD database (1987), up to the last available data in 
the database (2010). Patients with a previous diagnosis of the cancer being studied (either 
glioma or colorectal cancer) were excluded from the cohort, as were patients contributing 
less than 6 months of data to the GPRD. 
4.2.3 Outcome and exposures 
The outcome to be observed was all cause mortality. Date of patient death was determined 
from the existence of one of two records; either a patient wŝƚŚ Ă  “dƌĂŶƐĨĞƌ ŽƵƚ ƌĞĂƐŽŶ ?
ƐƉĞĐŝĨŝĞĚ ĂƐ  “ĚĞĂƚŚ ? ? Žƌ ďǇ Ă  “^ƚĂƚĞŵĞŶƚ KĨ ĞĂƚŚ ?  ?^Ž ) ĐŽĚĞ  ?Ă  “ůŝŶŝĐĂů ?Žƌ  “ZĞĨĞƌƌĂů ?
event with a Read/OXMIS code indicating a death).  Where both records existed, the date 
of death was determined preferentially from the SoD code. The survival time was 
determined to be the time between diagnosis and the death date determined by the above 
method. Follow up time for patients not dying in the study was determined either from the 
date that the patient transferred out from the GP or by the last data collection date for the 
GP. 
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The primary exposure was the use of tricyclic antidepressants (section 4.3.3 of the British 
National Formulary (BNF)). To be exposed, a patient must have had a repeat prescription 
(A?2) within the period being examined for exposure. In order to minimise reverse causality 
(i.e. patients who die soon after diagnosis being less likely to receive a prescription) a fixed 
period of 6 months post-diagnosis was used to determine drug exposure and patients who 
died or were censored within this period were excluded from the analysis. In addition, a 3 
month period post diagnosis was examined for drug exposure, to explore any early effects 
on mortality. 
Pre-diagnosis exposure was considered to determine whether it influenced the effect of 
post-diagnosis exposure. This was done in two ways; 1) by adjusting for pre-diagnosis use in 
the Cox proportional hazards model, and 2) by stratifying the analysis according to whether 
patients received pre-diagnosis tricyclics. 
Potential associations were examined further by investigating the dose used. To allow 
comparison of the effect of high and low doses across all the tricyclics. I standardized the 
definition of high dose and low dose between drugs relative to the maximum 
recommended doses for each drug (determined from the BNF). These standardized doses 
were then used to calculate the mean dose across all prescriptions for each patient 
individually. Patients with tricyclic use were divided into 'high' dose or 'low' dose groups 
based on the median corrected dose of 0.31 times maximum recommended dose.  
4.2.4 Other covariates 
I extracted data on gender, age, smoking status, alcohol use, body mass index (BMI), 
diagnosis of depression and comorbidity (coded as the Charlson Index (Charlson et al. 
1987)). Of these potential confounders, gender, age and smoking status were retained in 
multivariate models as a priori predictors of mortality risk. Other covariates were only 
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retained in the multivariate model if they produced a 10% or greater change in the 
measured size of effect. 
4.2.5 Statistical methods 
I used Cox proportional hazards modelling to assess the effect of tricyclic antidepressants 
on mortality risk, adjusting for multiple potential confounding variables as described above. 
Results are presented as hazard ratios (HR), with accompanying 95% confidence intervals 
(CIs).  
Validity of the proportional hazards assumption was tested using a log-log plot. If the 
proportional hazards assumption was found to be violated, this non proportionality was 
then further characterised. The approximate time period that a change in effects occurred 
was determined by using observed/predicted survival curves and observing where the 
observed curve deviated from the predicted. No serious violation of the proportional 
hazards assumption was found during this study, indicating that the effect size (hazard 
ratio) did not vary according to time since diagnosis of the cancer. 
All data handling and analysis was done using Stata v11.1 SE (Statacorp, 4905 Lakeway 
Drive, College Station, Texas 77845 USA). 
Further details of how and why the various statistical methods in this chapter (and chapter 
5) were used can be found in Appendix III. 
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4.3 Results 
4.3.1 Study population/ covariates 
2592 patients with glioma and 22,524 patients with colorectal cancer were identified. Of 
these patients, 1227 (47.3%) glioma and 6004 (26.7%) colorectal cancer patients were 
excluded from most of the study, as their death or loss to follow up occurred during the 6 
month post diagnosis period being examined for exposure. Analysis was carried out on the 
remaining cohort, where there were 679 deaths in the glioma group and 6,947 deaths in 
the colorectal cancer group. Median time of post diagnosis follow-up for those remaining 
alive to the end of follow-up was 3.2 years for glioma and 3.7 years for colorectal cancer. In 
total, 4.2% for glioma patients and 4.1% for colorectal cancer patients received tricyclic 
prescriptions (A?2 prescriptions between diagnosis and 6 months post diagnosis, as defined 
in methods). The patient population is summarised, along with other covariates used in the 
study in Table 4.1.  
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Table 4.1 Population/covariates 
Cancer type 
  Tricyclic 
user 
% 
Tricyclic 
nonuser 
% 
Glioma All patients   57  1307  
 Women   39 68.4 547 41.8 
  Mean age (SD)   56.7 (14.4) 45.5 (20.7) 
  Mean BMI   26.5 (4.2) 26.1 (4.9) 
  Smoking status No 29 50.9 661 50.6 
   Ex 10 17.5 205 15.7 
   Yes 13 22.8 227 17.4 
   Missing 5 8.8 214 16.4 
  Alcohol use No 9 15.8 166 12.7 
   Ex 1 1.8 25 1.9 
   Yes 36 63.2 753 57.6 
   Missing 11 19.3 363 27.8 
  Mean Charlson Index   11.6 (6.2) 10.0 (7.7) 
  Diagnosed depression   33 57.9 272 20.8 
Colorectal All patients   669  15 850  
 Women   425 63.5 7011 44.2 
  Mean age   70.6 (11.4) 69.7 (11.6) 
  Mean BMI   26.5 (4.9) 26.4 (4.5) 
  Smoking status No 331 49.5 8357 52.7 
   Ex 180 26.9 4445 28.0 
   Yes 128 19.1 2280 14.4 
   Missing 30 4.5 768 4.9 
  Alcohol use No 150 22.4 2438 15.4 
   Ex 26 3.9 273 1.7 
   Yes 404 60.4 10 919 68.9 
   Missing 89 13.3 2220 14.0 
  Mean Charlson Index   12.7 (8.3) 10.4 (7.5) 
  Diagnosed depression   401 59.9 3176 20.0 
Numbers in table represent N (%) for categorical variables and Mean (SD) for continuous 
variable 
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4.3.2 Binary analysis- glioma 
I found that post diagnosis tricyclic use (Table 4.2) was associated with a non-significant 
decrease in the hazard ratio among glioma patients (multivariate HR=0.83 95% confidence 
interval (CI) =0.53-1.28). This is similar when 3 months post diagnosis are used to 
determine exposure, rather than 6 months (HR=0.87 CI=0.57-1.33). This effect is due 
entirely to those not exposed to tricyclics before diagnosis. The size of effect was larger in 
this group, though still non-significant (HR=0.54, CI=0.25-1.14). In contrast to this, there 
was no substantial difference in mortality risk for those exposed to tricyclics pre diagnosis. 
If pre diagnosis tricyclic use is considered exclusively, there was no association with survival 
in glioma patients (multivariate HR=1.05 CI=0.88-1.25). This analysis using pre diagnosis 
exposure included the patients excluded in the rest of the study. Age was found to be an 
important confounding factor in this analysis, as tricyclic users tend to be older than non-
users. For this reason, only age adjusted results are displayed in the table. If an entirely 
univariate Cox regression is carried out, the hazard ratio is 1.21 (CI=0.85-1.73).  
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Table 4.2 Binary Cox regression- glioma 
 Prediagnosis 
drug exposure 
group 
Post 
diagnosis 
Exposure 
Patient 
status at end 
of follow-up 
Age adjusted 
Age and 
prediagnosis 
drug use 
adjusted 
Multivariate* 
Alive Dead HR 95% CI HR 95% CI HR 95% CI 
All participants Unexposed 660 647 1     1     1     
Exposed 25 32 0.81 0.57 1.16 0.87 0.59 1.28 0.83 0.53 1.28 
Tricyclic 
nonusers 
Unexposed 611 611 1     - - - 1     
Exposed 10 11 0.68 0.38 1.24 - - - 0.54 0.25 1.14 
Tricyclic users  Unexposed 49 36 1     -  - - 1    
Exposed 15 21 1.01 0.58 1.78 - - -  1.07 0.53 2.17 
*adjusted for age, gender, depression, Charlson index, BMI and smoking
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4.3.3 Kaplan-Meier curves- glioma 
Drawing a KM curve without excluding patients who died or were censored during the 
period examined for exposure (Figure 4.1) gives the impression that there is reduced 
mortality in drug users in the unadjusted analysis. This is corrected in Figure 4.2 by 
excluding these patients, and these curves reflect the unadjusted Cox regression, where a 
small increase in mortality in drug users is evident. 
To better reflect the multivariate Cox regression, the KM curves were adjusted for the 
same covariates as in this analysis (Figure 4.3). This shows that there is a reduction in 
mortality for drug users. 
 
106 
 
Figure 4.1 Glioma binary unadjusted analysis- without exposure time exclusion 
 
Survival curves for glioma. Exposed ƉĂƚŝĞŶƚƐƌĞĐĞŝǀĞĚA? ?ƉƌĞƐĐƌŝƉƚŝŽŶƐŝŶƚŚĞ ?ŵŽŶƚŚƐĨŽůůŽǁŝŶŐĐĂŶĐĞƌĚŝĂŐŶŽƐŝƐ ?dŚŝƐŐƌĂƉŚŝŶĐůƵĚĞƐƉĂƚŝĞŶƚƐǁŚŽĚŝĞĚŽƌ
were lost to follow up in the first 6 months after diagnosis. This introduced a bias in the initial part of the curve. 
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Figure 4.2 Glioma binary unadjusted analysis- with exposure time exclusion 
 
Survival curves for glioma. Exposed patients received A? ?ƉƌĞƐĐƌŝƉƚŝŽŶƐŝŶƚŚĞ ?ŵŽŶƚŚƐĨŽůůŽǁŝŶŐĐĂŶĐĞƌĚŝĂŐŶŽƐŝƐ ?WĂƚŝĞŶƚƐĚǇŝŶŐŽƌďĞŝŶŐůŽƐƚƚŽĨollow up in 
the 6 months post diagnosis were excluded from this graph. 
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Figure 4.3 Glioma binary multivariate analysis 
 
This multivariate survival curve depicts the same patients as in Figure 4.2, but was adjusted for age, gender, depression, Charlson index, BMI and smoking.
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4.3.4 Dose response- glioma 
These data were further investigated by looking at the dose of tricyclics used (Table 4.3). 
For glioma, there was no apparent dose response effect, as there was not a trend towards 
ŐƌĞĂƚĞƌ ĞĨĨĞĐƚ ƐŝǌĞ Ăƚ ŚŝŐŚĞƌ ĚŽƐĞƐ ? dŚĞ ŐƌĞĂƚĞƐƚ ĞĨĨĞĐƚ ƐŝǌĞ ǁĂƐ ƐĞĞŶ ŝŶ ƚŚĞ  ‘ůŽǁ ? ĚŽƐĞ
category, with a non-significant hazard ratio of 0.75 (CI=0.42-1.33). 
 
 
Table 4.3 Dose response- glioma 
 Post 
diagnosis 
Patient status at end of 
follow-up 
Age adjusted Multivariate* 
Exposure Alive Dead HR 95% CI HR 95% CI 
Unexposed 668 661 1    1    
Low dose 11 8 0.69 0.41 1.17 0.75 0.42 1.33 
High dose 6 10 0.95 0.59 1.52 0.88 0.51 1.54 
*adjusted for age, gender, depression, Charlson index, BMI and smoking 
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4.3.5 Binary analysis- colorectal cancer 
For colorectal cancer, post diagnosis tricyclic exposure was found to be associated with a 
significant increase in the hazard ratio (HR=1.40, CI=1.22-1.60). Once again when 3 months 
post diagnosis are used to determine exposure the effect is similar (HR=1.30 CI=1.11-1.51). 
This effect was only observed in those beginning tricyclic use after diagnosis having not 
used them prior to diagnosis (HR=2.02, CI=1.63-2.49). In concurrence with the glioma 
findings, no effects were observed when pre-diagnosis exposure only was considered 
(HR=1.01, CI=0.95-1.08). An entirely unadjusted Cox regression gives a hazard ratio of 1.32 
(CI=1.18-1.47). 
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Table 4.4 Binary Cox regression- colorectal cancer 
 Prediagnosis 
drug exposure 
group 
Post 
diagnosis 
Exposure 
Patient 
status at end 
of follow-up 
Age adjusted 
Age and 
prediagnosis 
drug use 
adjusted 
Multivariate*  
Alive Dead HR 95% CI HR 95% CI HR 95% CI 
All participants Unexposed 9,237 6,613 1 
 
  1 
 
  1 
 
  
Exposed 335 334 1.29 1.15 1.44 1.39 1.22 1.57 1.40 1.22 1.60 
Tricyclic 
nonusers 
Unexposed 8,338 6,075 1 
 
  - - - 1 
 
  
Exposed 70 107 1.93 1.59 2.33 - - - 2.02 1.63 2.49 
Tricyclic users  Unexposed 899 538 1 
 
  - - - 1 
 
  
Exposed 265 227 1.16 0.99 1.35  - - - 1.15 0.97 1.36 
*adjusted for age, gender, depression, Charlson index, BMI and smoking 
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4.3.6 Kaplan ȂMeier curves- colorectal cancer 
In a similar manner to the glioma curves without excluding patients who died or were 
censored during the period examined for exposure, there is an initial improvement in drug 
user mortality (Figure 4.4Error! Reference source not found.). This is corrected by 
excluding these patients (Figure 4.5) and shows an increase in mortality for tricyclic users. 
Adjustment for multiple confounders increases mortality in the KM curve (Figure 4.6), 
which is in line with the multivariate Cox regression. 
 
 
113 
 
Figure 4.4 Colorectal binary unadjusted analysis- no exposure time exclusion 
 
Survival curves for ĐŽůŽƌĞĐƚĂůĐĂŶĐĞƌ ?ǆƉŽƐĞĚƉĂƚŝĞŶƚƐƌĞĐĞŝǀĞĚA? ?ƉƌĞƐĐƌŝƉƚŝŽŶƐŝŶƚŚĞ ?ŵŽŶƚŚƐĨŽůůŽǁŝŶŐĐĂŶĐĞƌĚŝĂŐŶŽƐŝƐ ?dŚŝƐŐƌĂƉŚŝŶĐůƵĚĞƐ patients 
who died or were lost to follow up in the first 6 months after diagnosis. This introduced a bias in the initial part of the curve. 
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Figure 4.5 Colorectal binary unadjusted analysis- with exposure time exclusion 
 
Survival curves for colorectal cancer. Exposed patients received A? ?ƉƌĞƐĐƌŝƉƚŝŽŶƐŝŶƚŚĞ ?ŵŽŶƚŚƐĨŽůůŽǁŝŶŐĐĂŶĐĞƌĚŝagnosis. Patients dying or being lost to 
follow up in the 6 months post diagnosis were excluded from this graph. 
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Figure 4.6 Colorectal cancer binary multivariate analysis 
 
This multivariate survival curve depicts the same patients as in Figure 4.2, but was adjusted for age, gender, depression, Charlson index, BMI and smoking. 
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4.3.7 Dose response- colorectal cancer 
Similarly, with colorectal cancer, there was no consistent dose response trend for the 
ĚĞůĞƚĞƌŝŽƵƐĞĨĨĞĐƚŽďƐĞƌǀĞĚ ?KŶĐĞĂŐĂŝŶ ?ƚŚĞ ‘ůŽǁ ?ĚŽƐĞĐĂƚĞŐŽƌǇĞǆŚŝďŝƚĞĚƚŚĞůĂƌŐĞƐƚƐŝǌĞ
of effect (HR= 1.55, CI=1.31-1.83). 
Table 4.5 Dose response- colorectal cancer 
 Post 
diagnosis 
Patient status at end 
of follow-up 
Age adjusted  Multivariate*  
Exposure Alive Dead HR 95% CI  HR 95% CI  
Unexposed 9,367 6,766 1     1     
Low dose 90 79 1.49 1.28 1.74 A? 1.55 1.31 1.83 A? 
High dose 115 101 1.13 0.97 1.32  1.15 0.98 1.36  
*Adjusted for age, gender, depression, Charlson index, BMI and smoking. 
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4.3.8 Proportional hazards assumption 
The log-log plots for both glioma (Figure 4.7) and colorectal cancer (Figure 4.9) indicate that 
the proportional hazards assumption holds reasonably. Although the lines for tricyclic users 
and non users are quite close, they are reasonably parallel along their length. There is some 
fluctuation in the tricyclic using glioma patients, but this is likely due to small numbers 
rather than differential effects. 
The observed/predicted KM curves for both glioma (Figure 4.8) and colorectal cancer 
(Figure 4.10) give further indication of the characteristics of how the hazards change over 
time. Large deviations from the predicted line could be used to determine where changes 
in mortality hazard occur. However, given the findings from the log-log plot, and that the 
observed lines follow the predicted reasonably closely, it seems the proportional hazards 
assumption is reasonably valid. 
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Figure 4.7 Glioma log-log plot 
 
Assessment of the proportional hazards assumption for tricyclic antidepressant exposure in glioma mortality. 
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Figure 4.8 Glioma- observed vs predicted hazards 
 
Determination of how observed effects on mortality deviate from effects predicted in the regression model. 
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Figure 4.9 Colorectal cancer log-log plot 
 
Assessment of the proportional hazards assumption for tricyclic antidepressant exposure in colorectal cancer mortality. 
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Figure 4.10 Colorectal cancer- observed vs predicted hazards 
 
Determination of how observed effects on mortality deviate from effects predicted in the regression model. 
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4.4 Charlson Index coding assessment 
In order to assess whether the Charlson Index was a valid method of adjusting for 
comorbidity, the patient values for Charlson were divided into quartiles. This meant that 
both Cox regression could be performed and KM curves could be created. Both the Cox 
regression (Table 4.6) and KM curve (Figure 4.11) showed a statistically significant trend (p 
value for trend <0.001) trend towards higher comorbidity leading to increased mortality. 
Table 4.6 Charlson Index validation 
Quartile of Charlson Index OR 95% CI  
1 (lowest comorbidity) 1      
2 1.12 1.07 1.18 A? 
3 1.26 1.20 1.33 A? 
4 (highest comorbidity) 1.42 1.34 1.49 A? 
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Figure 4.11 Charlson index validation 
 
Survival curves to assess the effects of comorbidity, coded as the Charlson Index, on mortality in both glioma and colorectal cancer patients. Patients 
were divided into quintiles according to their Charlson Index score. 
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4.5 Discussion 
4.5.1 Summary of findings 
This study found that there was no observed reduction in mortality among colorectal 
cancer patients treated with tricyclics. In this group there was a statistically significant 
increase in mortality risk, which was only evident in patients beginning tricyclic treatment 
ƉŽƐƚĚŝĂŐŶŽƐŝƐ ?dŚĞĞĨĨĞĐƚǁĂƐĂůƐŽĐŽŶĨŝŶĞĚŽŶůǇƚŽ ‘ůŽǁ ?ĚŽƐĞƚƌŝĐǇĐůŝĐŐƌŽƵƉ ?ƐůŽǁĚŽƐĞ
tricyclics are commonly used for chronic pain management, these factors combined might 
suggest that the observed detrimental effect is related to pain management (which may be 
a proxy for poor prognosis if for example pain is caused by bony metastases), rather than a 
true decrease in survival time caused by tricyclics. 
Despite often observing hazard ratios below one, a statistically significant reduction in 
mortality for glioma patients treated with tricyclics was not observed. In addition, any 
observed effects were not backed up by a trend in the dose response analysis, though due 
to stratification patient numbers are small here. It is possible therefore that tricyclic 
antidepressant use does not confer a benefit in reducing mortality to glioma patients. It is 
also possible that these findings may be a type II error, which would mean that there is an 
association, but it was not found due to some factor such as lack of power. If this were the 
case, it seems from these findings that some groups are more likely to benefit than others. 
The majority of the observed effects were in patients who were not previously exposed to 
tricyclics before diagnosis. So this would seem to be a subset of patients which is more 
likely to benefit from tricyclics if there is a real effect on mortality. This is consistent with 
the hypothesis previously stated by Chan et al (Chan et al. 2009), in relation to aspirin use 
and colorectal cancer, that one would expect those tumours susceptible to the anti-
neoplastic effects of an agent not to reach diagnosis in subjects taking the drug, as the 
ĚƌƵŐ ?ƐĐŚĞŵŽƉƌĞǀĞŶƚĂƚŝǀĞĂĐƚŝŽŶǁŽƵůĚƉƌĞǀĞŶƚƚŚĞĐĂŶĐĞƌĚĞǀĞůŽƉŝŶŐ.  
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4.5.2 Strengths/weaknesses 
As no consistent significant effects were found and my previous data showing that tricyclic 
antidepressants are chemopreventative effect in glioma and colorectal cancer (Walker et 
al. 2011), study power might be the most obvious concern. Power calculations carried out 
whilst designing the study estimated that for glioma, the study would have 80% power to 
detect a hazard ratio of 0.67. This hazard ratio was not observed within the study, but the 
confidence intervals do not rule out a much greater effect size. For colorectal cancer, 
where there are around ten times more patients, it is quite certain that the study had 
sufficient power to detect any important changes.  
Our data have certain important strengths. The use of routinely collected general practice 
records (from the GPRD) ensured that there was little opportunity for recall bias to effect 
the ascertainment of exposures. In addition, by selecting all relevant malignancies within 
the population, the possibility of selection bias was greatly reduced. However, the data 
quality and completeness of all potential confounders may not be of the same standard. 
There is also some missing data with respect to smoking, obesity and alcohol, and therefore 
some potential for residual confounding by these factors. However, these factors, even 
when combined had a relatively small confounding effect and so it is likely that any residual 
confounding by these factors would be minor. A potentially greater issue is that there is no 
data on factors such as cancer stage and histological grade, though adjusting for these 
factors had a limited effect on mortality in a similar study (Chan et al. 2009). In addition, 
adjusting for factors such as comorbidity may have reduced the extent of this. There may 
be concern that excluding patients who die or are censored during the therapy observation 
period (up to 6 months after diagnosis) may cause some early effects to be overlooked. 
However the reduced opportunity for exposure among those dying quickly means that any 
beneficial association found would be more likely to be due to reverse causality were they 
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included.  My efforts to assess this by using a shorter 3 month period to determine 
exposure produced results that were broadly the same.  
4.5.3 Comparison with previous literature 
Previous laboratory evidence suggests a substantial anti-cancer effect for many of the 
tricyclics both in vitro (Pilkington et al. 2008) and in vivo (Tsuruo et al. 1983; Merry et al. 
1991; Pommerenke et al. 1995). While these are important in establishing a possible anti-
cancer effect, it is difficult to directly compare them to any study in humans. The in vitro 
studies for example are essentially qualitative in nature, and in many cases attempt to 
determine the mechanism of action (Daley et al. 2005; Arimochi et al. 2006). These are of 
course all important steps in determining efficacy of a drug, but it is all too common for a 
drug which shows promise in the laboratory to meet with a lack of efficacy in the clinic (for 
example Sparano et al (2004)). 
In addition, the previous study examining cancer incidence (Chapter 3), demonstrates a 
statistically significant chemopreventive effect in humans (Walker et al. 2011). This current 
study is the first known large-scale study to investigate the effect of tricyclics on cancer 
survival.  It is thought however that there are around 350 primary brain tumour patients in 
the UK who have at some point been treated with the tricyclic chlorimipramine (Higgins et 
al. 2010). In example of such treatment, 27 malignant patients were treated with up to 
150mg of chlorimipramine over a 4.5 year period (Beaney et al. 2005). This small scale 
study showed promising results but also hints at another important consideration. The 
dose used in this study is substantially higher than the typical dose of chlorimipramine used 
in the patient cohort (median= 50mg). Therefore, it may well be that therapeutic benefit 
can only be found at doses which are relatively rarely used in the general population, or in 
patients with lower grade or smaller tumours. It is clear then that this, combined with the 
relatively low power available (despite the very large size of the GPRD), means that it is 
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very difficult in this kind of study to reliably determine the effects that these drugs would 
have if used clinically for cancer treatment. 
4.5.4 Interpretation 
The obvious conclusion then is that further and larger scale interventional clinical work is 
required to truly reveal the potential of tricyclics in cancer therapy. From this and previous 
work, it would appear that glioma is the best candidate cancer for such clinical studies. 
Carrying out a simple calculation to determine the likely minimum size of a trial in glioma 
patients indicates that at least 130 patients would be required to achieve 90% power with a 
sensitivity of 5%. This is based on the hazard ratio of 0.83, obtained in the multivariate 
binary Cox regression for all participants. This figure would perhaps be lower for some sub-
groups, such as patients not using tricyclics before diagnosis. However, the evidence for 
these sub-groups being different to the population as a whole is arguably not sufficient to 
warrant a trial looking exclusively at such sub groups. It may however be useful to carry out 
a sub-group analysis within a more general trial. This trial seems like a realistic goal for 
glioma. For colorectal cancer however, it now seems unlikely that there are any real 
beneficial effects on mortality and therefore a clinical trial is not likely to be useful. 
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5 Non-steroidal anti-inflammatory drugs and cancer survival 
A cohort study using the GPRD 
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5.1 Introduction 
Although some targeted agents, such as bevacizumab, are beginning to be used in 
colorectal cancer chemotherapy (Welch et al. 2010), conventional chemotherapeutic drugs 
(for example 5-fluorouracil) are still the mainstay of chemotherapy treatment. Such drugs 
are renowned for their unpleasant side effects, so the search for alternative drugs that 
have a lower side effect profile, or could be used to increase effectiveness of conventional 
drugs could be potentially very rewarding. 
5.1.1 COX-2 and cancer 
Cyclooxygenase-2, also known as COX-2 or prostaglandin-endoperoxide synthase 2, is an 
enzyme with an important role in biosynthesis of prostanoid compounds such as 
prostaglandins. These compounds have a number of physiological functions, including 
vasodilation and mediation of inflammatory reactions. More recently they have been 
implicated in cancer development, including regulation of apoptosis, angiogenesis and 
invasion (Ghosh et al. 2010). 
COX-2 exists alongside two other isozymes, COX-1 and COX-3. All of these enzymes perform 
very similar functions, but are differentially expressed according to the tissue type. COX-1 is 
constitutively expressed throughout most tissues, whereas COX-2 is an inducible enzyme 
expressed in only a few tissues. A number of cancer types, including colorectal cancer are 
known to have a tendency to over express COX-2 (Antonacopoulou et al. 2008), which is 
likely a key part in their development. 
The implication of COX-2 in cancer development has led to a number of approaches to 
therapeutically target it. All NSAIDs are known to inhibit both COX-1 and COX-2, and this 
action is vital in their conventional use as analgesics, anti-inflammatories and antipyretics. 
Due to this non-specific inhibition, side effects such as GI bleeding can occur. This has led to 
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the development of more specific COX-2 inhibitors, which due to them not inhibiting the 
ubiquitously expressed COX-1, should have fewer side effects. However, these drugs still 
have issues, with rofecoxib (trade name Vioxx) having been withdrawn by drug company 
Merck due to an increase in risk of cardiovascular events (Bresalier et al. 2005). 
5.1.2 NSAIDs and cancer incidence 
Aspirin is known to reduce the incidence of colorectal cancer (Dube et al. 2007; Cuzick et al. 
2009; Elwood et al. 2009; Half et al. 2009). In addition, NSAIDs in general have also been 
linked anti-cancer effects (Iwama et al. 2009; Zell et al. 2009). However, effects of these 
drugs have been disputed by certain studies (Bosetti et al. 2009), For aspirin, it is thought 
to be most effective in reducing incidence at high doses, although recent evidence has 
emerged to suggest that low dose aspirin may also be efficacious (Din et al. 2010; Rothwell 
et al. 2010). 
5.1.3 NSAIDs and mortality? 
The chemopreventative effect of NSAIDs naturally leads to the question of whether these 
drugs may be of benefit as an adjuvant treatment in colorectal cancer. A recent study 
established that there may be a reduction in mortality in patients treated with aspirin after 
diagnosis (Chan et al. 2009). In this study the greatest effects were observed in patients 
who began aspirin use post diagnosis, and also in patients with tumours expressing high 
levels of cyclooxygenase-2 (COX-2). Inhibition of COX-2 is the main mechanism through 
ǁŚŝĐŚĂƐƉŝƌŝŶ ?ƐĂŶƚŝ-cancer action is mediated. Another study using pooled randomized trial 
data determined there to be a reduction in mortality in a number of cancer types, including 
colorectal cancer (Rothwell et al. 2011). Both of these studies were relatively small in size in 
terms of colorectal cancer numbers, and it would therefore be highly beneficial to attempt 
to replicate these findings in a different, larger dataset. 
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5.1.4 Study rationale 
Taking the previous evidence into account this study uses the GPRD as the source of a 
much larger colorectal cancer population, in order to further understand the effects of 
aspirin and NSAIDs on cancer mortality in a real world population. Other NSAID use 
(excluding aspirin) was also investigated. In addition to their anti-cancer action, aspirin and 
other NSAIDs have relatively few and minor side effects in contrast to the side effects of 
cytotoxic drugs discussed in section 4.1.3. Gastrointestinal toxicity such as discomfort, 
nausea, diarrhoea, and occasionally more serious bleeding and ulceration are the most 
important of these side effects. Elderly patients are at increased risk of these. However, 
careful management and drug selection (e.g. ibuprofen is associated with lower GI toxicity 
risk) can minimise the risk of such effects. 
The putative anti-cancer efficacy and mild side effect profile therefore makes aspirin and 
other NSAIDs a good candidate for further investigation. 
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5.2 Methods 
5.2.1 Study design 
A prospective cohort study was carried out in the GPRD to determine the relationship 
between aspirin and NSAID usage and survival post cancer diagnosis. 
5.2.2 Subjects 
Any person with a recorded diagnosis of colorectal cancer within the GPRD (see Appendix II 
for medical codes) occurring at least one year after their entry to the database was 
selected. Patient data were collected from the beginning of the GPRD database (1987), up 
to the last available data in the database (2010). Patients with a previous diagnosis of 
colorectal cancer were excluded from the cohort, as were patients contributing less than 1 
year of data to the GPRD. 
5.2.3 Outcomes and exposures 
The outcome to be observed was all cause mortality. Date of patient death was determined 
ĨƌŽŵ ƚŚĞ ĞǆŝƐƚĞŶĐĞ ŽĨ ŽŶĞ ŽĨ ƚǁŽ ƌĞĐŽƌĚƐ ? ĞŝƚŚĞƌ Ă ƉĂƚŝĞŶƚ ǁŝƚŚ Ă  “dƌĂŶƐĨĞƌ ŽƵƚ ƌĞĂƐŽŶ ?
ƐƉĞĐŝĨŝĞĚ ĂƐ  “ĚĞĂƚŚ ? ? Žƌ ďǇ Ă  “^ƚĂƚĞŵĞŶƚof ĞĂƚŚ ? (SoD) code (Ă  “ůŝŶŝĐĂů ? Žƌ  “ZĞĨĞƌƌĂů ?
event with a Read/OXMIS code indicating a death).  Where both records existed, the date 
of death was determined preferentially from the SoD code. The follow-up time was 
determined to be the time between diagnosis and the death date determined by the above 
method. Follow up time for patients not dying in the study was determined either from the 
date that the patient transferred out from the GP or by the last data collection date for the 
GP. 
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The primary exposure was the use of aspirin, or another NSAID (section 10.01.01 of the 
British National Formulary (BNF)). To be exposed, a patient must have had a repeat 
prescription (A?2) within the period being examined for exposure. In order to minimise 
reverse causality (i.e. patients who die soon after diagnosis being less likely to receive a 
prescription) a fixed period of 1 year post-diagnosis was used to determine drug exposure 
and patients who died or were censored within this period were excluded from the 
analysis. 
Ɛ ŝŶ ŚĂŶ Ğƚ Ăů ?Ɛ ƉĂƉĞƌ(Chan et al. 2009), pre-diagnosis exposure was considered to 
determine whether it influenced the effect of post-diagnosis exposure. This was done in 
two ways; 1) by adjusting for pre-diagnosis use in the Cox proportional hazards model and 
2) by stratifying the analysis according to whether patients received aspirin/NSAIDs pre-
diagnosis. 
Potential associations were examined further by investigating the dose used. For aspirin 
low dose was decided to be 75 milligrams or under and high dose anything over 75 
milligrams. Where multiple prescriptions with differing doses existed, the most frequently 
prescribed dose was used. 
To allow comparison of the effect of high and low doses across all the NSAIDs, I 
standardized the definition of high dose and low dose between drugs relative to the 
maximum recommended doses for each drug (determined from the BNF). These 
standardized doses were then used to calculate the mean dose across all prescriptions for 
each patient individually. Patients with NSAID use were divided into 'high' dose or 'low' 
dose groups based on the median corrected dose of 0.32 times maximum recommended 
dose.  
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5.2.4 Other covariates 
Data on gender, age, smoking status, alcohol use, body mass index (BMI) and comorbidity 
(coded as the Charlson Index (Charlson et al. 1987)) were extracted. Of these potential 
confounders, gender, age, comorbidity and smoking status were retained in multivariate 
models as a priori predictors of mortality risk. Other covariates were only retained in the 
multivariate model if they produced a 10% or greater change in the measured size of 
effect. 
5.2.5 Statistical methods 
I used Cox proportional hazards modelling to assess the effect of aspirin/NSAIDs on 
mortality risk, adjusting for multiple potential confounding variables as described above. 
Results are presented as hazard ratios (HR), with accompanying 95% confidence intervals 
(CIs).  
Validity of the proportional hazards assumption was tested using a log-log plot. If the 
proportional hazards assumption was found to be violated, this non proportionality was 
then further characterised. The approximate time period that a change in effects occurred 
was determined by using observed/predicted survival curves, and observing where the 
observed curve deviated from the predicted. The data could then be stratified using this 
time period to investigate the effects before and after. 
All data handling and analysis was done using Stata v11.1 SE (Statacorp, 4905 Lakeway 
Drive, College Station, Texas 77845 USA). 
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5.3 Results 
5.3.1 Study population/covariates 
13,944 patients with colorectal cancer were identified. 5,358 (38.4%) of these patients died 
during their period of registration and their median follow up time (survival time) for this 
group was 1.7 years. The remaining patients, alive up to the end of follow-up had a median 
time of post-diagnosis follow-up of 3.1 years (interquartile range 1.3-6.2). Aspirin use 
between diagnosis and 12 months post diagnosis was at 18.8% in patients surviving more 
than 12 months after diagnosis. 26.1% of patients received a prescription for aspirin 
prediagnosis. These results are summarised, along with other covariates used in the study 
in Table 5.1. 
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Table 5.1 Study population/covariates 
    
Aspirin 
nonuser 
(N=11,325) % 
Aspirin user 
(N=2,619) % 
NSAID 
nonuser 
(N=10,233) % 
NSAID user 
(N=3,711) % 
Women   6,067 53.6 1,632 62.3 5,493 53.7 2,206 59.4 
Mean age (SD)   74.5 (11.7) 68.3 (8.5) 72.3 (11.5) 68.4 (11.4) 
Mean BMI (SD)   27.0 (4.5) 26.2 (4.5) 27.1 (4.4) 26.1 (5.1) 
Smoking status No 6,074 53.6 1,306 49.9 5,503 53.8 1,877 50.6 
  Ex 3,053 27.0 948 36.2 2,774 27.1 1,227 33.1 
  Yes 1,645 14.5 322 12.3 1,462 14.3 505 13.6 
  Missing 553 4.9 43 1.6 494 4.8 102 2.8 
Alcohol use No 7,790 68.8 1,890 72.2 1,541 15.1 620 16.7 
  Ex 173 1.5 77 2.9 152 1.5 98 2.6 
  Yes 1,714 15.1 447 17.1 7,079 69.2 2,601 70.1 
  Missing 1,648 14.6 205 7.8 1,461 14.3 392 10.6 
Mean Charlson Index (SD) 13.0 (9.5) 9.5 (13.0) 12.1 (7.3) 9.5 (7.2) 
Numbers in table represent N (%) for categorical variables and Mean (SD) for continuous variables 
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5.3.2 Binary analysis 
Post diagnosis aspirin use (Table 5.2) was associated with a decrease in mortality in 
colorectal cancer patients (multivariate HR=0.91 95% confidence interval (CI)=0.82-1.00). 
The effect did not occur in patients not prescribed aspirin before diagnosis (HR=0.99 
CI=0.84-1.16), therefore the effect was entirely due to patients who did use aspirin pre 
diagnosis (HR= 0.86 CI= 0.76-0.98). If pre diagnosis aspirin use is considered exclusively, 
there was no association with survival (HR=1.04 CI=0.97-1.12). This analysis using pre 
diagnosis exposure included all patients excluded from the other parts of the study. 
With NSAID use, there was a statistically significant increase in mortality when all patients 
were considered together (HR=1.29, CI=1.18-1.42). However, there was a greater increase 
in mortality observed in those beginning NSAID use after diagnosis, having not used them 
prior to diagnosis (HR=1.69, CI=1.45-1.97). As with aspirin, no statistically significant effects 
were observed when pre-diagnosis exposure only was considered (HR=1.05, CI=0.99-1.12). 
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Table 5.2 Binary analysis 
  
Pre diagnosis exposure 
strata 
  
Drug type 
  
Post 
diagnosis 
exposure 
Patient status at end 
of follow-up 
Age adjusted 
 Age and 
prediagnosis 
drug use 
adjusted 
Multivariate* 
 
Alive Dead HR 95% CI  HR 95% CI HR 95% CI  
All participants Aspirin Unexposed 6,925 4,400 1      1     1      
   Exposed 1,661 958 0.94 0.87 1.01  0.89 0.81 0.98 0.91 0.82 1.00 A? 
  NSAIDs Unexposed 7,862 4,773 1 
  
 1 
  
1 
  
 
    Exposed 724 585 1.32 1.21 1.43 A? 1.32 1.21 1.43 1.29 1.18 1.42  
Aspirin/NSAID nonusers  Aspirin Unexposed 6,231 3,910 1      - - - 1      
prediagnosis  Exposed 284 192 0.99 0.86 1.15  - - - 0.99 0.84 1.16  
  NSAIDs Unexposed 4,835 3,162 1 
  
 - - - 1 
  
 
    Exposed 205 221 1.66 1.45 1.90 A? - - - 1.69 1.45 1.97 A? 
Aspirin/NSAID users  Aspirin Unexposed 694 490 1      - - - 1      
prediagnosis  Exposed 1,377 766 0.84 0.75 0.94 A? - - - 0.86 0.76 0.98 A? 
  NSAIDs Unexposed 3,027 1,611 1 
  
 - - - 1 
  
 
    Exposed 519 364 1.18 1.05 1.32 A? - - - 1.11 0.98 1.26  
*adjusted for: age, gender, smoking, BMI, alcohol use, comorbidity (Charlson index) 
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5.3.3 Kaplan-Meier curves- aspirin 
In a similar manner to the KM curves in chapter 4, these were first drawn without excluding 
patients who died or were censored during the first 12 months after diagnosis. This gives 
the impression of a large reduction in mortality for aspirin users early after diagnosis 
(Figure 5.1). With these patients excluded, the picture is very different (Figure 5.2), when 
the results are not adjusted for any confounders, there appears to be no benefit in 
mortality for either group early on, then after around 2000 days there is an increase in 
mortality for aspirin users. While these results do reflect the univariate Cox regression 
analysis, these results are confounded by a number of factors, particularly age. These 
factors are adjusted for in Figure 5.3, where there again appear to be differential effects 
between early and late follow up. Aspirin users appear to have reduced mortality initially, 
but it increases later on to become greater than non users. These differential effects are 
further explored in the proportional hazards assumption testing (Section 5.3.7). 
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Figure 5.1 Aspirin binary unadjusted analysis- without exposure time exclusion 
 
Colorectal cancer patient survival curves. Exposed patients received A?2 prescriptions for aspirin in the 1 year following diagnosis. For this curve, patients 
ĚǇŝŶŐŽƌďĞŝŶŐůŽƐƚƚŽĨŽůůŽǁƵƉĚƵƌŝŶŐƚŚŝƐ “ĞǆƉŽƐƵƌĞ ?ƚŝŵĞǁĞƌĞŶŽƚĞǆĐůƵĚĞĚĨƌŽŵƚŚĞĐŽŚŽƌƚ ?
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Figure 5.2 Aspirin binary unadjusted analysis- with exposure time exclusion 
 
Colorectal cancer patient survival curves. Exposed patients received A?2 prescriptions for aspirin in the 1 year following diagnosis. Exclusion of patients dying 
ŽƌďĞŝŶŐůŽƐƚƚŽĨŽůůŽǁƵƉĚƵƌŝŶŐƚŚĞ “ĞǆƉŽƐƵƌĞ ?ƚŝŵĞůĞĂĚƐƚŽĂĐŚĂŶŐĞŝŶƐŚĂƉĞŽĨƚŚĞŝŶŝƚŝĂůƉĂƌƚŽĨƚŚĞĐƵƌǀĞ ? 
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Figure 5.3 Aspirin binary multivariate analysis 
 
Multivariate colorectal cancer patient survival curves, adjusted for: age, gender, smoking, BMI, alcohol use, comorbidity (Charlson index). 
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5.3.4 Kaplan-Meier curves- NSAIDs 
Once again the KM curve drawn without excluding patients lost before 12 months post 
diagnosis (Figure 5.4) gives the impression of slightly improved initial mortality for NSAID 
users, which is corrected by their exclusion (Figure 5.5). This unadjusted curve suggests an 
increase in mortality for NSAID users. When the curve is adjusted for the various 
confounders, this effect appears to be increased (Figure 5.6). 
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Figure 5.4 NSAIDs binary unadjusted analysis- without exposure time exclusion 
 
Univariate colorectal cancer patient survival curves. Exposed patients received A?2 prescriptions for NSAIDs (excluding aspirin) in the 1 year following 
ĚŝĂŐŶŽƐŝƐ ?&ŽƌƚŚŝƐĐƵƌǀĞ ?ƉĂƚŝĞŶƚƐĚǇŝŶŐŽƌďĞŝŶŐůŽƐƚƚŽĨŽůůŽǁƵƉĚƵƌŝŶŐƚŚŝƐ “ĞǆƉŽƐƵƌĞ ?ƚŝŵĞǁĞƌĞŶŽƚĞǆĐůƵĚĞĚfrom the cohort. 
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Figure 5.5 NSAIDs binary unadjusted analysis- with exposure time exclusion 
  
Univariate colorectal cancer patient survival curves. Exposed patients received A?2 prescriptions for aspirin in the 1 year following diagnosis. Exclusion of 
ƉĂƚŝĞŶƚƐĚǇŝŶŐŽƌďĞŝŶŐůŽƐƚƚŽĨŽůůŽǁƵƉĚƵƌŝŶŐƚŚĞ “ĞǆƉŽƐƵƌĞ ?ƚŝŵĞůĞĂĚƐƚŽĂĐŚĂŶŐĞŝŶƐŚĂƉĞŽĨƚŚĞŝŶŝƚŝĂůƉĂƌƚŽĨƚŚĞĐƵrve. 
0.
00
0.
25
0.
50
0.
75
1.
00
0 2000 4000 6000 8000
analysis time
Unexposed Exposed
Kaplan-Meier survival estimates
146 
 
Figure 5.6 NSAIDs- binary multivariate analysis 
 
Multivariate colorectal cancer patient survival curves, adjusted for: age, gender, smoking, BMI, alcohol use, comorbidity (Charlson index). 
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5.3.5 Dose response 
/ŶǀĞƐƚŝŐĂƚŝŽŶ ŽĨ ĂƐƉŝƌŝŶ ĂŶĚ E^/Ɛ ? ĞĨĨĞĐƚƐ ŽŶ ŵŽƌƚĂůŝƚǇ ǁĞƌĞ ĐŽŶƚŝŶƵĞĚ ďǇ ŝŶǀĞƐƚŝŐĂting 
the dose of drug used (Table 5.3). For aspirin, a dose response effect was not observed, as 
there was a small, non-significant decrease in mortality in those using low dose aspirin 
(HR=0.94 CI=0.86-1.02) and a small, non-significant increase in mortality in patients using 
high dose aspirin (HR=1.13 CI=0.97-1.32). For high dose NSAID use, a significant increase in 
mortality was observed for NSAID users (HR=1.29 CI=1.11-1.49). 
Table 5.3 Dose response 
 Drug 
type 
Post 
diagnosis 
Exposure 
Patient status at 
end of follow up 
Age adjusted Multivariate* 
Alive Dead HR 95% CI HR 95% CI 
Aspirin Unexposed 6,925 4,400 1 
 
  1 
 
  
  Low dose 1,437 768 0.91 0.84 0.98A? 0.94 0.86 1.02 
  High dose 220 186 1.10 0.95 1.27 1.13 0.97 1.32 
NSAIDs Unexposed 7,862 4,773 1 
  
1 
  
  Low dose 378 288 1.18 1.05 1.33A? 1.18 1.04 1.35A? 
  High dose 290 233 1.35 1.19 1.54A? 1.29 1.11 1.49A? 
*Adjusted for: age, gender, smoking, BMI, alcohol use, comorbidity (Charlson index) 
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5.3.6 Binary analysis- low dose only 
If the original analysis (Table 5.2) is repeated with patients using high dose post diagnosis 
aspirin/NSAID excluded from the study, the results are broadly similar for aspirin, but with 
slightly greater size of effect (Table 5.4). For NSAIDs, the increase in mortality previously 
observed in patients who had not used them prior to diagnosis was increased somewhat, 
and still significant (HR=1.97 CI=1.64-2.36). 
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Table 5.4 Binary analysis- low dose only 
  
Prior drug exposure 
group 
  
Drug 
type 
  
Post diagnosis 
exposure 
Patient status at 
end of follow-up 
Age adjusted 
 Age and 
prediagnosis 
drug use 
adjusted 
Multivariate* 
 
Alive Dead HR 95% CI  HR 95% CI HR 95% CI  
All participants Aspirin Unexposed 6,925 4,400 1      1     1      
   Low dose 1,441 772 0.91 0.84 0.98 A? 0.86 0.79 0.94 0.89 0.80 0.98 A? 
  NSAIDs Unexposed 7,862 4,773 1 
  
 
   
1 
  
 
    Low dose 434 352 1.29 1.16 1.44 A? 1.29 1.16 1.44 1.29 1.15 1.46 A? 
Aspirin/NSAID nonusers  Aspirin Unexposed 6,231 3,910 1      - - - 1      
prediagnosis  Low dose 265 175 0.97 0.83 1.13  - - - 0.99 0.84 1.16  
  NSAIDs Unexposed 4,835 3,162 1 
  
 - 
  
1 
  
 
    Low dose 119 155 1.86 1.58 2.18 A? - 
  
1.97 1.64 2.36 A? 
Aspirin/NSAID users  Aspirin Unexposed 694 490 1      - - - 1      
prediagnosis  Low dose 1,176 597 0.81 0.72 0.92 A? - - - 0.83 0.73 0.95 A? 
  NSAIDs Unexposed 3,027 1,611 1 
  
 - 
  
1 
  
 
    Low dose 315 197 1.05 0.91 1.22  - 
  
1.02 0.87 1.2  
*Adjusted for: age, gender, smoking, BMI, alcohol use, comorbidity (Charlson index) 
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5.3.7 Proportional hazards assumption testing 
The log-log plot for aspirin demonstrates that there are differing effects between the early 
and late analysis time (Figure 5.7). The curves for exposed and unexposed patients clearly 
cross and are not parallel. This is in contrast to the log-log plot for NSAIDs (Figure 5.9), 
where the curves are somewhat more parallel and do not cross. 
In order to estimate when the difference in effects occurred, observed vs predicted KM 
curves were drawn. For aspirin (Figure 5.8), there appears to be a change at around 2300 
days (6.3 years). For other NSAIDs (Figure 5.10), there is some deviation from the predicted 
curve, but in a less striking manner than for aspirin. 
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Figure 5.7 Aspirin- log-log plot 
 
Assessment of the proportional hazards assumption for aspirin exposure. 
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Figure 5.8 Aspirin- observed vs predicted hazards 
 
Determination of how observed effects on mortality deviate from effects predicted in the regression model. 
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Figure 5.9 NSAIDs- log-log plot 
 
Assessment of the proportional hazards assumption for NSAID exposure. 
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Figure 5.10 NSAIDs- observed vs predicted hazards 
 
Determination of how observed effects on mortality deviate from effects predicted in the regression model. 
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5.3.8 Non proportional hazards stratification 
After it was determined that there were differential effects between early and late follow 
up after diagnosis, I tested for effects before and after this point (Table 5.5). For aspirin a 
reduction in mortality was observed up to 6.3 years (HR= 0.83 CI=0.75-0.91), whereas after 
this point the effect became an increase in mortality (HR=1.64 CI=1.32-2.03). Although 
NSAIDs did not display the same level of differential effects, the analysis was carried out in 
the same way, with a greater size of effect seen in the earlier follow up category (HR=1.32 
CI=1.19-1.46). 
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Table 5.5 Non proportional hazards stratification 
 Drug 
type 
 Period 
examined 
 Post 
diagnosis 
exposure 
Patient status at 
end of follow-up 
Age adjusted  Age and 
prediagnosis drug 
use adjusted 
 
Multivariate* 
 
Alive Dead HR 95% CI  HR 95% CI  HR 95% CI  
Aspirin <6.3 years Unexposed 7,262 4,520         1      
   Exposed 1,324 838 0.89 0.82 0.96 A? 0.81 0.74 0.89 A? 0.83 0.75 0.91 A? 
  >6.3 years Unexposed 8,249 5,238         1     
   Exposed 337 120 1.70 1.40 2.08 A? 1.72 1.40 2.11 A? 1.64 1.32 2.03 A? 
NSAIDs <6.3 years Unexposed 6,853 4,089         1 
  
 
   Exposed 1,733 1,269 1.36 1.24 1.48 A? 1.38 1.26 1.52 A? 1.32 1.19 1.46 A? 
  >6.3 years Unexposed 8,356 5,298         1 
  
 
    Exposed 230 60 1.07 0.82 1.40  1.08 0.83 1.41  1.16 0.88 1.52  
*Adjusted for: age, gender, smoking, BMI, alcohol use, comorbidity (Charlson index) 
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5.4 Discussion 
5.4.1 Summary 
It was found that there was a reduction in all-cause mortality for colorectal cancer patients 
using aspirin. This reduction was around 9% for all aspirin use, but increased to around 17% 
in the early follow up period. These were therefore modest in size but there were 
statistically significant reductions in mortality in various parts of the analysis. However no 
dose response relationship was found for aspirin, which may be due to confounding by 
indication. It is likely that patients with a poor prognosis would use high dose aspirin for 
pain management, whereas low dose (75mg) aspirin is not used in this way, which may 
have allowed its protective effects to be shown. 
In contrast, NSAID use did not appear to give any reduction in mortality, and in fact showed 
an increase in mortality in some cases. The reason for this is likely to be confounding by 
indication, in a similar manner to aspirin use. I therefore do not believe that there are any 
causal associations between mortality in colorectal cancer patients and NSAIDs. 
Though it is likely that NSAIDs are not associated with mortality in colorectal cancer 
patients, for aspirin, things are undoubtedly less clear cut. My findings are broadly similar 
ƚŽƚŚŽƐĞŽĨŚĂŶĞƚĂů ?ƐƐƚƵĚǇ(Chan et al. 2009) in that consistent reductions in mortality 
were observed. However, whereas Chan et al found their greatest size of effect in patients 
who started aspirin use for the first time post diagnosis, essentially no effect was found 
here. It is possible then that there are some tertiary factors affecting mortality, which also 
may be related to aspirin use. 
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5.4.2 Method refinements 
During the analysis, it was found that different doses varied the effect on mortality. It was 
therefore decided to investigate mortality while excluding patients on high dose 
aspirin/NSAIDs. This gave a greater size of effect for aspirin use. This is likely a result of 
removing confounding that may have been present in high dose users, as high dose aspirin 
is most commonly used as an analgesic and may therefore be a proxy for poor prognostic 
markers such as bone metastases. 
Although it was expected that the proportional hazards assumption would need to be 
tested, it was not known what the outcome of this testing would be. A substantial 
difference was found between the early and late effects in aspirin, which partially masked 
some of the mortality effects that occurred in aspirin users. Once the early and late follow 
up periods were analysed separately, it was clear that there was a more substantial 
reduction in mortality in the early part of follow up than was seen in the overall analysis. 
This new mortality estimate was approximately in line with the size of effect found in the 
Chan et al study, in a similar category. The effect of aspirin use in the late follow up period 
was to increase mortality. This may be due to aspirin use being a marker for previous 
cardiovascular disease, especially with the majority of use being low dose. 
5.4.3 Strengths/weaknesses 
This study used a dataset much larger than in all known previous studies on the same 
subject. As prescriptions are automatically recorded in the GPRD, the opportunity for recall 
bias to effect the ascertainment of exposures is limited. Since all relevant malignancies 
within the GPRD were selected, the possibility of selection bias was greatly reduced. 
However, the recording of all potential confounders may not be as reliable. 
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There is some missing data with respect to smoking, obesity and alcohol, and therefore a 
potential for residual confounding by these factors. However, these factors, even when 
combined had a relatively small confounding effect, and so it is likely that any residual 
confounding by these factors would be minor. The data used does however lack any data 
on factors such as cancer stage and histological grade. Though adjusting for factors such as 
comorbidity may have reduced the extent of confounding by these variables, it is still 
possible that increased morbidity would lead to both increased aspirin use (through pain 
management) and increased mortality. Indeed I believe this may be the reason for 
increases in mortality being observed in some cases. Adjusting for cancer stage and grade 
could therefore increase the size of the observed effects substantially. Related to this is 
COX-2 expression in colorectal tumours. It was determined that expression of COX-2 in a 
colorectal tumour led to a greater decrease in mortality (Chan et al. 2009). Lack of such 
histological data may therefore have contributed to the relatively small effect sizes found. 
It was not possible to look at cause-specific mortality in this dataset. Therefore another 
factor that would likely increase the observed size of effect is being able to look exclusively 
at cancer specific mortality. This would have the additional advantage of ascertaining to 
what extent the overall increase in mortality after 6 years was due to an increased risk of 
cardiovascular death. 
5.4.4 Comparison with previous literature 
While this study generally agrees with the results in previous literature on aspirin and 
colorectal cancer mortality, it does not entirely replicate them. One possible reason for this 
may be the type of data source. 
Chan et al used the EƵƌƐĞƐ ? Health Study (a questionnaire based study), and this may have 
led to substantial differences in determination of exposure. Rather than being based on 
prescribing, patients were simply asked if they were regular users of aspirin. This would 
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certainly lead to differences in terms of including patients using over the counter (and 
therefore frequently higher dose) aspirin. This may be important both in terms of the 
effects observed, and for any confounding by indication in this study. Another difference in 
the datasets is the length of follow up may have been greater in the EƵƌƐĞƐ ? Health Study 
than for most patients in the GPRD. 
Another study to look at aspirin use in relation to mortality used the California Teachers 
Study (Zell et al. 2009). This was a questionnaire based study, and therefore had relatively 
few participants. The study also used aspirin and ibuprofen use combined. However 
significant effects were noted for NSAID use, which were slightly higher, but comparable 
with my study in effect size. In contrast to my study, Zell et al looked only at NSAID use 
before cancer diagnosis, and therefore is somewhat at odds with my study, which found no 
effect here. However, with the dramatically different method of ascertainment of exposure 
between the different studies, this may in part explain any differences in timing of use etc. 
The most recent findings in this area (Coghill et al. 2011) present a similar story. They found 
that regular NSAID use conferred a survival benefit in an observational study using the 
survey based Seattle Colorectal Cancer Family Registry. This included around 1,700 
participants, but reports a significant survival benefit in NSAID users of comparable size to 
other studies (around 20%). This study again investigates only pre-diagnosis NSAID use, and 
it is therefore less generalisable in terms of using the drugs as cancer treatment. 
Pooled randomised trial data were used by one group to determine the effect of long term 
aspirin use on mortality (Rothwell et al. 2011). While the outcome of this study (mortality) 
was effectively the same as in my study, the population being examined was not. As these 
were trials of primary or secondary prevention of cancer, the baseline population did not 
have cancer, or were in remission from cancer. This means that this study is as much a 
comment on the preventative power of aspirin as it is on the treatment efficacy. It is 
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therefore difficult to separate these results, though it is clearly valuable to show that the 
preventative properties of aspirin do translate to a decrease in cancer death. The study also 
adds value in that the majority of individual trials did not find significant effects in this 
outcome measure, but combining them gave sufficient power to do this. 
In a similar manner to Rothwell et al, Din et al (2010) looked at aspirin and NSAID use in 
relation to survival from colorectal cancer. This study used the Study of Colorectal Cancer in 
Scotland, a large questionnaire based study. As it was a case control study it incorporated 
patient without cancer and therefore included incidence of colorectal cancer into the 
measure of survival. In a similar manner to my study, there was no association found for 
NSAIDs, but a survival benefit was found for low dose aspirin. Once again it is difficult to 
determine how much of this survival benefit is due to the change in cancer incidence. 
Additionally this study was mostly focused on cancer incidence rather than survival. 
5.4.5 Interpretation 
The body of evidence for the anti-cancer effect of aspirin is ever expanding, and it is 
therefore crucial that this is further investigated. While in observational studies consensus 
is beginning to form, due to the limitations of such studies, randomised intervention trials 
are the only way to fully determine whether these drugs can confer a benefit to cancer 
patients, and if so which patients are most likely to benefit. There is now strong evidence 
that aspirin may reduce colorectal cancer mortality, and now would seem a good time to 
carry out such a trial. 
The minimum size of a clinical trial to investigate this, based on the overall effect on 
mortality found in this study (a hazard ratio of 0.91) would be 260 patients. The potential 
difference in the effect of aspirin in patients over expressing the COX-2 protein could also 
be investigated in such a study. Histological determination of COX-2 expression is entirely 
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practicable and may be an important indicator of response to aspirin. Given the potential 
gain for colorectal cancer patients, it would be imprudent to not investigate this further in 
patients. The sizes of effect observed in this and other similar studies are of comparable 
magnitude to clinical trials which examine alternative chemotherapy regimens (for example  
oxaliplatin plus 5-FU/leucavorin (André et al. 2009)) in comparison with the more standard 
5-FU/leucavorin treatment (reviewed in (Jonker et al. 2011)). These types of study can be 
viewed as analogous to this study as here patients will either have been treated with 
standard therapy only, or standard therapy plus aspirin. It therefore seems plausible that a 
clinical trial of similar design to these others could find similar results. The additional 
benefit here is of course the greatly reduced toxicity of aspirin in comparison with drugs 
such as oxaliplatin. 
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6 ACE inhibitors and hepatocellular carcinoma 
A case-control study using the GPRD 
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6.1 Introduction 
Hepatocellular carcinoma (HCC) is amongst the commonest cancers globally and its 
incidence is thought to be rising in the UK, with incidence rates approximately trebling 
between 1971 and 2001 (West et al. 2006). Though survival rates have increased slightly in 
that time, prognosis is very poor. Known risk factors for HCC include cirrhosis, hepatitis B 
and C infection, sustained alcohol use, age and male gender (El-Serag et al. 2008; Kumagi et 
al. 2009). 
6.1.1 Angiogenesis in cancer 
On initial development, the structure of a tumour is much more homogeneous than that 
present in normal tissues, as it is derived from a single transformed cell. This means that 
support structures such as blood vessels are not present. A tumour can only grow to be a 
few millimetres across without a blood supply as growing bigger than this causes areas of 
hypoxia to develop within it, which leads to inhibition of growth and cell death. 
In order to develop past this stage, the tumour must induce blood vessel growth 
(angiogenesis). This is often achieved by hijacking normal physiological mechanisms for 
angiogenesis, whereby the tumour cells release growth factors which encourage 
surrounding blood vessels to develop into the tumour mass. These growth factors include 
vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF). These 
growth factors therefore offer a potential target for anticancer drugs and indeed various 
VEGF targeting monoclonal antibodies are now in clinical use, including bevacizumab. 
Neoangiogenesis is thought to occur early in hepatocellular carcinogenesis (Yang et al. 
2008b) due to the rapid nature of HCC growth. As a result of this dependence on 
angiogenesis, a focus on anti-angiogenic drugs in HCC treatment has emerged, including 
clinical trials of anti-angiogenic drugs, such as Sorafenib (Llovet et al. 2008). 
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6.1.2 Anti-cancer mechanism- ACE inhibitors 
Angiotensin converting enzyme (ACE) inhibitors are used conventionally as an 
antihypertensive agent. However, laboratory findings demonstrate both anti-angiogenic 
activity and inhibition of liver cancer growth in rodent models (Volpert et al. 1996). It has 
been suggested that the anti-angiogenic activity is mediated by inhibition of vascular 
endothelial growth factor (VEGF) (Yoshiji et al. 2001). Research into the anti-cancer 
properties of ACE inhibitors has included examination of possible synergistic effects with 
other drugs, such as 5-fluorouracil (5-FU) (Yanase et al. 2007), interferon-ɴ(Noguchi et al. 
2003; Yoshiji et al. 2005b) and vitamin K2 (Yoshiji et al. 2005a; Yoshiji et al. 2006; Yoshiji et 
al. 2007; Yoshiji et al. 2009). 
6.1.3 Previous epidemiology 
Although laboratory evidence on ace inhibitors and HCC is compelling, studies in humans 
are limited in size and number. One study using 100 patients indicates possible protection 
against recurrence of HCC (Yoshiji et al. 2009), but only a single case study describes the 
potential use as a chemopreventative agent in humans (Yoshiji et al. 2007). Intriguingly, a 
different but related class of drugs, angiotensin receptor blockers, have recently been 
associated with an increase in cancer risk in randomized controlled trials (Sipahi et al. 
2010).  
6.1.4 HCC and high risk groups 
HCC, having well defined high risk groups is an excellent candidate disease for the 
development of chemoprotective drugs. Risk factors for HCC mostly consist of chronic liver 
diseases, such as cirrhosis, haemochromatosis and hepatitis B/C infection. Other risk 
factors include alcohol use and diabetes. 
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This study assessed the potential therapeutic effects of ACE inhibitors in a large, population 
based study with robust measurement of ACE inhibitor exposure.  
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6.2 Materials and Methods 
6.2.1 Design 
A matched case-control study was conducted to determine the relationship between ACE 
inhibitor usage and cancer incidence using the General Practice Research Database. 
6.2.2 Participants 
Cases were defined as persons in the GPRD between 1987 and March 2002 with a recorded 
diagnosis of hepatocellular carcinoma (defined by Oxford Medical Information System or 
Read Codes). Two code sets were used, one including specific HCC codes only (referred to 
forthwith as definite), and the other adding codes for unspecified primary liver cancers 
(referred to as probable). The index date for cases was taken to be the first recorded 
diagnosis of HCC in cases and the same date for individually matched controls. Up to 10 
controls were matched to each case by GP, sex and age at the index date (within 5 years). 
Patients with below 2 years of follow up at the index date were excluded.  
6.2.3 Exposures 
Exposures were defined as a record of prescription for an ACE inhibitor (BNF, section 2.5.5) 
prior to the diagnosis of HCC. Due to potential differences in the duration of data collection 
for each patient and to reduce the chance of reverse causality, the period used to 
determine a paƚŝĞŶƚ ?ƐĞǆƉŽƐƵƌĞƐƚĂƚƵƐǁĂƐĐŽŶĨŝŶĞĚƚŽďĞƚǁĞĞŶ ? ?ŵŽŶƚŚƐĂŶĚ ? ?ŵŽŶƚŚƐ
ďĞĨŽƌĞƚŚĞŝŶĚĞǆĚĂƚĞ ?ǆƉŽƐƵƌĞǁĂƐĚĞĨŝŶĞĚĂƐA? ?ƉƌĞƐĐƌŝƉƚŝŽŶƐ ? 
To allow assessment of dose response I determined the dose received for each 
prescription. This was standardised across drug types by dividing by the maximum 
recommended doses for each drug (determined from the BNF). These standardized doses 
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were then used to calculate the mean dose across all prescriptions for each patient 
individually. Patients with prior ACE inhibitor use were divided into 'high' or 'low' dose 
groups based on the median corrected dose of 0.225 times maximum recommended dose. 
Length/consistency of exposure was assessed by the number of days of exposure within 
the 1 year period that exposure was examined. Exposure was categorized as greater or less 
than 6 months in this period. 
6.2.4 Other covariates 
Risk factors for HCC for which data were available in this study were diagnosed chronic liver 
disease, diabetes, smoking and alcohol use. These were defined by a code for these 
ĐŽŶĚŝƚŝŽŶƐĂƚĂŶǇƉŽŝŶƚĚƵƌŝŶŐƚŚĞƉĂƚŝĞŶƚ ?ƐƌĞŐŝƐƚƌĂƚŝŽŶ ? 
6.2.5 Statistical methods 
I used conditional logistic regression, initially using univariate analysis, then using a 
multivariate model. The covariates assessed for possible confounding were alcohol use, 
smoking, diabetes, and chronic liver disease (cirrhosis, haemachromatosis and hepatitis 
B/C). These potential confounders were only retained in the model if they caused a 10% or 
greater change in the observed size of effect. Results are presented as odds ratios (ORs), 
with accompanying 95% confidence intervals (CIs). All data handling and analysis was done 
using Stata v11.1 SE (Statacorp, 4905 Lakeway Drive, College Station, Texas 77845 USA). 
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6.3 Results 
6.3.1 Population 
I identified a total of 335 HCC cases, matched to a total of 3,339 controls by age, gender 
and general practice. The median duration of data available prior to the index date was 5.7 
years (range 1.0 to 12.3 years) for cases, and 5.0 years (range 1.0 to 12.3 years) for 
controls. 
The full set of patients, based on the code list used in Table 6.2, gave the greatest level of 
study power. However, the patient cohort based on the code list in Table 6.4 was thought 
to be a more representative HCC population. It is this population which is analysed in Table 
6.1, in terms of the various covariates investigated. The biggest difference between cases 
and controls here was for diagnosed chronic liver disease, where a 17 fold increase is seen 
in cases compared to controls. 
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Table 6.1 Covariates 
  Controls % Cases % 
Number  2313  224  
Sex Male 1,430 61.8 138 61.6 
 Female 883 38.2 86 38.4 
Age <50 249 10.8 23 10.3 
 50-60 385 16.7 36 16.1 
 60-70 580 25.1 58 25.9 
 70-80 661 28.6 64 28.6 
 >80 438 18.9 43 19.2 
Alcohol Never user 255 11.0 35 15.6 
 User 1,302 56.3 107 47.8 
 Missing 756 32.7 82 36.6 
Smoking Never smoker 896 38.7 101 45.1 
 Ex-smoker 169 7.3 15 6.7 
 Current smoker 171 7.4 27 12.1 
 Missing 1,077 46.6 81 36.2 
Diagnosed chronic 
liver disease 
No 2,289 99.0 185 82.6 
Yes 24 1.0 39 17.4 
ACE inhibitor use No 2,176 94.1 208 92.9 
 Yes 137 5.9 16 7.1 
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6.3.2 Analysis using all possible cases 
The study was initially carried out using a code list that included all the codes that could 
have been used to describe HCC. Some of these codes however were somewhat ambiguous 
and could have coded for other cancer types, such as cholangiocarcinoma. It is also 
conceivable that a few other cancer types that have metastasized to the liver may have 
ďĞĞŶ ?ŝŶĐŽƌƌĞĐƚůǇ )ĐŽĚĞĚĂƐ ?ĨŽƌĞǆĂŵƉůĞ “ĂƌĐŝŶŽŵĂůŝǀĞƌ ? ?
 
Table 6.2 Full code list 
GPRD 
Medical 
Code 
Read/OXMIS 
code 
Read/OXMIS term 
274664 1550A MALIGNANT NEOPLASM LIVER 
303102 1550AP MALIGNANT NEOPLASM LIVER PRIMARY 
219896 1550B HEPATOMA 
306049 1550C CARCINOMA LIVER 
201867 1550HC MALIGNANT NEOPLASM HEPATOCELLULAR 
206105 B15..00 Malignant neoplasm of liver and intra hepatic bileducts 
251481 B150.00 Primary malignant neoplasm of liver 
224132 B150000 Primary carcinoma of liver 
233261 B150300 Hepatocellular carcinoma 
206106 B150z00 Primary malignant neoplasm of liver NOS 
288093 B152.00 Malignant neoplasm of liver unspecified 
297513 B808000 Carcinoma in situ of liver 
206291 B903000 Neoplasm of uncertain behaviour of liver 
288302 BB5D.00 [M]Hepatobiliary tract adenomas and carcinomas 
297580 BB5D400 [M]Liver cell adenoma 
206320 BB5D411 [M]Hepatocellular adenoma 
233466 BB5D500 [M]Hepatocellular carcinoma NOS 
233467 BB5D511 [M]Hepatoma NOS 
251676 BB5D512 [M]Hepatoma, malignant 
297581 BB5D513 [M]Liver cell carcinoma 
206321 BB5D700 
[M]Combined hepatocellular carcinoma and 
cholangiocarcinoma 
297582 BB5D800 [M]Hepatocellular carcinoma, fibrolamellar 
242496 BB5Dz00 [M]Hepatobiliary adenoma or carcinoma NOS 
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Using the all patient population demonstrates that there are no significant associations 
between ACE inhibitor use and HCC, with the exception of the A?6 months group in the 
duration analysis. Here a significant increase in ACE inhibitor use in HCC patients is 
observed. 
Table 6.3 Analysis using full code list 
Analysis 
type 
ACE inhibitor 
use 
  Univariate  Multivariate*  
Controls Cases OR 95% CI  OR 95% CI  
Ever use Unexposed 3,003 294 1    1    
 Exposed 336 41 1.18 0.82 1.70  1.29 0.88 1.88  
Dose Unexposed 2,974 287 1    1    
 Low (A?0.225) 202 26 1.32 0.85 2.04  1.49 0.95 2.33  
 High (>0.225) 163 22 1.29 0.79 2.09  1.38 0.83 2.29  
Duration Unexposed 2,974 287 1    1    
 A?6 months 101 19 1.83 1.10 3.07 A? 2.13 1.26 3.62 A? 
 >6 months 264 29 1.09 0.72 1.66  1.17 0.76 1.81  
*Adjusted for alcohol use, smoking, and chronic liver disease. 
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6.3.3 Analysis using probable and definite cases 
This code list increases the likelihood of the selected cancer patients being HCC patients by 
excluding some of the more generic codes included in the previous list. This meant that 
essentially all the patients identified should be primary liver cancer patients, the large 
majority of which will be HCC patients. 
Table 6.4 Probable/definite code list 
GPRD 
Medical 
Code 
Read/OXMIS 
code 
Read/OXMIS term 
274664 1550A MALIGNANT NEOPLASM LIVER 
303102 1550AP MALIGNANT NEOPLASM LIVER PRIMARY 
219896 1550B HEPATOMA 
201867 1550HC MALIGNANT NEOPLASM HEPATOCELLULAR 
206105 B15..00 Malignant neoplasm of liver and intrahepatic bile ducts 
251481 B150.00 Primary malignant neoplasm of liver 
224132 B150000 Primary carcinoma of liver 
233261 B150300 Hepatocellular carcinoma 
206106 B150z00 Primary malignant neoplasm of liver NOS 
206320 BB5D411 [M]Hepatocellular adenoma 
233466 BB5D500 [M]Hepatocellular carcinoma NOS 
233467 BB5D511 [M]Hepatoma NOS 
251676 BB5D512 [M]Hepatoma, malignant 
297581 BB5D513 [M]Liver cell carcinoma 
206321 BB5D700 
[M]Combined hepatocellular carcinoma and 
cholangiocarcinoma 
297582 BB5D800 [M]Hepatocellular carcinoma, fibrolamellar 
242496 BB5Dz00 [M]Hepatobiliary adenoma or carcinoma NOS 
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As observed in Table 6.5, there was no significant difference in ACE inhibitor use between 
HCC cases and controls. 16 cases (7.7%) and 137 controls (6.3%) had prior ACE inhibitor 
use. Odds ratios were close to unity in the univariate analysis (OR=1.16, CI=0.67-2.00) and 
the multivariate model did not differ greatly (OR=1.18, CI=0.66-2.10). 
The median adjusted dose was 0.225 as a proportion of the BNF maximum recommended 
dose. The adjusted dose is the daily dose for each prescription as a proportion of the 
maximum daily dose recommended in the BNF. Although there is some difference between 
high and low dose exposure (Table 6.5), these results are not significant. The greatest size 
of effect is in the low dose category, where there is a non-significant increase in low dose 
ACE inhibitors for cases (multivariate OR=1.51, CI=0.66-3.44). In addition to this there was 
no significant trend in terms of dose of prescription (multivariate p value for trend=0.47). 
For the duration analysis, 28.1% of exposed patients were in the A?6 months category and 
the remaining 71.9% in the >6 months category. There was a non-significant increase in 
 ŝŶŚŝďŝƚŽƌ ƵƐĞ ŝŶ , ĐĂƐĞƐ ĨŽƌ ďŽƚŚ ƚŚĞ A?6 months category (multivariate OR=1.32, 
CI=0.45-3.82) and the >6 months category (OR=1.13, CI=0.58-2.21). No significant linear 
trend was observed (P=0.50). 
Table 6.5 Analysis using probable/definite code list 
Analysis 
type 
ACE inhibitor 
use 
  Univariate Multivariate* 
Controls Cases OR 95% CI OR 95% CI 
Ever use Unexposed 2,176 208 1   1   
 Exposed 137 16 1.16 0.67 2.00 1.18 0.66 2.10 
Dose Unexposed 2,176 208 1   1   
 Low (A?0.225) 59 7 1.20 0.53 2.68 1.51 0.66 3.44 
 High (>0.225) 78 9 1.13 0.55 2.31 0.98 0.45 2.12 
Duration Unexposed 2,176 208 1   1   
 A?6 months 34 4 1.20 0.42 3.44 1.32 0.45 3.82 
 >6 months 103 12 1.14 0.61 2.14 1.13 0.58 2.21 
*Adjusted for alcohol use, smoking, and chronic liver disease. 
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6.3.4 Analysis using highly specific code list 
The codes used in this analysis all explicitly describe hepatocellular carcinoma. It is 
therefore highly unlikely that any other cancer types could be coded for by this code list. 
Table 6.6 Definite code list 
GPRD 
Medical 
Code 
Read/OXMIS 
code 
Read/OXMIS term 
219896 1550B HEPATOMA 
201867 1550HC MALIGNANT NEOPLASM HEPATOCELLULAR 
251481 B150.00 Primary malignant neoplasm of liver 
233261 B150300 Hepatocellular carcinoma 
206320 BB5D411 [M]Hepatocellular adenoma 
233466 BB5D500 [M]Hepatocellular carcinoma NOS 
233467 BB5D511 [M]Hepatoma NOS 
251676 BB5D512 [M]Hepatoma, malignant 
297581 BB5D513 [M]Liver cell carcinoma 
206321 BB5D700 
[M]Combined hepatocellular carcinoma and 
cholangiocarcinoma 
297582 BB5D800 [M]Hepatocellular carcinoma, fibrolamellar 
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The more specific HCC code set was used to eliminate the possibility that other cancer 
types might affect the results. As can be seen in Table 6.7, 2,149 patients were identified by 
this method. ACE inhibitor use between cases and controls while using this code list 
remains non-significantly different (OR=1.33 CI=0.68-2.59). 
Table 6.7 Analysis using definite code list 
Analysis 
type 
ACE inhibitor 
use 
  Univariate Multivariate* 
Controls Cases OR 95% CI OR 95% CI 
Ever use Unexposed 1,424 136 1   1   
 Exposed 99 13 1.29 0.70 2.39 1.33 0.68 2.59 
Dose Unexposed 1,424 136 1   1   
 Low (A?0.225) 46 5 1.08 0.42 2.79 1.39 0.53 3.69 
 High (>0.225) 53 8 1.47 0.68 3.19 1.28 0.53 3.06 
Duration Unexposed 1,424 136 1   1   
 A?6 months 26 3 1.15 0.34 3.87 1.39 0.41 4.74 
 >6 months 73 10 1.34 0.67 2.69 1.30 0.61 2.81 
*Adjusted for alcohol use, smoking, and chronic liver disease. 
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6.4 Discussion 
6.4.1 Summary 
Despite contrary in vitro (Yoshiji et al. 2001; Noguchi et al. 2003; Yoshiji et al. 2005b; Yoshiji 
et al. 2005c; Yoshiji et al. 2006) and human (Yoshiji et al. 2007; Yoshiji et al. 2009) evidence, 
this study found no significant association between ACE inhibitor use and risk of developing 
HCC. There was no suggestion of a protective effect in any of the analyses, with the binary 
analysis suggesting, if anything, a very small non-significant increase in risk. Dose appeared 
to have little effect on incidence also and did not show any consistent pattern in those 
patients exposed for longer. 
6.4.2 Method refinements 
The main modifications to the methods in this study involved the code lists used to select 
HCC cases. This involved starting by selecting as many HCC cases as possible and then 
systematically increasing the specificity of case selection by removing the more ambiguous 
codes. While this will have most likely excluded some HCC cases when using the more 
specific code lists, it did allow for comparison of the results between different cohorts. 
It can be said with reasonable confidence that there were no substantial differences 
between the different cohorts in terms of associations between ACE inhibitor use and 
cancer incidence. This means that, despite some uncertainty in exactly what cancer types 
were coded for, particularly when using the less specific code lists, it is unlikely that any 
effect has been missed due to lack of precision in the case definitions used. 
6.4.3 Strengths/weaknesses 
As with any study that fails to discover an association, the statistical power of the study 
must be considered carefully. Though the power of this study is clearly not optimal, the 
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95% confidence intervals of the overall comparison exclude a protective odds ratio better 
than 0.66 (based on the probable/definite code list cohort). Hence these data suggest that 
if any protective association exists, the size of effect is likely to be small. Given the rarity of 
HCC, such a small change is unlikely to be clinically important. Yearly incidence of HCC in 
across the west is consistently under 10 per 100,000, while in some countries in East Asia 
and central Africa, incidence can approach closer to 100 per 100,000 (Bosch et al. 2004). 
Given this incidence, the number needed to treat based on an odds ratio of 0.66 is 
approximately 30,000 in western countries and 3,000 in the higher incidence countries. 
High risk groups might present a better target for these drugs, but  as this is based on an 
entirely hypothetical odds ratio, which at best could not be ruled out, it is very unlikely. 
An advantage of this study is that the use of routinely collected general practice records 
ensures that the recall bias affecting the ascertainment of drug exposures was minimised. 
Unfortunately I cannot be equally confident about the completeness of data on some 
confounders, such as smoking and alcohol use. Around 40% of patients did not have 
available data on these factors and this may have left residual confounding within the 
results. While some of the residual confounding is likely to be minimal (for example for 
smoking status), other confounders may continue to exhibit an effect. The most likely one 
of these is chronic liver disease. It is known that a large majority of HCC occurs in patients 
in high risk groups, such as those with chronic liver disease (for example cirrhosis, 
haemachromatosis and hepatitis B/C). However, these data suggest that only 17.4% of 
patients were diagnosed with chronic liver disease. This is difficult to explain, though may 
in part be due to cases not being diagnosed with chronic liver disease before diagnosis of 
HCC. This must therefore be acknowledged as a weakness of the study. 
Although the codes used to define HCC in most of the analysis will have selected the 
majority of HCC cases, there is some potential for selection of cancer types such as 
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cholangiocarcinoma. I therefore carried out a sensitivity analysis, using only codes that 
were highly specific to HCC. Although the power was reduced somewhat, the results 
continued to suggest that there remains little association between ACE inhibitor use and 
HCC. 
6.4.4 Previous literature 
There is extensive laboratory research suggesting the anti-cancer effect of ACE inhibitors in 
HCC, particularly in murine models (Volpert et al. 1996; Yoshiji et al. 2001; Noguchi et al. 
2003; Yoshiji et al. 2005a; Yoshiji et al. 2006). They use a variety of methods to assess the 
potential anti-cancer efficacy of ACE inhibitors, including a number of cell lines and animal 
models. They also go some way into investigating the mechanism of action of ACE 
inhibitors. While these studies undoubtedly have some merit, slight concern might be 
expressed given that the majority of these studies arise from just one research group in 
Japan. This does not discredit their individual findings, but it would certainly become a 
more compelling story if a greater variety of research groups were to investigate this. 
The same group again produced two small clinical studies that suggest that ACE inhibitors 
do have an anti-cancer effect in HCC in patients in synergy with other agents (Yoshiji et al. 
2007; Yoshiji et al. 2009). The first study is a case report and suggests that a precancerous 
condition (a dysplastic nodule) was regressed so as to be clinically undetectable after a year 
of ACE inhibitor treatment. While this case study does provide a rich source of information 
on the case itself, it can only ever make vague qualitative suggestions, which of course 
warrant further investigation in greater numbers. Their follow up to this was to look at 
secondary prevention (i.e. prevention of recurrence) of HCC. Using just 50 patients (100 
including other studies in the paper) they suggest that around a 50% reduction in 
recurrence was observed after 2 years of treatment. While size of effect is impressive, the 
small number of patients in this study means that further large scale study is still required. 
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There are also epidemiological studies that suggest effects in other cancers, in terms of 
incidence (Lever et al. 1998; Sjoberg et al. 2007), where one study suggests that overall 
cancer incidence can be reduced by around 30% in ACE inhibitor users (Lever et al. 1998). 
dŚŝƐ ƐƚƵĚǇ ?ďǇ ƚŚĞĂƵƚŚŽƌ ?ƐŽǁŶĂĚŵŝƐƐŝŽŶŵĂǇŽŶůǇďĞƵƐĞĨƵů ĨŽƌŚǇƉŽƚŚĞƐŝƐŐĞŶĞƌĂƚŝŽŶ ?
perhaps because the comparison cohort was taken from a different data source than the 
cases, but also it also suggests that interventional trials are necessary to change treatment 
strategy. The other study, which looked specifically at oesophageal and gastric cancer in 
the GPRD (Sjoberg et al. 2007), found that there was only a benefit in oesophageal cancer 
incidence. The dose dependency that was also found suggests that the association found is 
more likely to be causal. 
Survival may also be improved by ACE inhibitors (or angiotensin receptor blockers) (Wilop 
et al. 2009). In this case lung cancer patients were involved in an observational study to 
assess survival. An increase in median survival of 3.1 months was observed. While this small 
study is indeed valuable, more reliable data could be achieved in a randomised 
interventional study. In addition, this study does not distinguish between ACE inhibitors or 
angiotensin receptor blockers, meaning that it is difficult to tell what effect each class of 
drugs has. 
Given these previous findings it is possible that my study, which found no such effects, 
does not represent the true effects. One epidemiological study does agree with my 
conclusions, but in general cancer incidence (Friis et al. 2001). Here a prescription database 
combined with the Danish Cancer Registry was used, allowing a large study size (17,897 
cancer cases). However the comparison group used for this study was county specific 
cancer incidence rates. It is therefore perhaps questionable whether these groups are 
comparable. The study does suggest a (non-significant) decreased risk of upper digestive 
system cancers, which perhaps prompted the study by Sjoberg et al. 
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6.4.5 Implications  
Given the relatively limited power of this study, ŝƚ ƚŚĞƌĞĨŽƌĞ ĐĂŶ ?ƚ ďĞ ƐĂŝĚ ǁŝƚŚ Ă ŚŝŐŚ
degree of certainty what the true effects are. It might be suggested however, that use of 
ACE inhibitors does not exert a large protective effect against HCC, and the prospect of 
further studies finding a substantial and clinically important protective effect seems 
unlikely. Smaller effects, or perhaps effects that are enhanced by synergy with other 
compounds, such as vitamin K2, cannot be ruled out. 
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7 Conclusions 
Interpretation, implications and recommendations 
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7.1 Conclusions 
The aims of this thesis were: 
1. To determine the effects of tricyclic antidepressants on cancer incidence 
2. To determine the effect of tricyclic antidepressants on post diagnosis cancer 
survival. 
3. To investigate aspirin and colorectal cancer survival. 
4. To determine if ACE inhibitors have an effect on hepatocellular carcinoma 
incidence. 
7.2 Summary of findings 
 
7.2.1 Tricyclic antidepressants and cancer incidence 
31,953 cancers were identified, each matched with up to 2 controls. I found a statistically 
significant reduction in tricyclic prescriptions compared to controls in glioma (Odds Ratio 
(OR)= 0.59, 95% Confidence Interval (CI)= 0.42 W0.81) and colorectal cancer patients (OR= 
0.84, CI= 0.75 W0.94). These effects were dose-dependent (p-values for trend, glioma= 
0.0005, colorectal= 0.001) and time-dependant (p-values for trend glioma= 0.0008, 
colorectal= 0.008). The effects were cancer type specific, with lung, breast and prostate 
cancers largely unaffected by antidepressant use. 
This biologically plausible, cancer specific, dose and time dependant inverse association 
suggests that tricyclics may have potential for prevention of both colorectal cancer and 
glioma. The other cancer types studied seem to be largely unaffected by tricyclic 
antidepressant use. 
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7.2.2  Tricyclic antidepressants and survival in glioma and colorectal cancer 
A total of 1364 glioma and 16,519 colorectal cancer patients were used in the final analysis. 
There was a non-significant reduction in the hazard ratio for glioma patients treated with 
tricyclics (HR= 0.83, CI= 0.53-1.28). This was mainly found in patients who were not 
previously exposed to tricyclics (HR= 0.54, CI= 0.25-1.14). In contrast, a significant increase 
in the hazard ratio was found for colorectal cancer (HR= 1.40, CI= 1.22-1.60). This was 
mostly due to patients prescribed low dose tricyclics (HR= 1.55, CI= 1.31-1.83). 
This study has shown no significant benefit in terms of mortality reduction in colorectal 
cancer or glioma patients treated with tricyclics. An apparent detrimental effect observed 
in colorectal cancer may be related to prescription of low dose tricyclics in the 
management of pain related to disseminated cancer. I cannot rule out small effects or an 
effect that occurs exclusively at higher doses. 
7.2.3 Aspirin, NSAIDs and survival in colorectal cancer  
In the final cohort used for analysis, there were a total of 13,994 colorectal cancer patients. 
Overall mortality, in the whole cohort, was slightly lower in patients treated with aspirin, 
(Hazard Ratio (HR)= 0.91 95% Confidence Interval (CI)= 0.82-1.00). This effect was observed 
only in patients treated with low dose aspirin (HR= 0.89 CI= 0.80-0.98). Differential effects 
on mortality were also observed depending on the length of time after diagnosis. Up to 6.3 
years, a reduction in mortality was observed for aspirin users (HR= 0.83 CI= 0.75-0.91), 
whereas a after this period there was an increase in mortality (HR= 1.64 CI= 1.32-2.03). For 
NSAID use, there was no significant observed effect on overall mortality (HR= 1.07 CI= 0.98-
1.15). Any effects that were observed for NSAID use displayed an increase in mortality, for 
example in high dose NSAID use (HR= 1.41 CI= 1.26-1.56). 
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While the findings of this study are not wholly consistent with previous findings, they do 
still provide further indication that aspirin may be beneficial in reducing mortality in 
colorectal cancer patients. 
7.2.4 ACE inhibitors and incidence of hepatocellular carcinoma 
335 HCC patients were identified, each matched to up to 10 controls by age, sex and 
general practice. The data show that HCC is associated with a small, non-significant 
increase in prior use of ACE inhibitors (OR= 1.16, CI= 0.67-2.00). ACE inhibitor use was 7.1% 
in cases and 5.9% in controls. No significant effects were found when investigating the 
effect of dose and exposure duration. 
This study therefore found no clear protective effect of ever or long term use of ACE 
inhibitors against the development of HCC.  My study suggests that it is unlikely that this 
class of drugs will be a clinically useful cancer chemoprevention therapy. 
7.3 Implications 
It is rare that descriptive epidemiology alone is sufficient to directly alter clinical practice. 
Clinical trials are required in order to fully establish the efficacy of a drug for a new 
indication. The value of this thesis lies in its ability to give an indication of potential 
effectiveness of a drug, and also in assisting in clinical trial design by estimating the size of 
effect that might be seen with a particular treatment. This can help in determining the 
study size required for an effective trial. 
7.3.1 Tricyclic antidepressants and cancer incidence 
The strong association between tricyclic usage and reduced glioma incidence is intriguing, 
but is of little immediate use in terms of cancer prevention. This is due to the rarity of 
glioma, which means that the cost/benefit ratio is poor in terms of the number of treated 
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people needed to prevent one glioma. For colorectal cancer the positive association found 
is a good indication of the potential anticancer action of tricyclics, but due to the relatively 
small size of effect found, using tricyclics for chemoprevention may be of limited value 
given the side effect profile of tricyclics. 
7.3.2 Tricyclic antidepressants and survival in glioma and colorectal cancer 
While little substantial evidence of improved mortality in tricyclic users was found, I cannot 
rule out that tricyclics could be useful in glioma treatment. The results obtained do still hint 
at a possible survival benefit and should certainly not deter any glioma patient currently 
using the drug to continue its use. It seems unlikely at this point that tricyclics could confer 
a survival benefit to colorectal cancer patients. 
7.3.3 Aspirin, NSAIDs and survival in colorectal cancer  
The evidence displayed here provides a small amount of support to previous findings that 
aspirin may benefit colorectal cancer patients. This is despite the GPRD not being an ideal 
setting to carry out such a study, with its lack or histological of stage data. Though aspirin 
may not yet be ready for full use as a colorectal cancer therapy, it seems appropriate at this 
point for clinical work to further establish its potential benefits. 
7.3.4 ACE inhibitors and incidence of hepatocellular carcinoma 
Based on my findings, it seems unlikely that ACE inhibitors have a substantial effect on HCC. 
Though a small effect may still be possible it is unlikely such an effect would be clinically 
significant, as HCC is not one of the most common cancers. Even using a hugely optimistic 
value of effect size, it is estimated that between 3,000 and 30,000 patients (depending on 
incidence rates) would need to be treated with ACE inhibitors to prevent one HCC case. 
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7.4 Recommendations for further studies 
It may at some point be possible to identify high risk groups for glioma, through for 
example genetic profiling or molecular biomarkers. This would be of huge value as it could 
allow those identified as high risk to use tricyclics as a prophylactic against glioma 
development. Though a number of common cancer types were studied for their association 
with tricyclics here, there may be other cancer types that are particularly sensitive to 
mitochondrial inhibition. This is where molecular profiling of cancers may be important. 
Grouping cancers by site of origin does not necessarily give groups that are homogeneous 
in terms of drug response. Each tumour will have a specific set of malignant 
transformations. It is this that determines drug response, rather than the site of origin. 
Further clinical use of tricyclics in glioma patients is vital for to provide further evidence of 
its potential in treating glioma. As discussed at the end of chapter 4, the minimum trial size 
based on the effect size that seems most likely in this thesis (a hazard ratio of 0.83) would 
be 130. Given that there were around 4,500 incident primary brain tumours in the UK in 
2007 (Cancer Research UK), with a large proportion of these being gliomas, it seems 
realistic that such a trial could be carried out. 
Future linkage of the GPRD to additional cancer registries and hospital episode statistics 
(which is now starting to be implicated) may well provide the additional data required to 
fully replicate the previous findings on the association between aspirin and colorectal 
cancer. Clinical studies are however a vital next step in the development of this drug as an 
anti-cancer drug. Trials involving cancer prophylaxis and aspirin have been successful 
previously and it seems there is a good chance that the same may be true for its use in 
treatment. The likely minimum size of such a trial would be 260 patients based on data in 
this study. However, given the range of values for the potential size of effect in this area, 
using more patients may be advisable, particularly as colorectal cancer is very common. 
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For the ACE inhibitors and HCC, another epidemiological study may provide further insight 
into their association. Despite being powered sufficiently to provide some insight, the study 
in this thesis was still limited in power to detect small associations. As time passes the 
GPRD continues to accrue more data and the dataset used for this study was a extracted a 
number of years ago. This means that a larger cohort would now be available, which may 
allow detection of changes not found in this study. In addition, the GPRD continues to 
improve in quality in terms of recording of covariates, meaning that these factors could be 
better adjusted for. 
Though a number of drugs and cancer types have been investigated in this thesis, there are 
others hypotheses that would be testable using this type of data. Peroxisome proliferator 
activated receptors (PPARs) are a class of proteins with a diverse range of physiological 
ĨƵŶĐƚŝŽŶƐ ?ŵŽŶŐƐƚƚŚĞƐĞ ?ŝƚŝƐƚŚŽƵŐŚƚƚŚĂƚWWZɶŵĂǇŚĂǀĞĂƌŽůĞŝŶĐĂŶĐĞƌ(Grommes et 
al. 2004) ? dŚĞƌĞ ĂƌĞ ƚǁŽ ĐůĂƐƐĞƐ ŽĨ ĚƌƵŐƐ ŬŶŽǁŶ ƚŽ ŝŶƚĞƌĂĐƚ ǁŝƚŚ WZɶ ? ŐůŝƚĂǌŽŶĞƐ ĂŶĚ
aminosalicilates. These are collectively known as PPAR antagonists and have been studied 
in relation to various types of cancer (Hatton et al. 2008), including prostate cancer (Jiang 
et al. 2009; Murtola et al. 2009) and melanoma (Freudlsperger et al. 2006). 
Sodium valproate is conventionally used in the treatment of epilepsy and bipolar disorder. 
It has also been linked to an anti-cancer action in several cancer types, including 
neuroblastoma, glioma, breast cancer, prostate cancer and leukaemia (Singh et al. 2005). 
Its anti-cancer action is thought to be mediated trough inhibition of histone deacetylase 
(Gottlicher et al. 2001). Histone deacetylase is an important protein in both normal 
physiology and cancer development (Kortenhorst et al. 2006). 
The value of this thesis and other similar epidemiological work is in exploring the effects of 
drugs in humans without the expense of an interventional trial. While this approach yields 
data that are far from the ideal of randomised, blinded, well dosed drug exposure inherent 
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in good clinical trials, it can still give results which give an indication of the efficacy of a 
drug in a new application. Given the continuing improvements to data quality and quantity 
and the ongoing linkage of databases to provide greater depth of information on patients, 
it seems that there is still plenty of potential for further studies to find new uses for old 
drugs. 
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Appendix I: Data specification for tricyclics incidence study 
 
 
 
 
 
Date: 22nd February 2010 
 
Epidemiological study to investigate the effect of tricyclic 
antidepressants and reduced incidence of various cancer 
types.  Protocol No. 08_016 
1. Data-set specification 
Authors: Tarita Murray-Thomas, Dr. Tim Williams GPRD, MHRA, UK 
Distribution:  Alex Walker, University of Nottingham 
 
2. Description of cohort as defined in the protocol 
The baseline population will consist of all up-to-standard patients (UTS) in GPRD 
during the period 01/01/1987 ± 31/12/2007 inclusive. 
 
Cases will consist of all patients with an incident medical diagnosis of brain tumour 
including glioma, colorectal, lung, breast or prostate cancer in their clinical or 
referral record during 01/01/1987 ± 31/12/2007 inclusive. 
&DVHV ZLOO EH  \HDUV RI DJH RQ WKH LQGH[ GDWH RI WKHLU GLDJQRVLV LQ WKH VWXG\
window. The index date of diagnosis will be defined as the first date when the GP 
records a diagnosis of one or more of the relevant cancers of interest in the study 
window and during the patient UTS follow-up period. 
Cases will have at least 5 years of UTS follow-up prior to the first recorded 
diagnosis of the relevant cancers in the study window.  
A medical diagnosis of the relevant cancers of interest will be defined by the list of 
the Read OXMIS codes provided by the researcher and agreed with the GPRD 
research team (Annex I to V).  
 
Cases with a diagnosis of any other cancer (including benign, malignant, secondary,  
cancers of uncertain behaviour or carcinomas in situ), prior to the diagnosis of the 
study cancers of interest will be excluded from the cohort. Cancer events recorded in 
the patient UTS and/or non-UTS follow-up period will be evaluated to identify cases 
for exclusion. 
 
Controls will include all patients without a recorded medical diagnosis of the 
relevant cancers of interest prior to the index date of the case ± in other words are 
cases allowed to become controls before the date they become a case. Controls will 
have at least 5 years of UTS follow-up prior to the index date of the case and will be 
matched on the same year of birth, gender and practice as that of the case. Controls 
will be matched to cancer cases on a ratio of up to 4:1 
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Controls with a diagnosis of any other cancer (including benign, malignant, 
secondary, cancers of uncertain behaviour or carcinomas in situ) prior to the index 
date of the case will be excluded from the cohort. 
 
 
 
Index date matching will be undertaken as shown below. 
 
          Index date Matching 
 
 
For the purposes of efficiency GPRD may not apply all cohort identification criteria. 
The criteria applied by GPRD however must result in a cohort that wholly contains 
the study cohort as defined in the protocol. The section below outlines the proposed 
GPRD data cut, and the researcher must be happy that they can generate the study 
cohort from this data cut, by further application of inclusion / exclusion criteria. 
 
 
 
Cohort provided by GPRD data cut: 
 
The following criteria will be applied by GPRD: 
 
Cases 
 
Inclusions 
x All patients with a recorded incident diagnosis of brain tumour including 
glioma, colorectal, lung, breast or prostate cancer in their clinical or referral 
files during the period 01/01/1987 ± 31/12/2007 inclusive. 
x $JHDWLQGH[GLDJQRVLV\HDUVRIDJH 
x Gender - Male or Female 
x Patient will have at least 5 years of UTS follow-up prior to the index date of 
diagnosis in the study window. 
 
Exclusions 
x Cases with a diagnosis of any other cancer ((including benign, malignant, 
secondary, cancers of uncertain behaviour or carcinomas in situ)  prior to 
the diagnosis of the study cancers of interest 
x Patients with less than 5 years of UTS follow-up prior to the index date of 
diagnosis in the study window. 
 
Case 
Contr
ol 
End (index date of cancer) 
Registration Start + 5 yrs 
Registration End: minimum 
(regend, cancer date  W 1) 
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The following criteria will not be applied by GPRD: 
x None 
 
 
Controls:  Up to 4 
 
Inclusions 
x All patients without a recorded diagnosis of brain tumour including glioma, 
colorectal, lung, breast or prostate cancer in their clinical or referral record 
prior to the index date of the case.  
x Patient will have at least 5 years of UTS follow-up prior to the index date of 
diagnosis of the case in the study window. 
The controls will be will be matched to cases on: 
Year of birth  (±2 )as the case 
Same gender as the case 
Same practice as the case 
 
Exclusions 
x  Controls with a diagnosis of any other cancer (including benign, malignant, 
secondary, cancers of uncertain behaviour or carcinomas in situ) prior to the 
index date of the case.  
Index date matching will be undertaken: The end date of the case will be set to the index 
date of the case. 
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Annex I: List of Read/OXMIS codes as evidence of Brain tumour & Glioma 
 
 
GPRD 
Medical 
Code 
Term 
Type 
Read / OXMIS 
Code Read / OXMIS Term 
Brain 
   
219944 (OXMIS)  2259F FIBROBLASTOMA MENINGEAL 
265551 (OXMIS)  191 BC CEREBRAL NEOPLASM 
303132 (OXMIS)  191 A MALIGNANT NEOPLASM CEREBRAL 
210814 OXMIS  1929DG OLIGODENDROGLIOMA 
210816 OXMIS  1990NB NEUROBLASTOMA DISSEMINATED 
229004 OXMIS  191 MB MEDULLOBLASTOMA BRAIN 
229005 OXMIS  1929MN MENINGIOMA BRAIN MALIGNANT 
247109 OXMIS  190 B RETINOBLASTOMA 
247111 OXMIS  1929D OLIGODENDROBLASTOMA 
256329 OXMIS  1925GN MALIGNANT GANGLIONEUROMA 
265591 OXMIS  2259B MENINGIOMA DIFFUSE 
292899 OXMIS 1923 MENINGIOMA SPINAL CORD MALIGNANT 
303133 OXMIS  1925NB NEUROBLASTOMA 
303134 OXMIS  1929AC ASTROCYTOMA 
303135 OXMIS  1929GL GLIOMA 
303218 OXMIS 2381 BRAIN TUMOUR 
306093 OXMIS  2259A MENINGIOMA 
206161 READ B510z00 Malignant neoplasm of cerebrum NOS 
206162 READ B515000 Malignant neoplasm of choroid plexus 
215160 READ B510000 Malignant neoplasm of basal ganglia 
215161 READ B511.00 Malignant neoplasm of frontal lobe 
215162 READ B512.00 Malignant neoplasm of temporal lobe 
215163 READ B512z00 Malignant neoplasm of temporal lobe NOS 
215164 READ B51y.00 Malignant neoplasm of other parts of brain 
224192 READ B515.00 Malignant neoplasm of cerebral ventricles 
224193 READ B515z00 Malignant neoplasm of cerebral ventricle NOS 
224194 READ B517300 Malignant neoplasm of pons 
224306 READ B7F4000 Spinal meningioma 
233311 READ B512100 Malignant neoplasm of uncus 
242345 READ B510.00 
Malignant neoplasm cerebrum (excluding lobes and 
ventricles) 
242346 READ B515100 Malignant neoplasm of floor of cerebral ventricle 
242347 READ B516.00 Malignant neoplasm of cerebellum 
251533 READ B510400 Malignant neoplasm of hypothalamus 
251534 READ B510500 Malignant neoplasm of thalamus 
251535 READ B513.00 Malignant neoplasm of parietal lobe 
251536 READ B514.00 Malignant neoplasm of occipital lobe 
251537 READ B51y000 Malignant neoplasm of corpus callosum 
260726 READ B510300 Malignant neoplasm of globus pallidus 
269967 READ B51yz00 Malignant neoplasm of other part of brain NOS 
270063 READ B7F2000 Cerebral meningioma 
270253 READ ByuA.00 [X]Malignant neoplasm of eye, brain and other parts of cent 
279035 READ B510200 Malignant neoplasm of corpus striatum 
279036 READ B517.00 Malignant neoplasm of brain stem 
279037 READ B517000 Malignant neoplasm of cerebral peduncle 
279038 READ B51z.00 Malignant neoplasm of brain NOS 
288139 READ B517100 Malignant neoplasm of medulla oblongata 
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288140 READ B51y100 Malignant neoplasm of tapetum 
288141 READ B51y200 Malignant neoplasm, overlapping lesion of brain 
288433 READ ByuA300 [X]Malig neopl, overlap lesion brain & other part of CNS 
297389 READ B51..00 Malignant neoplasm of brain 
297390 READ B51..11 Cerebral tumour - malignant 
297391 READ B510100 Malignant neoplasm of cerebral cortex 
297392 READ B512000 Malignant neoplasm of hippocampus 
297393 READ B517200 Malignant neoplasm of midbrain 
297394 READ B517z00 Malignant neoplasm of brain stem NOS 
340924 READ b51y.00 Malignant neoplasm of other parts of brain 
Glioma 
   
210814 (OXMIS)  1929DG OLIGODENDROGLIOMA 
229004 (OXMIS)  191 MB MEDULLOBLASTOMA BRAIN 
247111 (OXMIS)  1929D OLIGODENDROBLASTOMA 
265554 (OXMIS)  1929EP EPENDYMOMA 
265592 (OXMIS)  2259G GLIOMA BENIGN 
303134 (OXMIS)  1929AC ASTROCYTOMA 
303135 (OXMIS)  1929GL GLIOMA 
206401 READ BBbA.00 [M]Myxopapillary ependymoma 
206402 READ BBbM.00 [M]Giant cell glioblastoma 
206403 READ BBbT.00 [M]Medulloblastoma NOS 
215374 READ BBb3.12 [M]Subependymal astrocytoma NOS 
215375 READ BBb3.13 [M]Subependymoma 
215376 READ BBb4.00 [M]Subependymal giant cell astrocytoma 
215377 READ BBbE.11 [M]Gemistocytoma 
215378 READ BBbJ.00 [M]Spongioblastoma polare 
215379 READ BBbL.12 [M]Spongioblastoma multiforme 
215380 READ BBbW.00 [M]Cerebellar sarcoma NOS 
224439 READ BBb0.12 [M]Gliosarcoma 
224440 READ BBb5.00 [M]Choroid plexus papilloma NOS 
224441 READ BBbE.00 [M]Gemistocytic astrocytoma 
224442 READ BBbP.00 [M]Primitive polar spongioblastoma 
224443 READ BBba.00 [M]Primitive neuroectodermal tumour 
224444 READ BBbz.00 [M]Glioma NOS 
233553 READ BBb..00 [M]Gliomas 
233554 READ BBb0.00 [M]Glioma, malignant 
233555 READ BBbC.00 [M]Astrocytoma, anaplastic type 
233556 READ BBbK.00 [M]Astroblastoma 
242572 READ BBb2.11 [M]Mixed glioma 
242573 READ BBb3.00 [M]Subependymal glioma 
242574 READ BBb6.00 [M]Choroid plexus papilloma, malignant 
242575 READ BBbF.00 [M]Fibrillary astrocytoma 
242576 READ BBbL.11 [M]Glioblastoma multiforme 
251737 READ BBb3.11 [M]Subependymal astrocytoma NOS 
251738 READ BBb7.00 [M]Ependymoma NOS 
251739 READ BBb8.11 [M]Ependymoblastoma 
260947 READ BBb2.00 [M]Mixed glioma 
260948 READ BBbU.00 [M]Desmoplastic medulloblastoma 
270213 READ BBbG.00 [M]Pilocytic astrocytoma 
270214 READ BBbL.00 [M]Glioblastoma NOS 
270215 READ BBbN.00 [M]Glioblastoma with sarcomatous component 
270216 READ BBbQ.00 [M]Oligodendroglioma NOS 
270217 READ BBbR.00 [M]Oligodendroglioma, anaplastic type 
270218 READ BBbS.00 [M]Oligodendroblastoma 
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279292 READ BBb8.00 [M]Ependymoma, anaplastic type 
279293 READ BBbB.12 [M]Astroganglioma 
279294 READ BBbG.11 [M]Juvenile astrocytoma 
279295 READ BBbG.12 [M]Piloid astrocytoma 
279296 READ BBbX.00 [M]Monstrocellular sarcoma 
288387 READ BBb0.11 [M]Glioma NOS 
288388 READ BBb1.00 [M]Gliomatosis cerebri 
288389 READ BBb9.00 [M]Papillary ependymoma 
288390 READ BBbB.00 [M]Astrocytoma NOS 
288391 READ BBbH.00 [M]Spongioblastoma NOS 
288392 READ BBbZ.00 [M]Pleomorphic xanthoastrocytoma 
297665 READ BBbB.11 [M]Astrocytic glioma 
297666 READ BBbD.00 [M]Protoplasmic astrocytoma 
297667 READ BBbV.00 [M]Medullomyoblastoma 
 
 
Annex II: List of Read/OXMIS codes as evidence of Colorectal cancer 
 
 
GPRD 
Medical 
Code 
Term 
Type 
Read / 
OXMIS Code Read / OXMIS Term 
201875 (OXMIS)  1736CN CARCINOMA ANUS 
219895 (OXMIS)  1542A MALIGNANT NEOPLASM ANAL CANAL 
237937 (OXMIS)  1538B SARCOMA COLON 
247092 (OXMIS)  1542C CARCINOMA ANAL CANAL 
274663 (OXMIS)  1541A MALIGNANT NEOPLASM RECTUM 
292886 (OXMIS)  1736AN MALIGNANT NEOPLASM ANUS 
303101 (OXMIS)  1541C RECTUM CARCINOMA 
303203 (OXMIS) 2304 TUMOUR RECTAL 
201865 OXMIS  1539AT MALIGNANT NEOPLASM INTESTINE 
210799 OXMIS  1530AD ADENOCARCINOMA ASCENDING COLON 
237936 OXMIS  1533A MALIGNANT NEOPLASM SIGMOID 
283743 OXMIS  1530AC MALIGNANT NEOPLASM CAECUM 
292877 OXMIS  1538AN MALIGNANT NEOPLASM LARGE BOWEL NONRECTAL 
292878 OXMIS  1538CN LARGE BOWEL CARCINOMA NONRECTAL 
303095 OXMIS  1530CC CARCINOMA CAECUM 
303096 OXMIS  1533AD ADENOCARCINOMA SIGMOID COLON 
303097 OXMIS  1538A MALIGNANT NEOPLASM LARGE INTESTINE 
303098 OXMIS  1538AD ADENOCARCINOMA COLON 
303099 OXMIS  1538C COLON CARCINOMA 
303100 OXMIS  1539A MALIGNANT NEOPLASM BOWEL 
206104 READ B140.00 Malignant neoplasm of rectosigmoid junction 
224129 READ B133.00 Malignant neoplasm of sigmoid colon 
224130 READ B136.00 Malignant neoplasm of ascending colon 
224131 READ B14y.00 Malig neop other site rectum, rectosigmoid junction and anus 
233260 READ B141.00 Malignant neoplasm of rectum 
242290 READ B13z.11 Colonic cancer 
242291 READ B141.11 Carcinoma of rectum 
242292 READ B142.11 Anal carcinoma 
242293 READ B142000 Malignant neoplasm of cloacogenic zone 
251477 READ B137.00 Malignant neoplasm of splenic flexure of colon 
251478 READ B13z.00 Malignant neoplasm of colon NOS 
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251479 READ B14..00 Malignant neoplasm of rectum, rectosigmoid junction and anus 
251480 READ B143.00 Malignant neoplasm of anus unspecified 
260672 READ B13y.00 Malignant neoplasm of other specified sites of colon 
269916 READ B130.00 Malignant neoplasm of hepatic flexure of colon 
269917 READ B14z.00 
Malignant neoplasm rectum,rectosigmoid junction and anus 
NOS 
270073 READ B804000 Carcinoma in situ of rectosigmoid junction 
278983 READ B134.11 Carcinoma of caecum 
278984 READ B141.12 Rectal carcinoma 
279149 READ B803400 Carcinoma in situ of caecum 
288088 READ B13..00 Malignant neoplasm of colon 
288089 READ B131.00 Malignant neoplasm of transverse colon 
288090 READ B134.00 Malignant neoplasm of caecum 
288091 READ B138.00 Malignant neoplasm, overlapping lesion of colon 
297335 READ B132.00 Malignant neoplasm of descending colon 
297336 READ B135.00 Malignant neoplasm of appendix 
297337 READ B142.00 Malignant neoplasm of anal canal 
 
 
Annex III: List of Read/OXMIS codes as evidence of Breast cancer 
 
 
GPRD 
Medical 
Code 
Term 
Type 
Read / 
OXMIS 
Code Read / OXMIS Term 
201877 (OXMIS)  174 AN MALIGNANT NEOPLASM NIPPLE 
210809 (OXMIS)  174 CI CARCINOMA BREAST INDURATED 
256319 (OXMIS)  174 DL ADENOCARCINOMA BREAST ULCERATION 
303115 (OXMIS)  174 C CARCINOMA BREAST 
303116 (OXMIS)  174 DC ADENOCARCINOMA BREAST 
303185 (OXMIS)  217 AF FIBROADENOMA BREAST 
306054 (OXMIS)  174 A NEOPLASM MALIGNANT BREAST 
206147 READ B342.00 Malignant neoplasm of upper-inner quadrant of female breast 
206148 READ B34yz00 Malignant neoplasm of other site of female breast NOS 
215142 READ B341.00 Malignant neoplasm of central part of female breast 
215143 READ B345.00 Malignant neoplasm of lower-outer quadrant of female breast 
224176 READ B340100 Malignant neoplasm of areola of female breast 
224177 READ B344.00 Malignant neoplasm of upper-outer quadrant of female breast 
224178 READ B347.00 Malignant neoplasm, overlapping lesion of breast 
224179 READ B34y000 Malignant neoplasm of ectopic site of female breast 
233301 READ B34z.00 Malignant neoplasm of female breast NOS 
260706 READ B340.00 Malignant neoplasm of nipple and areola of female breast 
260707 READ B340000 Malignant neoplasm of nipple of female breast 
260708 READ B340z00 Malignant neoplasm of nipple or areola of female breast NOS 
260709 READ B343.00 Malignant neoplasm of lower-inner quadrant of female breast 
269951 READ B346.00 Malignant neoplasm of axillary tail of female breast 
297372 READ B34..00 Malignant neoplasm of female breast 
297373 READ B34..11 Ca female breast 
297374 READ B34y.00 Malignant neoplasm of other site of female breast 
 
 
Annex IV: List of Read/OXMIS codes as evidence of Lung cancer 
GPRD Term Read / Read / OXMIS Term 
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Medical 
Code 
Type OXMIS 
Code 
201873 OXMIS  1620C TRACHEA CARCINOMA 
219900 OXMIS  1620A NEOPLASM MALIGNANT TRACHEA 
256312 OXMIS  1621A NEOPLASM MALIGNANT LUNG 
283748 OXMIS  1621AB NEOPLASM MALIGNANT BRONCHUS 
303106 OXMIS  1621C LUNG CARCINOMA 
303107 OXMIS  1621CB CARCINOMA BRONCHUS 
303108 OXMIS  1621D PANCOAST TUMOUR 
303204 OXMIS  2313L TUMOUR LUNG 
215101 READ B221100 Malignant neoplasm of hilus of lung 
215102 READ B223000 Malignant neoplasm of middle lobe bronchus 
215103 READ B224100 Malignant neoplasm of lower lobe of lung 
215104 READ B22z.00 Malignant neoplasm of bronchus or lung NOS 
224142 READ B220000 Malignant neoplasm of cartilage of trachea 
224143 READ B220z00 Malignant neoplasm of trachea NOS 
224144 READ B221z00 Malignant neoplasm of main bronchus NOS 
224145 READ B222.11 Pancoast's syndrome 
224146 READ B224.00 Malignant neoplasm of lower lobe, bronchus or lung 
224147 READ B22y.00 Malignant neoplasm of other sites of bronchus or lung 
233275 READ B225.00 Malignant neoplasm of overlapping lesion of bronchus & lung 
242303 READ B220100 Malignant neoplasm of mucosa of trachea 
242304 READ B223.00 Malignant neoplasm of middle lobe, bronchus or lung 
251491 READ B222100 Malignant neoplasm of upper lobe of lung 
260679 READ B222z00 Malignant neoplasm of upper lobe, bronchus or lung NOS 
269932 READ B22..00 Malignant neoplasm of trachea, bronchus and lung 
269933 READ B222.00 Malignant neoplasm of upper lobe, bronchus or lung 
269934 READ B22z.11 Lung cancer 
278992 READ B220.00 Malignant neoplasm of trachea 
278993 READ B221.00 Malignant neoplasm of main bronchus 
288097 READ B222000 Malignant neoplasm of upper lobe bronchus 
288098 READ B223100 Malignant neoplasm of middle lobe of lung 
288099 READ B223z00 Malignant neoplasm of middle lobe, bronchus or lung NOS 
288100 READ B226.00 Mesothelioma 
297344 READ B221000 Malignant neoplasm of carina of bronchus 
297345 READ B224000 Malignant neoplasm of lower lobe bronchus 
297346 READ B224z00 Malignant neoplasm of lower lobe, bronchus or lung NOS 
Annex V: List of Read/OXMIS codes as evidence of Prostate cancer 
GPRD 
Medical 
Code 
Term 
Type 
Read / 
OXMIS 
Code Read / OXMIS Term 
303125 OXMIS  185 C PROSTATE CARCINOMA 
303126 OXMIS  185 CA ADENOCARCINOMA PROSTATE 
306055 OXMIS  185 A MALIGNANT NEOPLASM PROSTATE 
233306 READ B46..00 Malignant neoplasm of prostate 
332056 READ 4M0..00 Gleason grading of prostate cancer 
339526 READ 4M00.00 Gleason prostate grade 2-4 (low) 
339842 READ 4M01.00 Gleason prostate grade 5-7 (medium) 
339892 READ 4M02.00 Gleason prostate grade 8-10 (high) 
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Appendix II: Data specification for tricyclics/aspirin survival study 
 
 
 
 
 
Date: 16th June 2008 
Prospective study to further characterise the effects of tricyclic antidepressants 
on glioma and colorectal cancer.  
Protocol 09_087R 
1 Data-set specification 
Authors: Tarita Murray-Thomas, MHRA, UK 
Distribution: Alex Walker, University of Nottingham 
 
Prospective Cohort Study  
 
Study requirements as per protocol 
 
Inclusions 
Cases will consist of all patients with an incident medical diagnosis of glioma or 
colorectal cancer during the period 01/01/1987 -31/12/2009 inclusive. The index date 
of diagnosis of a glioma or colorectal cancer will be defined as the first date that the GP 
records such a diagnosis in the patient clinical or referral record.  Patients will have at 
least 12 months of up-to-standard (UTS) follow-up prior to the index date of diagnosis 
of cancers of interest.  
 
The list of Read codes for identifying glioma or colorectal cancer will be provided by 
the researcher and agreed with the GPRD Research Team (Annex 1 & 2).  
 
Exclusions 
Patients with <12 months of up-to-standard (UTS) follow-up prior to the index date of 
diagnosis of cancers of interest will be excluded from the cohort.  
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COHORT TO BE PROVIDED BY GPRD DATA CUT: 
 
RETROSPECTIVE COHORT STUDY 
 
Inclusion Criteria  
x All patients with an incident medical diagnosis of glioma or colorectal cancer 
recorded during the period 01/01/1987 - 31/12/2009  
x  Age at index diagnosis: No restriction 
x Gender: Male or  Female  
x Patients will have at least 12 months of up-to-standard (UTS) follow-up prior to the 
index date of glioma or colorectal cancer.  
 
 
Exclusion Criteria  
x Patients with <12 months of up-to-standard (UTS) follow-up prior to the index date 
of glioma or colorectal cancer.  
 
 
 
Criteria that will not be applied by GPRD 
 
x None 
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Annex I:  Read codes for identifying glioma 
Readoxmiscode Readoxmisterm 
191 MB MEDULLOBLASTOMA BRAIN 
1929AC ASTROCYTOMA 
1929D OLIGODENDROBLASTOMA 
1929DG OLIGODENDROGLIOMA 
1929EP EPENDYMOMA 
1929GL GLIOMA 
2259G GLIOMA BENIGN 
BBb..00 [M]Gliomas 
BBb0.00 [M]Glioma, malignant 
BBb0.11 [M]Glioma NOS 
BBb0.12 [M]Gliosarcoma 
BBb1.00 [M]Gliomatosis cerebri 
BBb2.00 [M]Mixed glioma 
BBb2.11 [M]Mixed glioma 
BBb3.00 [M]Subependymal glioma 
BBb3.11 [M]Subependymal astrocytoma NOS 
BBb3.12 [M]Subependymal astrocytoma NOS 
BBb3.13 [M]Subependymoma 
BBb4.00 [M]Subependymal giant cell astrocytoma 
BBb5.00 [M]Choroid plexus papilloma NOS 
BBb6.00 [M]Choroid plexus papilloma, malignant 
BBb7.00 [M]Ependymoma NOS 
BBb8.00 [M]Ependymoma, anaplastic type 
BBb8.11 [M]Ependymoblastoma 
BBb9.00 [M]Papillary ependymoma 
BBbA.00 [M]Myxopapillary ependymoma 
BBbB.00 [M]Astrocytoma NOS 
BBbB.11 [M]Astrocytic glioma 
BBbB.12 [M]Astroganglioma 
BBbC.00 [M]Astrocytoma, anaplastic type 
BBbD.00 [M]Protoplasmic astrocytoma 
BBbE.00 [M]Gemistocytic astrocytoma 
BBbE.11 [M]Gemistocytoma 
BBbF.00 [M]Fibrillary astrocytoma 
BBbG.00 [M]Pilocytic astrocytoma 
BBbG.11 [M]Juvenile astrocytoma 
BBbG.12 [M]Piloid astrocytoma 
BBbH.00 [M]Spongioblastoma NOS 
BBbJ.00 [M]Spongioblastoma polare 
BBbL.00 [M]Glioblastoma NOS 
BBbL.11 [M]Glioblastoma multiforme 
BBbL.12 [M]Spongioblastoma multiforme 
BBbM.00 [M]Giant cell glioblastoma 
BBbN.00 [M]Glioblastoma with sarcomatous component 
BBbP.00 [M]Primitive polar spongioblastoma 
BBbQ.00 [M]Oligodendroglioma NOS 
BBbR.00 [M]Oligodendroglioma, anaplastic type 
BBbS.00 [M]Oligodendroblastoma 
BBbT.00 [M]Medulloblastoma NOS 
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BBbU.00 [M]Desmoplastic medulloblastoma 
BBbV.00 [M]Medullomyoblastoma 
BBbZ.00 [M]Pleomorphic xanthoastrocytoma 
BBba.00 [M]Primitive neuroectodermal tumour 
BBbz.00 [M]Glioma NOS 
BBc6.00 [M]Ganglioglioma 
BBc7.11 [M]Neuroastrocytoma 
BBm0.00 [M]Microglioma 
K055 G EXCISION GLIOMA BRAIN 
 
 
 
 
Annex 2:  Read codes for identifying colorectal cancer 
Readoxmiscode Readoxmisterm 
1530AC MALIGNANT NEOPLASM CAECUM 
1530AD ADENOCARCINOMA ASCENDING COLON 
1530CC CARCINOMA CAECUM 
1533A MALIGNANT NEOPLASM SIGMOID 
1533AD ADENOCARCINOMA SIGMOID COLON 
1538A MALIGNANT NEOPLASM LARGE INTESTINE 
1538AD ADENOCARCINOMA COLON 
1538AN MALIGNANT NEOPLASM LARGE BOWEL NONRECTAL 
1538C COLON CARCINOMA 
1538CN LARGE BOWEL CARCINOMA NONRECTAL 
1539A MALIGNANT NEOPLASM BOWEL 
1539AT MALIGNANT NEOPLASM INTESTINE 
1539C CARCINOMA BOWEL 
1541A MALIGNANT NEOPLASM RECTUM 
1541C RECTUM CARCINOMA 
159 GASTROINTESTINAL MALIGNANCY 
159 A NEOPLASM MALIGNANT GASTROINTESTINAL TRAC 
159 C GASTROINTESTINAL CARCINOMA 
2304 TUMOUR RECTAL 
B13..00 Malignant neoplasm of colon 
B130.00 Malignant neoplasm of hepatic flexure of colon 
B131.00 Malignant neoplasm of transverse colon 
B132.00 Malignant neoplasm of descending colon 
B133.00 Malignant neoplasm of sigmoid colon 
B134.00 Malignant neoplasm of caecum 
B134.11 Carcinoma of caecum 
B136.00 Malignant neoplasm of ascending colon 
B137.00 Malignant neoplasm of splenic flexure of colon 
B138.00 Malignant neoplasm, overlapping lesion of colon 
B13y.00 Malignant neoplasm of other specified sites of colon 
B13z.00 Malignant neoplasm of colon NOS 
B13z.11 Colonic cancer 
B14..00 Malignant neoplasm of rectum, rectosigmoid junction and anus 
B140.00 Malignant neoplasm of rectosigmoid junction 
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B141.00 Malignant neoplasm of rectum 
B141.11 Carcinoma of rectum 
B141.12 Rectal carcinoma 
B14y.00 Malig neop other site rectum, rectosigmoid junction and anus 
B14z.00 Malignant neoplasm rectum,rectosigmoid junction and anus NOS 
B1z0.00 Malignant neoplasm of intestinal tract, part unspecified 
B1z0.11 Cancer of bowel 
Byu1200 [X]Malignant neoplasm of intestinal tract, part unspecified 
 
 
A full set of data files will be provided with this analysis. In addition the cohort 
identifying list of codes will be included. To maximise the quality of data, the cohort will 
be limited to acceptable patients only, as defined by a standard set of conditions relating 
to registration details.  
 
The files are provided as raw data, in tab-delimited ASCII files. These files can be 
uploaded into statistical software such as Stata or SAS, or into data management 
packages such as Microsoft Access for further data processing and analysis.  
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Appendix III: Glossary of survival analysis methods 
Below is a list of technical terms used within chapters 4 and 5 of this thesis. The aim of this 
is to explain the use of the various types of analysis and technical plots used, in terms of 
how they help to interpret the results.  
Cox proportional hazards modelling is a method used to model survival times. It creates an 
estimate of the ratio of risks (called the hazard ratio) between two groups. This allows a 
quantitive measurement of the size and direction of the effects observed. The model 
assumes that the hazard rate remains stable over time. This is known as the proportional 
hazards assumption and is assessed in various ways in this thesis. 
Kaplan-Meier curves are a method of producing a graphical representation of mortality in 
populations. The curve depicts the proportion of the start population still alive at each time 
point. Each death in the population causes the curve to drop by the proportion of the 
population that the dying patient represents. As patients are lost to follow up during the 
study, the population gets smaller and each subsequent death causes a greater drop in the 
curve. When curves representing two populations are drawn on the same plot, a 
comparison can be made of how (and when) morality in the two groups differs. This can 
also give an initial indication of whether the proportional hazards assumption is met, 
though this is better determined by using the log-log plot. 
Log-log plots are a method of determining whether the hazard rate remains proportional 
over time between two groups in a survival study. They are created by plotting the 
logarithm of the survival curve verses the logarithm of study time. If the curves produced 
by in this graph are approximately parallel and do not cross, the proportional hazards 
assumption can be said to be met. However any deviation from parallel may be an 
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indication that the proportional hazards assumption is not met. This lack of proportionality 
can then be further assessed. 
An observed/predicted plot can be used to assess how much and when the proportional 
hazards assumption is not met. It is created by drawing the same curve as in the Kaplan-
Meier plot and then on top of that, drawing a curve created using Cox predicted values. If 
the two lines are separated at any point, then it is likely the proportional hazards 
assumption has not been met. Additionally, it can be seen where the deviation occurs in 
the time scale. This is useful when further analysing the data. 
A number of approaches can be taken if non-proportionality is found to exist. Firstly the 
model can be reassessed to determine if there are any missing covariates which may, when 
adjusted for, cause proportionality to be restored. If this is not possible however, often the 
best strategy to use is stratification of the data according to the time after study initiation. 
This allows the effects for each time period to be assessed independently and this may 
reveal effects for different time periods that were masked by the non-proportionality in the 
overall model. 
 
The Charlson Index is a measure of comorbidity in a patient. It encompasses 22 different 
conditions, such as cardiovascular disease, cancer and AIDS. Each patient is assigned a 
score for each condition that they are diagnosed with, and these are then totalled to 
produce an overall score. Scores associated with each condition are 1, 2, 3 or 6 depending 
on the impact of the disease on mortality.  
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Appendix IV: Other achievements 
 
I have completed 2 modules in statistics within the School of Community Health Sciences. 
The results of exams and assignments in these modules are as follows: 
Research Methods in Epidemiology 
and Basic Statistics 
Statistics assignment: 80.5% 
Statistics exam: 77.8% 
Epidemiology exam: 56.3% 
Overall Mark: 67.4% 
Advanced Research Methods in 
Epidemiology and Statistics 
Exam: 86.5% 
Assignment: 61% 
Overall Mark: 74% 
 
 
  
I attended the National Cancer Research Institute (NCRI) conference in Birmingham in 
October 2008. I also attended the same conference in 2009, where I was invited to speak in 
a proffered paper presentation, and also to present in a poster session: 
http://www.ncri.org.uk/ncriconference/2009abstracts/abstracts/Para6.htm 
 
I have also completed a programme of Graduate School research training courses. These 
can be seen on the next page. 
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Appendix V: Publications arising from this work 
The following papers have been published in relation to this thesis. A copy of the first paper 
follows this page. The other article was in press at the time of writing. 
 
 
Walker, A. J., T. Card, T. E. Bates and K. Muir (2011). "Tricyclic antidepressants and the 
incidence of certain cancers: a study using the GPRD." Br J Cancer 104(1): 193-7. 
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